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SUMMARY
Chronic diseases are the leading causes of death and disability in the United
States and most of the developed world. Chronic diseases also account for the vast
majority of healthcare spending, and the cost of care continues to rise. Mathematical
models and operations research methods may serve as useful tools to systematically
analyze chronic disease management problems, derive useful insights, and possibly
inform policy decisions. This dissertation addresses three important problems related
to care of cancer and hepatitis C, and uses quantitative analyses to inform the best
management strategies for these chronic conditions.
We divide this thesis in four chapters. In Chapter 1, we provide overall motivation
and highlight our main findings and contributions. In Chapter 2, we study the eco-
nomic and disease burden of chronic lymphocytic leukemia (CLL) with the emerging
therapeutic options. Recently available oral targeted therapies represent a significant
advance for the treatment of CLL, but their high cost has raised concerns about af-
fordability and value to the society. To evaluate the impact of new oral therapies
for CLL on the economic and disease burden, we develop a comprehensive simulation
model to project the economic and clinical outcomes for the CLL population with the
evolving treatment strategies. Our results show that the oral targeted therapies will
substantially increase the annual cost of CLL management and per-patient lifetime
out-of-pocket cost by more than 5-fold from the year 2011 to 2025, which far out-
paces the rising cost of treating other cancers. At current prices, the new oral targeted
treatment strategy is deemed not cost-effective at the willingness to pay threshold of
$100,000/quality-adjusted life-year. Our findings remain robust against parameter
uncertainties through extensive sensitivity analyses. Our results highlight that such
xiii
an economic impact could result in financial toxicity, limited access, and lower ad-
herence to the oral therapies, which may undermine their clinical effectiveness. More
sustainable pricing strategy for oral targeted therapies is imperatively needed.
In Chapter 3, we study optimal surveillance of liver cancer in hepatitis C-infected
population. In the United States, hepatitis C-related liver cancer has become the
fastest-growing cause of cancer-related deaths. Although surveillance in hepatitis C
patients has shown improved early detection of cancer, the optimal use of surveil-
lance remains unknown. In this study, we develop a mixed-integer programming
(MIP)-based framework to systematically examine the cost-effectiveness of different
surveillance policies and identify the optimal policy that will maximize societal net
benefit. Our MIP-based framework captures two problem features that make dy-
namic programming-based formulation computationally intractable. In particular,
our proposed framework allows to (1) explicitly formulate a class of policies that are
practical for implementation, which we call “M-switch policies”, and (2) tailor surveil-
lance policies for each subpopulation by stratifying surveillance intervals based on the
observable disease states. We analyze structural properties and a) identify the suf-
ficient conditions under which additional surveillance improves the cost-effectiveness
of a policy, b) characterize when the surveillance policies should be adapted to popu-
lations with different disease progression rates, and c) quantify the trade-off between
decreasing cancer incidence and increasing treatment outcomes. We parameterize our
model using data from a clinical trial, a previously validated simulation model, and
published clinical studies. Our numerical analyses provide two main results with im-
portant policy implications. First, unlike the current one-size-fits-all type policies, the
optimal surveillance interval should be stratified based on the stage of hepatitis C in-
fection and age; second, expanding surveillance to patients in earlier stage of hepatitis
C infection improves the cost-effectiveness of liver cancer surveillance program.
In Chapter 4, we study an optimal resource allocation problem motivated by
xiv
the ongoing efforts by the World Health Organization to eliminate hepatitis C virus
(HCV) by 2030. More than 170 million people are chronically infected with HCV glob-
ally. Although new antiviral treatments for HCV offer a hope to eliminate HCV, most
countries do not have national programs to screen and treat HCV. To guide the policy
decisions in hepatitis C epidemic control, we develop two optimal control formulations
considering HCV screening and treatment interventions. In the first formulation, we
consider a cost minimization problem subject to a final target prevalence constraint.
We analytically show that the optimal treatment is a pure bang-bang policy without
singular arcs for any given screening rate. The simple policy structure with constant
screening and treatment rates does not result in a significant loss compared with
policies with dynamic rates, which represents a simple, effective and practical policy
structure for implementation. In the second formulation, we consider a budget allo-
cation problem that aims to minimize the disease burden subject to a fixed budget.
We show that optimal allocation policy follows a simple treatment-first rule both
analytically and numerically. Using this model framework, we numerically solve the
optimal control problems and identify optimal screening and treatment strategies for




Chronic diseases and conditions, such as cancer, cardiovascular disease, and arthritis,
have become the most common health problems worldwide. Chronic diseases are the
leading causes of death since the end of twentieth century. They contributed to more
than 62% of all deaths worldwide in 2009, and this number is expected to increase
to 73% by 2020 (88). Chronic diseases are also prevalent in the United States (US).
Data from 2005 showed that 45% Americans—133 million people—had at least one
chronic condition, and the prevalence is predicted to increase to 157 million by 2020
(233). Chronic diseases are responsible for 7 out of every 10 deaths of Americans each
year; in particular, cardiovascular disease and cancer together account for 46% of all
deaths (234).
Chronic diseases are costly. Management of chronic diseases accounts for the vast
majority of health care spending in the US. Eighty-six percent of all US health care
spending, about $2.2 trillion, was attributed to chronic disease in 2010 (83), including
81% of all hospital admissions and 76% of all physician visits (12). Moreover, the
cost of chronic diseases is expected to increase to $4.2 trillion by 2023 (57). Such
a substantial amount of spending on chronic disease is not proportional to the per-
centage of people with chronic diseases. In particular, more than 80% of spending of
private insurance, Medicare, and Medicaid is attributed to only less than 50% people
with chronic diseases (12). Thus, people with chronic diseases represent the heaviest
users of health care services, and management for these patients leads to substantial
economic burden to society.
1
One of the important reasons for significant cost burden of chronic disease man-
agement is the high drug prices, especially in cancer care. Cancer drug prices have
increased substantially in the past few decades (Figure 1.1). The average annual
cost of cancer treatment was below $10,000 before 2000, and increased to more than
$100,000 per year in 2012 (114, 136). The cost for almost all new cancer drugs
approved in 2014 range between $120,000 and $170,000 per year per person (48).
Figure 1.1: Rising cost of cancer drugs in the United States.
The median monthly cost for new cancer drugs in the United States has soared since
the 1970s despite an increasing number of available brands. Adapted from (186):
Saltz, L. B. (2016). “Perspectives on Cost and Value in Cancer Care”. JAMA
Oncology, 2(1), 19-21.
At such a high price, cancer treatment is hardly affordable, even for well-insured
patients. Studies have shown that cancer patients were three times more likely to
experience bankruptcy than those without cancer (176); 1 in 5 cancer survivors re-
ported financial hardship associated with cancer care, and 12% could not cover the
share of medical care cost (235). The financial burdens to cancer patients could limit
their access to therapeutic advancements, and lower their adherence to prescribed
treatment, which eventually impairs patients’ well-being. Such consequence of high
drug cost has recently been considered as a side effect of cancer treatment, referred
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to as “financial toxicity” (222). Given the financial strain that both society and
individual patients are facing, a better understanding of the financial impact and
cost-effectiveness of cancer treatment options is important for effectively utilizing
scarce health care resources.
The substantial economic burden associated with chronic diseases has also been fu-
eled by the increasing incidence and prevalence, mainly due to a rise in disease-specific
risk factors and an aging population (27). Since many risk factors are behavioral, such
as lack of physical activities, smoking, and excessive alcohol use, which are control-
lable through health promotions, several chronic diseases are indeed preventable (42).
In addition, early intervention can also be effective to control, or even to cure the
disease at an early stage. For example, many cancers including breast, prostate, liver
cancers are curable if detected in early stages through regular screenings; risks of
liver cancer can even be completely eliminated in hepatitis C infected patients if their
hepatitis is cured in early stages. As a result, health intervention policies can play a
critical role in disease prevention and control, as well as in alleviating the stress of
total disease and economic burden on the society.
To better support health policy decisions in chronic disease management, math-
ematical models can serve as useful tools. Because of time and resource constraints,
randomized controlled trials, the gold standard in medicine, are not suitable for assess-
ing and comparing various policies for chronic disease management at the population
level. Alternatively, mathematical models may be useful in many ways. First, models
are helpful in evaluating health economic outcomes of novel interventions and strate-
gies that have not yet become the standard of practice. For instance, models can
project the economic impact of emerging therapeutic options, and assess the cost-
effectiveness of multiple possible treatment options. Second, mathematical models
can be used to optimize complex decisions with respect to complex dynamics of the
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disease in the population, where all alternative options cannot be exhaustively enu-
merated and tested through real-world experiments, such as sequential decisions of
cancer screening, and dynamic resource allocations in epidemic control.
Motivated by these research opportunities, we focus on modeling and analysis of
three important questions related to the care for cancer patients and elimination of
hepatitis C in this dissertation. In Chapter 2, we study the economic and disease
burden of chronic lymphocytic leukemia (CLL) in the era of oral targeted therapies
in the US. Novel oral targeted agents have shown marked improvement in patients’
survival, but their high cost has raised concerns about their affordability and the
economic impact to payers, patients, and society. We develop a comprehensive sim-
ulation model to evaluate economic and clinical outcomes for the CLL population.
This model captures the evolving treatment strategies with emerging oral therapies,
and dynamics of disease incidences in an aging population. Our analyses show that
oral targeted therapies will substantially increase the cost of CLL management from
both payers’ and patients’ perspective. The increasing cost burden is driven by high
drug prices, improved survival, and extended treatment duration. At current prices,
these therapies would not be considered cost-effective to become the new standard of
care.
In Chapter 3, we study the liver cancer surveillance problem for the hepatitis
C-infected population. In the US, hepatitis C-related liver cancer has become the
fastest growing cause of cancer-related death. Although surveillance in hepatitis C-
infected patients has shown improved early cancer detection and survival outcomes,
the optimal surveillance policy remains unknown. In this chapter, we develop a mixed-
integer programming-based framework to identify the most cost-effective surveillance
policies. Our proposed framework allows (1) explicit formulation of “M-switch” policy
structures that are practical for implementation, and (2) surveillance policies tailored
for subpopulations which are stratified by observable clinical factors. We find that,
4
unlike current one-size-fits-all policies, the optimal surveillance interval should depend
on patients’ liver fibrosis stage and age. Moreover, expanding surveillance to patients
with earlier fibrosis stage improves overall cost-effectiveness of liver cancer surveillance
program.
In Chapter 4, we study an optimal resource allocation problem motivated by
the ongoing efforts by the World Health Organization to eliminate hepatitis C virus
(HCV) by 2030. Global HCV burden is massive: more than 170 million people are
chronically infected with HCV. Although elimination is theoretically feasible with
therapeutic and diagnostic tools that are currently available, the challenges persist
due to ongoing transmission, unawareness of infection, high treatment cost, and lim-
ited resources. Most countries do not have any national program to screen and treat
HCV. Several questions need to be answered such as how to allocate resources be-
tween screening and treatment to reach HCV elimination targets. In this study, we
consider two different intervention modes, namely screening and treatment for HCV.
We analyze the optimal intervention policies in two problem formulations, and show-
case the numerical solutions and policy implications in a case study of hepatitis C
elimination in India. In the first formulation, we consider a cost minimization problem
subject to a final target prevalence constraint. We analytically show that the optimal
treatment is a pure bang-bang policy without singular arcs for any given screening
rate. The simple policy structure with constant screening and treatment rates does
not result in a significant loss compared with policies with dynamic rates, implying a
simple, effective and practical policy for implementation. In the second formulation,
we consider a budget allocation problem that aims to minimize the disease burden
subject to a fixed budget. We show that optimal allocation policy follows a simple
treatment-first rule in both analytical and numerical results.
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CHAPTER II
PREVALENCE AND ECONOMIC BURDEN OF
CHRONIC LYMPHOCYTIC LEUKEMIA
2.1 Background
Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in the western
world. In the US, there are approximately 130,000 patients living with CLL, and
about 15,000 new cases occur every year (200). While most patients with CLL have
early stage disease at the time of initial diagnosis and are recommended for watchful
waiting (107), the majority eventually require treatment, typically after a few years
of observation and often experience prolonged survival (92, 96).
Chemoimmunotherapy (CIT) regimens such as fludarabine, cyclophosphamide,
and rituximab (FCR) have been the standard first-line treatment for young patients
with CLL (219, 95). In a single-center experience, FCR regimen led to a complete
remission (CR) rate of 72% and median progression-free survival (PFS) of 80 months
(115, 212). Subsequently, the German CLL8 trial established FCR as the standard
first-line therapy (95). For patients with age >65 years or with comorbidities, the
combination of chlorambucil and obinutuzumab is considered standard of care, based
on the results of the CLL11 trial (84).
In the last few years, major strides have been made in understanding the biology
of CLL and this led to significant advances in the treatment of CLL. In particular,
oral targeted agents such as ibrutinib and idelalisib have demonstrated remarkable
outcomes in patients with CLL. In the relapse setting, ibrutinib showed an overall
response rate (ORR) of 90% and an estimated PFS of 69% at 30-months (38); ide-
lalisib showed an ORR of 72% and a median PFS of 15.8 months as monotherapy
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in a phase I study (32), and an ORR of 81% and estimated overall survival (OS) of
92% at 12 months when used in combination with rituximab in a phase III study
(81). Subsequently, in 2014, the Food and Drug Administration (FDA) approved two
oral targeted therapies: ibrutinib for patients with relapsed/refractory CLL and for
patients with del(17p), and idelalisib in combination with rituximab for patients with
relapsed/refractory CLL. In March 2016, ibrutinib was approved for first-line man-
agement of CLL. In addition, several other targeted therapies are expected to become
available in the near future (108). Venetoclax was approved for patients with relapsed
CLL with del(17p) in April 2016 (77). These novel therapies have revolutionized the
CLL treatment paradigm.
However, the high cost of these targeted therapies raises concerns for payers as
well as patients (192, 235). Both ibrutinib and idelalisib are priced around $130,000
per year and are recommended to be taken until patients have progressive disease
or significant toxicities. In contrast, the costs for CIT-based treatments range from
$60,000-100,000 for a finite duration, a typical 6-cycle course lasting for about 6
months. Therefore, novel targeted therapies could strain the budget of both private
and government payers, such as Medicare, and co-payments and other expenses can
be a substantial burden to patients. Yet, the budget impact and cost-effectiveness of
these therapies are not well understood. In this study, our objective was to project the
changing economic as well as disease burden of CLL in the US in the era of targeted
therapies, and to evaluate the affordability and value of these new therapies.
2.2 Methods
We developed a microsimulation model, simCLL (simulation model of CLL manage-
ment), that simulated the dynamics of patient population under given management
strategies in the US from 2011 to 2025.
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2.2.1 Patient population characteristics
Patient characteristics were defined by age, phase of CLL treatment (watchful waiting,
first-line, or relapse), and del(17p) status. The age at diagnosis of each individual
patient was sampled from the age distribution based on the SEER data between 2000-
2011. (211). Del(17p) was assumed to be present in 7% of CLL patients (95). New
CLL cases were added to the simulated population in each year based on the published
annual incidence estimates from the American Cancer Society (200) (Table A.1).
The prevalence of CLL from the simulation model was calibrated to Surveillance,
Epidemiology, and End Results (SEER) data between 2000 and 2011 (Figures A.1
and A.2).
2.2.2 Simulated clinical pathways
We modeled the clinical course of patients with CLL using a patient-level state-
transition model, which included the following health states: watchful waiting, first-
line treatment, relapse, and death (Figure A.3). Majority of newly diagnosed patients
do not need immediate treatment (96) and were assumed to start in the watchful wait-
ing state (229) (the probability was determined through the model calibration). Upon
the failure of the first-line treatment, patients entered relapse state. The probabilities
of health state transitions were estimated based on time-to-treatment, progression-
free survival, and overall survival data observed in clinical trials (Tables 2.1, A.2,
and A.3). We selected the trials representing the best available evidence (e.g., phase
III trial, or large observational studies) for the major regimens in general practice,
with the reference to clinical guidelines (96) and expert opinions. We also validated
our model by comparing the simulated survival curves with observed survival data






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A treatment strategy defined the specific therapy for a patient by his status of relapse,
fitness (determined by age), del(17p), and the year of treatment (Figure 2.1). We
first simulated a clinical scenario that considered the current standard-of-care and
emerging treatment options (Figure 2.1A). In particular, prior to 2014, CIT was the
mainstay treatment for patients with CLL. The most common choices for the first-line
treatments were FCR for fit patients and chlorambucil for unfit patients. From 2014
onwards, the oral targeted therapies were approved for patients with relapsed CLL
and for patients with del(17p) (37, 81). From 2016 onwards, oral targeted therapies
became the standard-of-care in the first-line setting (36). The scenario described
above is referred to as the oral targeted therapy scenario.
For comparison, we simulated a scenario where CIT would have remained the
standard-of-care in future (Figure 2.1B). In this scenario, first-line unfit patients
would receive obinutuzumab plus chlorambucil after 2014 (84). This scenario is re-
ferred as chemoimmunotherapy scenario.
2.2.4 Costs
Direct medical costs were considered, including the cost of drugs and administration,
the cost of routine follow-up, and the cost of management of adverse events. Drug
costs were calculated based on the doses of the standard regimen and the average
sales price (ASP) of each drug. ASP was estimated as 26% lower than the average
wholesale price (AWP (2), see estimates in Tables 2.1-2.2, and details in Table A.5)
as suggested by an Office of Inspector General study (134). For oral targeted agents,
drug costs were accumulated for an indefinite period until treatment was discontinued.
As observed in the clinical studies with ibrutinib, 87% of patients in first-line setting
and 75% in relapsed setting would continue oral targeted therapy beyond 18 months
(36, 146).
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Figure 2.1: Management strategies for chronic lymphocytic leukemia (CLL) patients.
(A) The oral targeted therapy scenario with evolving therapeutic options for CLL patients. (B)
The chemoimmunotherapy scenario which continues to use chemoimmunotherapy as the standard of
care. We assumed equal allocation to multiple therapies if more than one therapies are considered for
patients in the same condition. For example, for fit patients in the relapse setting during 2014–2017,
50% patients receive ibrutinib and 50% receive idelalisib plus rituximab. Moreover, 5% relapsed
patients were assumed to receive hematopoietic stem cell transplantation (now shown in figure).
FCR, fludarabine, cyclophosphamide, and rituximab; Clb, chlorambucil; GClb, obinutuzumab plus
chlorambucil; Idel, idelalisib; R, rituximab; BR, bendamustine plus rituximab.
Administration costs such as physician visit and chemotherapy infusions were cal-
culated based on the Medicare physician fee schedule (43) (Tables 2.3 and A.4, using
the approach described elsewhere (221). Common serious adverse events, including
grade 3/4 infection and hematological toxicities, were simulated based on the re-
ported incidence for each therapy (Tables 2.1-2.2), and the management cost for each
was derived from the corresponding treatment and hospitalization costs (Table 2.3)
(44). We also considered the risk and the cost of atrial fibrillation with oral targeted
therapy because it has emerged as an important concern with ibrutinib (36).
12
Table 2.3: Model input parameters.
Variable Base value Range Reference
Probabilities
Prevalence of del17p 7% (95)
Probability of WW at diagnosis 0.85 Calibrated
Probability of fitness
Age: <65 0.95 Assumption






Probability of discontinuing oral targeted therapy at 18 months:
First-line treatment b 0.13 (0.109, 0.151) (36)






Relapsed 0.68 (25, 151)
Disutility for FC treatment periods -0.07 (4)
Cost ($)
Chemo intravenous infusion:
First hour 135.87 CPT96413 (43)
Additional hour 28.25 CPT96415 (43)
Each additional seq 62.93 CPT96417 (43)
Office/outpatient visit 51.13 CPT99213 (43)
Blood test 80 (93)
Cost of adverse events
Anemia 1967 (1910, 1998) (44)
Neutropenia 3207 (2885, 3539) (44)
Thrombocytopenia 1136 (620, 1191) (44)
Infection 12097 (7418, 28926) (44)
Atrial fibrillation 17342 (16123,18322) (131)
a: Assume all patients older than 70 at diagnosis are unfit patients;
b, Range is calculated based on the confidence interval of binomial distribution, corresponding to treatment
discontinuation probabilities of 0.007 (0.006, 0.008) for each 4-week cycle;
c, Correspond to treatment discontinuation probabilities 0.014 (0.008, 0.021) for each 4-week cycle.
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2.2.5 Health-related quality-of-life
The health-related quality of life weights (utilities) were adjusted by health states
and patients’ age (25, 75). We assumed utility of one in watchful-waiting state. For
the first-line treatment state, a patient’s utility was determined by his response type
(i.e., complete, partial, or no response), which was sampled according to the response
rate of his treatment. In addition, the utilities were adjusted based on patients’ age
(97), and a disutility was applied to fludarabine and cyclophosphamide-containing
regimens (41, 4).
2.2.6 Model outcomes
We projected the number of people living with CLL and the annual cost of CLL
management in the US from 2011 to 2025. In addition, we calculated per patient
life-time cost with oral targeted therapies as well as with CIT as the standard-of-
care. Because the majority of patients are older than 65 at the time of CLL diagnosis
and covered by Medicare, we also estimated the life-time out-of-pocket cost of the
oral targeted therapies for patients enrolled in Medicare Part D plan (Tables A.6
and A.7). We estimated total discounted person-LYs and person-QALYs as the total
health outcomes at the population-level from 2011-2025, and finally estimated the
incremental cost-effectiveness ratio (ICER) of oral targeted therapies in comparison
with chemoimmunotherapy scenario. All costs were converted to 2015 US dollar. In
the cost-effectiveness analysis, future outcomes were discounted to value in 2015 at
3% per year (64). For simplicity we presented the rounded values of all our numerical
results.
2.2.7 Sensitivity analysis
To evaluate the robustness of outcomes against uncertainty in model inputs, we per-
formed one-way deterministic sensitivity analyses. Utilities and probabilities of dis-
continuation of oral targeted therapies were varied within their reported confidence
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interval, other transition probabilities and costs were varied within 20% range, and
survival distributions were adjusted with hazard ratios between 0.8 and 1.2. We also
performed probabilistic sensitivity analysis (PSA) that accounted for joint uncertainty
in all model inputs.
In addition, we performed two scenario analyses. First, considering the aging US
population (Table A.8) (170), we adjusted the CLL incidence with the US population
projection data (Table A.9) and simulated a scenario with a higher CLL incidence
rate. Second, we evaluated a scenario simulating partial uptake of oral targeted
therapies representing a gradual transition from CIT. Specifically, we assumed 25%
utilization of oral targeted therapies in first-line treatment for fit patients after the




The total number of people living with CLL is projected to increase from 128,000
in 2011 to 199,000 (55% increase) in 2025 because of improved survival with the use
of oral targeted therapies. In contrast, if CIT remained the standard-of-care, the
number of people living with CLL would be 162,000 (26% increase) by 2025 (Figure
2.2).
2.3.2 Cost burden
Annual cost of CLL care. Under the oral targeted therapy scenario, the annual cost of
CLL management is projected to increase from $0.74 billion in 2011 to $5.13 billion
(593% increase) in 2025 (Figure 2.3). The first surge in the annual cost occurred
in 2014 when oral targeted therapies became available for relapsed patients, and the
second surge will occur in 2016 because of the approval of oral targeted therapy in
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Figure 2.2: Trend in disease burden of CLL.
Note. The use of oral targeted therapies is projected to increase the number of people with CLL
from 128,000 in 2011 to 199,000 (55% increase) in 2025 because of improved survival with the use
of oral targeted therapies.
the first-line setting. In contrast to the increasing cost trend with oral targeted ther-
apies, the annual cost under the chemoimmunotherapy scenario would have remained
relatively stable from 2014 onwards, reaching $1.12 billion in 2025. Compared with
chemoimmunotherapy scenario, oral targeted therapies would result in an additional
spending of $29 billion from their availability in 2014 until 2025. Among the total
cost of CLL management, drug costs constituted 96% in the oral targeted therapy
scenario and 86% in the chemoimmunotherapy scenario.
Lifetime cost of CLL treatment. The per-person lifetime cost of CLL treatment for
patients initiating therapy in 2011 was $147,000, which increased to $331,000 (125%
increase) for patients initiating therapy in 2014 (Figure 2.4A). For patients initiating
therapy in 2016 with oral therapies (now approved in first-line), the lifetime cost of
CLL treatment is projected to reach $604,000 (310% increase from 2011).
Out-of-pocket cost for Medicare patients. The majority of patients with CLL in
the US are covered by Medicare, and have drug coverage through Medicare Part D
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Figure 2.3: Annual management cost of CLL.
Note. The use of oral targeted therapies is projected to increase the annual cost in CLL management
from $0.74 billion in 2011 to $5.13 billion (593% increase) in 2025, which is mainly driven by high
drug prices, prolonged treatment duration of oral agents, and increased number of patients living
with CLL.
plan. The out-of-pocket cost of oral agents for Medicare patients was estimated based
on the deductible and coverage limits in the Medicare Part D plan (Table A.6), and
was estimated to be $9200 for those initiating therapy in 2011, which increased to
$27,000 (193% increase) for patients initiating therapy in 2014, and to $57,000 (519%
increase) for patients initiating treatment from 2016 onwards (Figure 2.4B). Use of
oral targeted therapies in first-line setting after 2016 also substantially increased the
first-line treatment cost, which constituted the major proportion of the lifetime cost.
2.3.3 Cost-effectiveness analysis
From 2011 to 2025, the total discounted health outcomes were 1,850,000 person-
QALYs (2,193,000 person-LYs) under the oral targeted therapy scenario and 1,743,000
person-QALYs (2,044,000 person-LYs) under the chemoimmunotherapy scenario. Com-
pared with the chemoimmunotherapy scenario, the oral targeted therapy scenario re-
sulted in an increase of 107,000 person-QALYs (149,000 person-LYs) with additional
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Figure 2.4: Lifetime treatment cost grouped by the year of initiating first-line treat-
ment for the oral targeted therapy scenario.
(A) Lifetime treatment cost to payers; (B) lifetime out-of-pocket cost for Medicare patients.
discounted treatment costs of $20.2 billion. The incremental cost-effectiveness ratio
(ICER) of oral targeted therapies was $189,000 per QALY ($136,000 per LY).
2.3.4 Sensitivity analyses
We examined the sensitivity of results to oral drug cost discounts. Considering a
37% discount off the AWP as the lowest price paid by private-sector payer for drug
product (104), the total incremental cost was $24 billion, lifetime out-of-pocket cost
for patients with first-line oral targeted therapy was $52,000, and the ICER of oral
targeted therapy was $161,000/QALY (Table A.10). When the oral targeted agent
cost was reduced to 50% of AWP, the ICER would reduce to $107,000 per QALY. A
threshold cost analysis showed that the cost of oral targeted therapies needs to be at
least 69% lower than the current AWP to bring the ICER below $50,000-per-QALY
threshold.
One-way sensitivity analysis showed that the cost of CLL management was sen-
sitive to treatment cost, discontinuation rate of oral targeted therapies, immediate
treatment probability at initial visit, and time to first-line-treatment from watchful
waiting state (Figure A.5). The ICER was most sensitive to survival distributions of
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Figure 2.5: Sensitivity analysis of the cost-effectiveness of the oral targeted therapy
scenario compared with chemoimmunotherapy scenario.
(A) Tornado diagram for one-way sensitivity analysis of incremental cost-effectiveness ratio; (B)
cost-effectiveness acceptability curves from the probabilistic sensitivity analysis.
treatments, as well as health-related utilities for partial response in first-line treat-
ment and in the relapse setting (Figure 2.5A). PSA showed that oral targeted therapy
was deemed cost-effective with a very low probability even at a willingness-to-pay as
high as $150,000/QALY (Figure 2.5B). We also found that increase in CLL incidence
because of the aging population in the US would further escalate the cost burden and
reduce the cost-effectiveness of oral targeted therapies, and the partial uptake of oral
targeted therapies for first-line fit patients had limited changes to all model results
and would not change the conclusions (Table A.11).
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2.4 Discussions
Oral targeted therapies represent a major advance for patients with CLL with im-
provement in overall survival compared to conventional therapies (36). Our study
projected an increase in the number people living with CLL over time, largely due to
improved survival in the era of oral targeted therapies. We also projected a substan-
tial increase in the cost of CLL management in the era of targeted therapies. The
annual cost of CLL management is projected to reach $5.13 billion by 2025, a 590%
increase from that in 2011. The cost of new therapies will add considerable finan-
cial burden to both patients and payers. At the current price, oral therapies are not
deemed cost-effective using the willingness to pay threshold of $100,000-per-QALY.
This study provides a comprehensive view and analysis of the changing burden of
CLL care in the US To our knowledge, no study has evaluated the cost-effectiveness
of oral targeted cancer therapies from a population level. Earlier studies on the cost
of CLL did not consider recent data and changing population dynamics. One study
examined the life-time cost of CLL treatment for Medicare patients equal to $87,000
using data from older drugs regimens from 1999—2007 (123). Another study by
Shanafelt and colleagues estimated the annual societal cost of CLL equal to $0.73
billion using chemoimmunotherapy and $2.63 billion and $1.24 billion using ibrutinib
in first- and second-line, respectively (192). However, their estimates were lower than
our projections because they did not account for the growing disease population due
to improved survival. Our results highlighted the expected societal impact of the
rising disease burden from CLL that compounded the increased cost associated with
a long-term oral therapy.
Our study has several limitations. First, our model did not consider all possible
treatment sequences in practice. We also did not account for individual practice pat-
terns that deviate from standard-of-care and guidelines because no data exist for com-
prehensive utilization estimates for each treatment option. However, we believe that
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our approach is sufficient to capture the most commonly accepted practice patterns
and population-level trends in costs and prevalence of CLL. Second, we considered
constant drug prices and did not capture the possible fluctuation of drug prices over
time in reality. We performed a series of sensitivity analyses on drug prices and found
that our findings remained valid across a wide range of drug price discount, and that
the oral therapies could be deemed cost-effective if the prices were at least 69% lower
than our current AWP estimates.
Although the cost of cancer care is rising, our results indicate that the rising
trend in the cost CLL management will outpace that of other cancers. The annual
cost of cancer care in the US due to the aging population is expected to increase
by 27∼50% from $143 billion in 2010 to $180 billion in 2020 (150). For breast and
prostate cancers, the annual cost of care is expected to increase by 24∼38% from
2010 to 2020. In contrast, the annual cost of the CLL is estimated to increase by
500% from $0.7 billion in 2011 to $4.2 billion in 2020. The substantial increase in the
cost of CLL management is mainly driven by the high cost of oral targeted drugs and
prolonged treatment duration along with the improved survival. While our analysis
suggests that the cost of CLL management will rise faster than that of other cancers,
future advances in treatments could increase the costs of care of other cancers as well.
Such increase could strain the budget of private as well as government payers.
Patients also will suffer from the escalating cost burden of expensive treatments,
as the higher overall cost could translate into higher health insurance premium and
cost sharing for individual patients (213). One study found that medical bankruptcies
ranked number one constituting of 67% of all US family bankruptcies, for whom the
out-of-pocket cost ranged from $18,000 to $27,000 (103). Our results showed that
the lifetime out-of-pocket costs of CLL treatment for Medicare patients is expected
to increase by nearly 4-fold to $57,000 for those initiating first-line oral targeted ther-
apy after 2016, which could further exacerbate the likelihood of medical bankruptcy
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and result in discontinuation of treatment. Especially for patients from low-income
families, the high out-of-pocket cost of oral targeted therapies could result in limited
access to these therapies and thus adversely affecting their clinical outcomes. In addi-
tion to the material financial hardship—a survey showed 12% of cancer patients could
not cover their share of medical care costs, the high out-of-pocket costs could also
lead to psychological financial hardship (235). Furthermore, high out-of-pocket costs
could result in disparities in access to these therapies. For instance, CLL patients
with lower income level may not be able to afford these therapies, adversely affecting
their outcomes. Their health could remain suboptimal even in the era of oral targeted
therapies (111, 177).
The high drug price has been a disturbing concern not only in the area of CLL
management, but also in the setting of cancer care in general. The cost of cancer
care has been rising drastically in the past 15 years. The average annual cost of
cancer treatment before 2000 was below $10,000, which has now increased to more
than $100,000 (114, 136). A recently published systematic review found that the
majority of drugs for hematologic malignancies are not cost-effective at their current
prices (48). Similar trend is observed in other cancer treatments (87, 86, 193). The
cost of care has become an important component for delivering high quality-care
(163, 20, 21).
We do not recommend that clinicians should choose less effective management
strategies; instead we propose that the price of oral-targeted therapies need to be
reduced such that the treatment becomes cost-effective and more affordable. Besides
price reduction, strategies to optimize drug and dose schedule are needed. Minimal-
residual disease (MRD) negative remissions have been reported with drugs such as
venetoclax. Clinical trials are needed to ascertain if drug-discontinuation in patients
meeting certain parameters (such as MRD negative remission) would be an effective
approach. Similar approaches have been utilized in patients with CML who have
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received imatinib (STIM trial (147)).
In conclusion, this study provides a comprehensive analysis of the changing preva-
lence and cost of CLL care in the US Oral targeted therapies will substantially increase
survival rates; however, with the current price structure, they will dramatically in-
crease the cost of CLL management for both patients and payers. Such an economic
impact could result in financial toxicity, limited access, and lower adherence to the
oral therapies, which may undermine their clinical effectiveness. More sustainable
pricing strategy is needed for targeted therapies.
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CHAPTER III
OPTIMAL LIVER CANCER SURVEILLANCE IN
HEPATITIS C-INFECTED POPULATION
3.1 Introduction
Hepatocellular carcinoma (HCC) is the most common type of liver cancer accounting
for more than 90% of liver cancer cases (143). The disease burden has been growing
at a rapid pace in the past few decades (185). The incidence of HCC in the US has
tripled since 1975 (10). Also, while the overall death rate for cancers has declined
by about 18% in the past two decades, HCC-related mortality has increased by 40%
during the same period (143).
The leading cause of HCC is chronic hepatitis C virus infection, which affects
nearly 3 million Americans (61) and contributes to more than 50% of HCC cases
in the US (143). Currently, hepatitis C-related HCC is the fastest-growing cause of
cancer-related deaths (68). Even though hepatitis C prevalence is declining, HCC
mortality is likely to continue to increase for several years (110, 55).
HCC progression is often silent with rare clinical symptoms, and thus HCC is
usually fatal or significantly impairs patients’ quality of life (207). While treatment
is highly effective at earlier stages, no curative options are available at later stages
(209, 33). Therefore, early detection is the key to a successful management of HCC
patients.
Recent research has shown that regular surveillance with ultrasound in hepatitis
C patients can detect HCC at earlier and most curable stages (202). However, unlike
many other major cancers such as breast, prostate, and colorectal cancers, surveillance
for HCC has been heavily underutilized in practice (204). Currently, only about 10%
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of HCC cases are detected at earlier stages and are eligible for curative therapies
such as surgical resection, ablation, or liver transplantation (39, 68). As a result,
although timely diagnosis and treatment can lead to favorable survival outcomes
(5-year survival is about 70% with early detection), most HCC patients have poor
prognosis with a 5-year survival of less than 5% (69).
On the other hand, the rapid increase in HCC incidence and mortality, and ad-
vancements in detection and treatment in recent years have drawn greater attention
and led to wider advocacy for surveillance for HCC (202, 17). However, there is no
consensus on the optimal HCC surveillance policies (236, 113). To date, no random-
ized controlled trial, the clinical gold standard, has assessed the mortality benefits
from different HCC surveillance strategies. Further, such trials are considered “uneth-
ical” to conduct given that the benefits of ultrasound surveillance have been observed
and recognized in clinical practice (174).
In the absence of randomized trials, a comprehensive mathematical can be instru-
mental in answering several important policy questions. In this study, we propose
a general and flexible mathematical modeling framework for chronic disease preven-
tion and treatment problems and utilize it to seek answers to many important health
policy questions in the context of HCC surveillance. For example, which hepatitis
C patients should be targeted for HCC surveillance? What are the long-term health
and economic consequences of HCC surveillance? Should the frequency of surveil-
lance depend on the extent of hepatitis C infection? Should surveillance strategies be
adjusted by age? What is the optimal age to terminate surveillance?
In the operations research/management science (OR/MS) literature, chronic dis-
ease screening/surveillance problems have been commonly formulated using Markov
decision process (MDP) and partially observable MDP (POMDP) modeling frame-
works and the optimal policies are computed in an iterative manner based on back-
ward induction-type algorithms (such as value iteration or policy iteration), which we
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refer to as the dynamic programming (DP)-based approaches. For example, Chhat-
wal et al. develop an MDP model to determine the optimal strategy for breast
cancer biopsy based on mammogram results and age (46) . Maillart et al. enumerate
and evaluates numerous breast cancer screening policies using a partially observable
Markov chain (148). Ayer et al. propose a POMDP model to optimize breast can-
cer screening strategies from individual patients’ perspective (18, 19). Zhang et al.
determine the optimal biopsy referral decision based on the results of screening tests
for prostate cancer using a similar approach (243). Kırkızlar et al. formulate an
MDP model to identify the optimal timing of testing and treatment for a class of
asymptomatic diseases from a policy cost-effectiveness perspective (119). Yang et al.
formulate a dynamic program and approximately solves the optimal age- and gender-
specific threshold of biennial screening for childhood obesity to minimize the disease
prevalence (237). Rauner et al. consider a bi-objective optimization problem for risk-
group based screening for chronic diseases, and utilize a metaheuristic algorithm to
determine Pareto-optimal policies (180).
Unless handled specially, solutions to DP-based approaches typically lead to fully
dynamic policies, policies that have frequent changes of decisions over time. How-
ever, in a population-based cancer screening program, frequently changing screening
intervals are not practical from a health policy perspective. Instead, policy-makers
typically prefer structured policies with less frequently changing intervals. In a DP-
based framework, while it is technically possible to impose structured policies with
less frequent changes over time by expanding the state space, such an approach usu-
ally comes at a cost of significant computational complexity to the extent that it
often becomes computationally intractable. Therefore, rather than pursuing such a
DP-based formulation and solution route, we instead introduce M-switch policies in a
mixed integer programming (MIP)-based framework, where the surveillance intervals
can change at most M times in a given subpopulation. For example, in a 1-switch
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policy (i.e., M = 1), surveillance intervals can change at most once for each fibrosis
subpopulation (e.g., for patients with advanced fibrosis, screen every 6 months until
age 60 and switch to one year afterwards).
Another important feature to be captured as in many disease screening/surveillance
problems is that the natural history of the disease is jointly characterized by multiple
co-existing conditions, and that the surveillance/screening decisions for one condition
can be stratified by the status of other co-existing conditions. For example, in our
HCC surveillance problem, disease progression is jointly characterized by observable
liver fibrosis states (capturing the stage of hepatitis C infection) and unobservable
HCC states (capturing the cancer stage), where liver fibrosis stages affect the cancer
risks. In identifying HCC surveillance policies that are stratified by fibrosis stages,
we need to ensure that the surveillance policy recommends the same action for pa-
tients with the same fibrosis state, irrespective of their unobservable cancer states.
For instance, if a policy recommends annual HCC surveillance in advanced fibrosis
stage, this policy applies to all patients with advanced fibrosis irrespective of their
unknown cancer status (e.g., some may have cancers, and others may not). Math-
ematically, this implies that while the system is characterized by a tuple of states
(e.g., (s1, s2)), the optimal action is determined based on only part of them (e.g.,




2) should be the same as long as s1 = s
′
1). While
such a phenomenon is common in many health policy problems, ensuring it requires
expanding the state space and comes at a significantly increased computational cost
in a DP-based formulation and solution approach.
In this study, we propose a flexible modeling framework for chronic disease preven-
tion and treatment decisions based on mixed integer programming (MIP), which over-
comes the above mentioned limitations of the commonly used DP-based approaches
in the chronic disease prevention literature. While in this paper we focus on liver can-
cer surveillance problem, our modeling framework is general and could be extended
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to other population-based disease prevention problems, such as cervical cancer or
colorectal cancer screenings, as well as disease screening/surveillance problems when
co-morbid conditions exist (e.g., coronary artery disease screening in patients with
hypertension and breast cancer screening in pre-diabetic and diabetic patients).
Our contributions are twofold. From the modeling and theoretical perspective,
(1) we propose a general modeling framework to ensure practical surveillance recom-
mendations at the policy level, which is applicable to a broad family of disease pre-
vention/treatment problems; and (2) we theoretically analyze the HCC surveillance
problem and a) identify the sufficient conditions under which additional surveillance
improves the cost-effectiveness of a policy, b) characterize when the surveillance poli-
cies should be adapted to populations with different disease progressions, and c)
quantify the trade-off between decreasing HCC incidence and increasing treatment
outcomes due to advancements in hepatitis C treatment and characterize their net
effect on the surveillance policies. From the health policy perspective, we use the
best evidence based on large datasets and clinical literature in parameterizing our
model and find that (1) unlike the existing guidelines, expanding HCC surveillance
to patients in earlier stage of hepatitis C infection improves health outcomes and cost-
effectiveness; (2) stratified surveillance policies based on hepatitis C infection stages
are more cost-effective than the currently recommended one-size-fits-all type policies;
and (3) cost-effectiveness improves when surveillance is adjusted dynamically based
on age, and ultimately terminates at a certain age (depending on the hepatitis C in-
fection stages), as continuing surveillance beyond a certain age has minimal outcome
benefit.
The remainder of this paper is organized as follows. In Section 3.2, we provide
background information on disease dynamics and management. In Section 3.3, we
present our model formulation for different classes of surveillance policies, and in
Section 3.4, we present our analytical results. In Section 3.5, we describe model
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inputs and parameter estimations, and present numerical results. Finally, in Section
3.6, we summarize our findings and conclude.
3.2 Background
Stages of hepatitis C infection (Precursor states of HCC). Chronic hepatitis C infec-
tion causes liver inflammation, which leads to a scarring process and forms fibrous scar
tissues in liver, called liver fibrosis. The extent of fibrosis is graded by the METAVIR
scoring system from F0 to F4 stages (23), where F0, F1, and F2 stages represent none,
mild, and moderate fibrosis respectively, F3 stage represents advanced fibrosis, and
F4 stage represents compensated cirrhosis (CC) (see Table 3.1 for a summary). In CC
stage, the entire liver is scarred but still has well-preserved liver functions. Further
degradation in liver functionality leads to decompensated cirrhosis (DC), where the
disease starts to interfere normal liver functions and may cause many life-threatening
complications, including ascites, bleeding varices, and encephalopathy (73). Patients
in F3 or more advanced fibrosis stages (i.e., CC and DC) are at risk of developing
HCC.
Table 3.1: Overview of stages of hepatitis C infection and liver cancer.
Stages of hepatitis C infection (fibrosis)
F0 No fibrosis
F1 and F2 Mild and moderate fibrosis, respectively
F3* Advanced fibrosis without cirrhosis
F4(CC)* Compensated cirrhosis (CC): the liver is heavily scarred but without
serious complications
DC* Decompensated cirrhosis (DC): the liver is unable to function properly
with life-threatening complications
Stages of HCC (BCLC staging system)
BCLC-0 Very early stage, with single tumor <2cm
BCLC-A Early stage, single 2-5cm or 3 nodules 3cm, candidate for liver transplant
BCLC-B,C,D Intermediate, advanced, and terminal stages, respectively, which are not
eligible for curative treatments
*: Fibrosis stages that are at risk of developing liver cancer.
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Surveillance and diagnosis of HCC. As advocated in practice guidelines, abdomi-
nal ultrasonography has been the mainstay test for HCC surveillance (33, 143). While
there are other tests such as serological tests like α-fetoprotein (AFP), they are not
recommended for surveillance due to inadequate sensitivity (78). Any positive re-
sult from an ultrasound surveillance test needs to be further evaluated by diagnostic
tests such as computerized tomography (CT), magnetic resonance imaging (MRI),
or biopsy. If the diagnostic tests confirm the presence of HCC, the patient receives
immediate treatment. Otherwise, the patient undergoes no further intervention until
the next surveillance test.
HCC staging and treatments. Staging of HCC is typically determined by the
Barcelona-Clinic Liver Cancer (BCLC) staging system (142, 79). Available treatment
options include resection, liver transplantation, local ablation (with radiofrequency or
percutaneous ethanol injection), and palliative treatment (i.e., chemoembolisation),
and selection of the specific treatment depends on HCC and fibrosis stages at diag-
nosis. For example, patients with advanced stage HCC typically receive palliative
treatment such as chemotherapy, patients without decompensation are eligible for
liver resection, and liver transplantation is offered only to patients meeting the Milan
criteria (a set of criteria characterizing the size of tumors which is used for selecting
patients with better prognosis after transplantation) (33, 143).
Currently, annual management cost for hepatitis C-related HCC in the US is
estimated to be $1 billion, and is expected to peak to about $1.4 billion in 2025 (181).
Given such high economic burden, it is important to provide “care that is based on
the wise and cost-effective management of limited clinical resources” (3). As noted
in (167), assessing the cost-effectiveness of population-based policies is undoubtedly
critical in directing the limited societal health care resources towards the greatest
health gains efficiently.
Few simulation-based cost-effectiveness studies in public health literature have
30
examined HCC surveillance strategies. These studies found that surveillance every 6-
12 months is cost-effective in hepatitis C-related cirrhotic patients (137, 51, 13). Based
on these pieces of evidence, surveillance every 6-12 months for cirrhotic patients is
now recommended in HCC management guidelines, including the guidelines by the
American Association for the Study of Liver Disease (AASLD) (33), the European
Association for the Study of the Liver (EASL) (143), and the National Comprehensive
Cancer Network (NCCN) (24).
However, the existing studies that provided the initial evidence for the current
practice guidelines have several common limitations. First, they consider only a very
limited number of policies (about 2-3 policies such as no screening, semiannual screen-
ing, and annual screening). Second, these studies assume that surveillance should only
be offered to patients in an advanced stage of hepatitis C (i.e., cirrhosis), and do not
consider the recently emerging evidence from a large clinical trial demonstrating that
patients in an earlier stage of hepatitis C (i.e., advanced fibrosis without cirrhosis)
may also develop HCC (144). Third, they assume the surveillance interval should
be the same in all cirrhotic stages, while the evidence suggests that HCC incidences
are different depending on the liver fibrosis stage (144, 73, 173). Lastly, the existing
studies only consider a fixed surveillance interval throughout patients’ lifetimes (i.e.
routine policies). However, patients’ life expectancy and thus the value of a surveil-
lance strategy is likely to change with age, which suggests that policies adjusted by
age may outperform routine policies.
3.3 Model formulation
In this section, we first formulate a stochastic disease progression model to character-
ize the disease dynamics and clinical process in Section 3.3.1. Then in Section 3.3.2,
we provide a base MIP formulation for identifying the optimal surveillance policy.
Later, in Section 3.3.3, we extend our base MIP formulation to enforce M-switch
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policies, a class of structured policies, that are practical for implementation.
Our target population for HCC surveillance are hepatitis C-infected people who
are aware of their infection and fibrosis stage. We take a societal perspective where
the objective is to optimize cost-effectiveness of population-based surveillance poli-
cies in the target population. The effectiveness, or the health outcome, of a policy is
measured in terms of total expected quality-adjusted life years (QALYs), which simul-
taneously measure quantity and quality of life (85, 64). The cost of a policy includes
the costs of surveillance tests, diagnostic tests, fibrosis-related maintenance care, and
HCC treatment. We start with providing formal definitions of cost-effectiveness,
willingness-to-pay, and net monetary benefit, which are commonly used concepts in
the health economics literature.
Definition 3.1 (Drummond et al. 2005) Let Π be the policy space, E(π) and
C(π) be the total QALYs and costs of a policy π ∈ Π, and π0 ∈ Π be the comparator
policy.
• Incremental cost-effectiveness ratio (ICER) of policy π compared with π0 is
defined as
ICER = ∆C/∆E, where ∆C = C(π)− C(π0) and ∆E = E(π)− E(π0).
• Willingness-to-pay (WTP) value λ> 0 is defined as the cost that the society
is willing to pay for an additional QALY, representing the acceptable cost-
effectiveness threshold.
• A policy π is said to be more cost-effective than policy π0 if ∆E > 0, ∆C >
0, and ICER < λ.
• A policy π is said to be dominated by policy π0 if ∆E < 0 and ∆C > 0.
• The net monetary benefit, often referred to as net benefit (NB), of policy π is
defined as NB(π) = λE(π)− C(π).
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The notion of ICER has been used extensively for comparing two health interven-
tion programs: if a new program can improve health outcomes at a reasonable price
which is acceptable to the society (i.e., maintaining ICER below the WTP thresh-
old), it is considered more cost-effective than the comparator. NB is later proposed
by Stinnett and Mullahy (208). The policy with the maximum NB is known to be
the most cost-effective one ((74), also see a formal proof as Lemma B.1 in Appendix
B.3.2), and therefore NB has been commonly used to choose the most cost-effective
intervention among multiple alternatives.
3.3.1 Disease natural history model
In line with the published studies in clinical literature (51, 13), we model the dis-
ease progression as a discrete-time finite-horizon Markov process. We assume that
surveillance frequency is at most every 3-month, the minimum surveillance interval
considered in clinical practice (236). Let k ∈ N = {1, 2, · · · , N} be the time index
where each period represents three months. The components of the Markov model
are defined as follows.
• f ∈ F = {0, 1, 2}: Fibrosis state, which reflects the severity of degradation in
liver functioning and can be easily assessed by non-invasive tests (40). Specifi-
cally, 0 represents advanced fibrosis (F3), 1 represents CC, and 2 represents DC.
Hereinafter, we refer to the patients with fibrosis state f as the f -subpopulation.
• h ∈ H = {0, 1, 2, 3}: Tumor state, representing HCC (i.e., tumor, or cancer)
stage, where 0 represents cancer-free state, and 1, 2, and 3 represent small,
medium, and large HCC, respectively. As noted earlier, HCC state definitions
are based on the BCLC staging system: small HCC (h = 1) corresponds to
very early stage (BCLC-0), medium HCC (h = 2) corresponds to early stage
(BCLC-A), and large HCC (h = 3) corresponds to late stage (BCLC-B/C/D).
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• S = Sd ∪Se: State space, including disease states Sd and absorbing states
Se. Disease states, Sd = {(f, h) : f ∈ F , h ∈ H }, consist of fibrosis state
(f) and tumor state (h). Absorbing states, Se = {PTX,DLD,DOC}, include
post-treatment state (PTX), death from liver disease (DLD), and death from
other causes (DOC).
• P|S |: State distribution space, which is a probability simplex of |S | dimensions
and includes all possible distributions over the state space S .
• a ∈ As: Available action to take in state s ∈ S . We let As = {W,E} for s ∈ Sd,
where W and E represent Wait and Examine (Screen) actions, respectively, and
As = {W} for s ∈ Se, as there is no decision in absorbing states.
• π: HCC surveillance policy, which specifies screening actions to be taken for
each f -subpopulation at every time period, given the underlying state distri-
bution in the population, i.e., π : P|S | ×N 7→ {W,E}|F |. For example, given
the distribution of the tumor states, a surveillance policy may recommend no
screening in F3 and CC subpopulations and screening in DC subpopulation in
a given period. In order to compute the HCC distribution at any given time
period, it is sufficient to know the initial state distribution and prior sequence of
actions, because the distribution in each subsequent period only depends on the
action taken and the distribution at the previous period. As such, policy π is re-
duced to a function that maps the triplet of an initial HCC distribution, a time
period, and an f -subpopulation to an action, i.e., π : P|S |×N ×F 7→ {W,E}.
Properties and structures of surveillance policies are discussed in more detail in
Section 3.3.3.
• O(o|(f, h)), o ∈ {+,−}: Observation probability, representing the probability
of observing test outcome o given the true underlying disease state (f, h). The
test outcome o represents the final result of a two-step surveillance-diagnostic
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process, where o is positive (+) if both surveillance and diagnostic tests are
positive. Observation probabilities are specified by test accuracies, which are
characterized by sensitivity (the probability of a positive outcome given that the
patient has HCC) and specificity (the probability of a negative outcome given
that the patient is cancer-free). Let senss and sensd denote the sensitivity
of the surveillance and diagnostic tests, respectively. Similarly, let specs and
specd denote the specificity of surveillance and diagnostic tests, respectively.
We assume perfect specificity for diagnostic tests, which is reasonable because
specificity of HCC diagnosis tests is typically greater than 95% (188, 133) and a
false positive diagnosis of liver cancer is rare in practice. Then, for any f ∈ F ,
we can compute observation probabilities as follows:
O (o|(f, h)) =

sensssensd, if o = +, h ∈ {1, 2, 3}
1− sensssensd, if o = −, h ∈ {1, 2, 3}
(1− specs)(1− specd) = 0, if o = +, h = 0
specs + (1− specs)specd = 1, if o = −, h = 0
• Pk(s′|(f, h),W),∀(f, h) ∈ Sd, s′ ∈ S : Natural progression probability, i.e.,
the probability of transition from state (f, h) ∈ Sd in period k to s′ ∈ S
in the next period, given the action a = W. For transitions to death states,
Pk(DLD|(f, h),W) represents excess mortality due to specific liver disease state
(f, h) and Pk(DOC|(f, h),W) represents background mortality (i.e., other-cause
mortality).
• Pk(s|s,W) = 1,∀s ∈ Se : Absorbing states have self-transition probability of 1.
• Pk(s′|(f, h),E): Transition probability that a patient will be in state s′ ∈ S in
period k + 1, given that he is in state (f, h) ∈ Sd and takes Screen action in
period k. Cancer-free patients (i.e., h = 0) do not need treatment, and thus the
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state transitions simply follow the natural progression, i.e., Pk(s
′|(f, 0),E) =
Pk(s
′|(f, 0),W), ∀f ∈ F , s′ ∈ S . For patients with HCC (i.e., h ∈ {1, 2, 3}),
either the tumor could be detected and patients then receive immediate treat-
ment, i.e., Pk(PTX|(f, h),E) = O(+|(f, h)) = sensssensd; or the tumor could
be missed by screening tests and hence patients follow the natural history until
the next surveillance test, i.e., Pk(s
′|(f, h),E) = O(−|(f, h))Pk(s′|(f, h),W) =
(1 − sensssensd)Pk(s′|(f, h),W), ∀f ∈ F , s′ 6= PTX (see Figure 3.1 for an
illustration of state transitions).






































Figure 3.1: State transition diagram.
Note. Health states are two dimensional, including fibrosis state and tumor state;
absorbing states include death states and post-treatment (PTX) state. Progression
can occur in fibrosis and tumor states simultaneously in one period. Transition to
post-treatment state is possible only when the action is screening E.
• qk(s, a, s′) and ck(s, a, s′), k = 1, · · · , N − 1: Intermediate QALYs and costs,
respectively, for taking action a, given that a patient is in state s at period
k and transits to state s′ in period k + 1. A Screen action incurs additional
costs of surveillance and possible diagnostic tests. In particular, with respective
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probabilities (1 − specs) and senss, a cancer-free patient and a cancer patient
will undergo diagnostic tests to confirm the surveillance test results. Therefore,
we define the test costs for cancer-free patients (i.e., h = 0) as κ0 := cs +
(1 − specs)cd, and for patients with missed cancers (i.e., h ≥ 1 and s′ 6= PTX)
as κ1 := cs + sensscd, where cs and cd represent the cost of surveillance and
diagnostic tests, respectively. We remark that while specificity of surveillance
test does not affect state transitions, it affects cost calculations because lower
specificity (i.e., higher false positive rate) leads to more costly further diagnostic
tests. Thus, when either the patient is cancer-free or his cancer is missed by
screening and diagnostic tests (i.e., s′ 6= PTX), the expected intermediate costs





′) + κ0, if h = 0,
ck((f, h),W, s
′) + κ1, if h ≥ 1.
When s′ = PTX, qk(s,E,PTX) and ck(s,E,PTX) represent the lump-sum QALYs
from treatment capturing the cumulative remaining life expectancy adjusted by
quality of life under treatment, and the cumulative cost of surveillance, diagno-
sis, and treatment, respectively.
• qk(s, a) and ck(s, a), k = 1, · · · , N−1: Expected QALYs and costs accumulated
in state s when action a is taken in period k, which are respectively computed
as qk(s, a) =
∑
j∈S qk(s, a, j)Pk(j|s, a) and ck(s, a) =
∑
j∈S ck(s, a, j)Pk(j|s, a),
for k = 1, · · · , N − 1.
• qN(s) and cN(s): Terminal QALYs and costs in state s ∈ S , respectively.
• rk(s, a) for k = 1, · · · , N − 1 and rN(s): Expected NB accumulated in period
k given state s and action a, and the terminal NB for state s, respectively.
The intermediate NB is computed as rk(s, a) = λqk(s, a) − ck(s, a) for k =
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1, · · · , N − 1, and the terminal NB is computed as rN(s) = λqN(s)− cN(s).
3.3.2 The base model
In a proper HCC surveillance policy, patients in a given f -subpopulation should be
recommended the same screening action. That is, patients with the same fibrosis state
f should share the same screening action, regardless of their true tumor states. This
implies that the surveillance policy inherently depends on the underlying distribution
of HCC states (i.e., the cancer prevalence). Thus, our problem in principle can be
formulated as a continuous-state dynamic program, and be considered a special case
of a POMDP without belief updates. However, POMDP models for problems of our
size suffer from the “curse of dimensionality” and are notoriously difficult to solve.
Indeed, in Appendix B.1, we develop and present such a POMDP model formulation
for our problem and report its performance. As we show there, suffering from the
curse of dimensionality, even a simplified POMDP model without the M-switch policy
structure cannot be solved for more than a few iterations.
Hence, we turn our attention to alternative modeling approaches and instead pro-
pose an MIP-based model formulation, which naturally allows formulation of struc-
tured policies without losing computational tractability. It is well-known that sequen-
tial decision making problems can be modeled and solved using linear programming
(LP) (112, 11). Building upon this LP-based modeling framework, we first present
a base HCC surveillance (HS) MIP model , which ensures that actions are adapted
to f -subpopulations, irrespective of unobservable tumor states, as follows. Later in































PN−1(s|j, a)xN−1(j, a) = xN(s), ∀s ∈ S , (3.3)
∑
a∈As
x1(s, a) = α(s), ∀s ∈ S (3.4)
xk(s, a) ≤ yk(s, a), ∀s ∈ S , a ∈ As, k = 1, · · · , N − 1, (3.5)∑
a∈As
yk(s, a) = 1, ∀s ∈ S , k = 1, · · · , N − 1, (3.6)
yk((f, h), a) = yk((f, h
′), a),
∀f ∈ F , h, h′ ∈H ,∀a ∈ A(f,h), k = 1, · · · , N − 1, (3.7)
xk(s, a), xN(s) ≥ 0, ∀s ∈ S , a ∈ As, k = 1, · · · , N − 1, (3.8)
yk(s, a) ∈ {0, 1}, ∀s ∈ S , a ∈ As, k = 1, · · · , N − 1, (3.9)
where α(s) is the initial distribution of state s, and γ is the discount factor. xk(s, a) is
the occupancy measure (11), which can be interpreted as the (discounted) joint prob-
ability of being in state s and choosing action a in period k, i.e., if we let random vari-
ables Sk and Ak to denote the state and action at time t, then xk(s, a) = γ
k−1P(Sk =
s, Ak = a). The objective function (3.1) maximizes the expected total discounted
NB. Constraints (3.2) and (3.3) represent the flow balance equations capturing the
dynamic updates for the occupancy measures over time, which can be easily veri-








a∈Aj P(Sk+1 = s|Sk =
j, Ak = a) = γ
kP(Sk+1 = s) =
∑
a∈As γ
kP(Sk+1 = s, Ak+1 = a) =
∑
a∈As xk+1(s, a).
Constraint (3.4) captures the initial condition for the system dynamics.
We consider only deterministic (i.e., non-randomized) policies because randomized
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policies (e.g., screen 50% of the CC patients) are not practical to implement. Let
yk(s, a) be an indicator variable, which equals to 1 if action a is chosen at state s ∈ S
in period k, and 0 otherwise. Then, Constraint (3.5) links the occupancy measures
and indicator variables, and Constraint (3.6) ensures the policy to be deterministic.
Lastly, Constraint (3.7), which we call the state-linking equation, ensures that the
same action is taken in the same fibrosis state, irrespective of the tumor states.
3.3.3 Construction of M-switch policies and the full model
The solution to HS leads to a fully dynamic policy, where intervals between surveil-
lance tests may be irregular and may change frequently over time. For example, in
a fully dynamic policy as illustrated in Figure 3.2, a specific f -subpopulation may
be recommended to undergo surveillance following 6, 3, 12, and then again 6 months
surveillance intervals subsequently.
Figure 3.2: A schematic diagram of different types of policies for one f -subpopulation.
Note. 6m represents 6-month, and so forth.
While from a theoretical point of view the fully dynamic policy is optimal among
all feasible HCC surveillance policies, such a policy would be difficult to implement
due to frequently changing surveillance intervals. In contrast, routine policies sim-
ply recommend a single fixed surveillance interval for all patients throughout their
lifetimes, irrespective of their fibrosis stage and age (see Figure 3.2). While routine
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policies are practical due to their simplistic form, they, on the other hand, may not
well capture the dynamics of disease progression over time, and thus may have a poor
performance.
To balance the effectiveness of the fully dynamic policy and the practicality of
routine policies, we consider another class of structured policies, which we call M-
switch policies. In M-switch policies, we allow switches in surveillance intervals but
explicitly limit the total number of switches. Specifically, for each f -subpopulation,
surveillance intervals are allowed to change at most M times until surveillance ter-
minates in that f -subpopulation (see Figure 3.2). For instance, in a 1-switch policy,
surveillance intervals for CC subpopulation can be 6 months until age 60, and switch
to one year afterwards. We remark that while we optimally determine the terminal
age, terminating surveillance is not counted as an additional switch in an M-switch
policy.
We are especially interested in two special cases where M = 0 or M = 1. In a 0-
switch policy (i.e., M = 0), surveillance intervals do not change until the surveillance
terminates, but they are stratified by fibrosis states and can be different across f -
subpopulations. Therefore, we call such policies stratified policies. A 1-switch policy
(i.e., M = 1) can have at most one switch in surveillance intervals until surveillance
terminates for each f -subpopulation, which enables the surveillance strategy to con-
sider and adapt to the aging effects in the population. Yet, compared with a fully
dynamic policy, such a policy has much fewer changes in surveillance intervals, and
hence is easier to follow. Maillart et al. call 1-switch policies as “two-phase policies”
and compares more than 1200 such policies via explicit enumeration (148).
Remark 3.1 Although M-switch policies have a much simpler structure compared
with the fully dynamic policies, the total number of M-switch policies is still pro-
hibitively large for explicit enumeration within a reasonable computation time. For
example, to determine a 1-switch policy in a practical setting which we shall specify
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shortly, we will choose the switching and terminating period from 100−40
4
possible time
points (i.e., every 4 years from age 44 to 100), select 2 different surveillance intervals
from a list of 5 intervals for the periods before and after the switching period respec-
tively, and repeat such selection for all 3 different f -subpopulations. Thus, the total







∼ 9.3× 109. Assuming
that evaluating each policy takes about 0.005 seconds, it takes 9.3×109×0.005/(3600×
24) days > 1.4 years to evaluate all such possible policies.
Now we introduce the mathematical formulation for M-switch policies. Let d
be the screening interval, and D be the set of possible screening intervals. For no
surveillance, we define screening interval d = ∞. Surveillance intervals can only
change every C periods, called a switching cycle, which is a common multiple of all
possible intervals {d ∈ D : d 6=∞}. Let l ∈ L = {1, 2, · · · , dN−1
C
e} be the index for
the switching cycles and Ji denote the set of screening periods with interval length
di∈ D . Then,
Ji =

{1 + ndi : n = 0, 1, · · · , Cdi − 1} for di <∞,
∅ for di =∞.
3.3.3.1 Formulation with nested structure of screening intervals
Because practical cancer screening strategies typically consider every 3-month, semi-
annual, annual, and biennial screenings, they naturally form a “nested structure”.
That is, screening periods J1 ⊃J2 if screening interval d1 ≤ d2. For example, Figure
3.3 illustrates the screening periods J for d ∈ D = {d1 = 1, d2 = 2, d3 = 4, d4 =
8, d5 = 16, d6 = ∞}, which represent three-month, semiannual, annual, biennial,
four-year, and no surveillance, respectively, with a cycle length C = 16 (i.e., 4 years).
In this section, we first present the model formulation for cases where such a nested
structure exists. Later, in Section 3.3.3.2, we extend this and present a more general
model formulation.
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Figure 3.3: Surveillance periods for different surveillance intervals in one switching
cycle.
Clearly, we observe J1 ⊃J2 ⊃ · · · ⊃J6, which implies that surveillance periods
in a less aggressive policy (i.e., a policy with larger surveillance intervals) is a subset
of those in a more aggressive policy. This nested structure implies that given a
policy Ji+1, we can construct a more aggressive policy Ji by adding all surveillance
periods in Ji\Ji+1 to Ji+1 (see Figure 3.3, where the set of surveillance periodF’s
in each row i corresponds to Ji\Ji+1). For example, we can construct semiannual
surveillance policy J2 by adding additional surveillance at periods J2\J3 to annual
surveillance policy J3. We can generalize this as Ji = ∪5i′=i(Ji′\Ji′+1) for i =
1, · · · , 5, where (Ji′\Ji′+1)’s are disjoint.
We let I denote the set of interval identifiers, which means that the surveillance
interval d in one cycle is uniquely determined by the actions at periods in I . In par-
ticular, given {Ji} considered in this problem, we have I = {1, 2, 3, 5, 9} (see Figure
3.3). For example, for any given cycle l ∈ L , the case that y(l−1)C+j((f, h),E) = 1
for j ∈ {1, 5, 9} and y(l−1)C+j′((f, h),E) = 0 for j′ ∈ {2, 3} represents every 12-month
surveillance in f -subpopulation.
Based on these arguments, we first introduce the following two constraints, which
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ensure that each switching cycle is designated to a specific surveillance interval.
y(l−1)C+j((f, h),E) ≤ y(l−1)C+j′((f, h),E),
∀l ∈ L , f ∈ F , h ∈H , j ∈Ji\Ji+1, j′ ∈Ji+1, i = 1, 2, 3, 4, (3.10)
y(l−1)C+j((f, h),E) = y(l−1)C+j′((f, h),E),
∀l ∈ L , f ∈ F , h ∈H , j, j′ ∈Ji\Ji+1, i = 1, 2, 3, 4, 5, (3.11)
where Constraint (3.10) reflects the nested structure of {Ji}: if we choose any surveil-
lance period in Ji\Ji+1, we must also choose all the periods in Ji+1. Constraint
(3.11) ensures that the same action is taken in all periods in Ji\Ji+1. We remark
that if N−1
C
is not integral, Constraints (3.11) and (3.10) hold for periods k ≤ N − 1
in the last (incomplete) cycle l = dN−1
C
e.
Next, we formulate the number of interval switches using additional constraints.
Since terminating surveillance (i.e., switching to no screening J6 = ∅ in the next
cycle) is not counted as a separate switch, we first need to determine whether surveil-
lance terminates in the next period or not. For this purpose, we define a binary
variable zl,f and let it equal 0 if f -subpopulation has no surveillance in cycle l, and
1 otherwise. We remark by Constraint (3.10), y(l−1)C+1((f, h),E) = 0 implies that
actions in all periods in cycle l are Wait. Therefore, to determine the value of zl,f , it
is sufficient to check the value of y(l−1)C+1((f, h),E). That is,
zl,f = y(l−1)C+1((f, h),E), ∀l = 1, · · · , |L |, f ∈ F , h ∈H , (3.12)
zl,f ∈ {0, 1}, ∀l = 1, · · · , |L |, f ∈ F . (3.13)
Also, to determine the change of surveillance intervals across cycles, we define a
binary variable wl,f and let it equal 1 if surveillance interval for the f -subpopulation in
cycle l switches to a different non-stopping interval in the next cycle, and 0 otherwise.
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Then,
wl,f − (1− zl+1,f ) ≤
∑
j∈I
|y(l−1)C+j((f, h),E)− ylC+j((f, h),E)|
≤ |I |(wl,f + 1− zl+1,f ), ∀l = 1, · · · , |L | − 1, f ∈ F , h ∈H , (3.14)
|L |−1∑
l=1
wl,f ≤M, ∀f ∈ F , (3.15)
y(l−1)C+1((f, h),E) ≥ ylC+1((f, h),E), ∀l = 1, · · · , |L | − 1, f ∈ F , h ∈H , (3.16)
wl,f ∈ {0, 1}, ∀l = 1, · · · , |L | − 1, f ∈ F . (3.17)
In Constraint (3.14), the set I represents the set of interval identifiers that we defined
earlier. Constraint (3.14) becomes redundant if surveillance stops in cycle l + 1 (i.e.,
zl+1,f = 0); otherwise, it ensures that wl,f = 1 if and only if the screening actions in
the interval identifier periods of cycle l do not exactly match with those in the next
cycle l + 1 (i.e., surveillance interval in cycle l changes to a different non-stopping
surveillance interval in cycle l+1). Constraint (3.15) explicitly restricts that intervals
can switch at most M times for each fibrosis state f . Lastly, Constraint (3.16) ensures
that once surveillance terminates at some period, there will be no more surveillance
thereafter. Note that Constraint (3.14) can be linearized by change of variables using
x = x+ − x− and |x| = x+ + x− where x+, x− ≥ 0.





NB(x) s.t. (3.2)− (3.17)
}
(3.18)
3.3.3.2 General formulation without nested structure of screening intervals
While the screening intervals in our problem have a nested structure, in the follow-
ing, we provide a more generalized formulation, which do not require such a nested
structure, and can be useful in some other problems.
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As stated earlier, the cycle length C needs to be a common multiple of all possible
intervals {d ∈ D : d 6= ∞}. Since the nested structure is not assumed here, it is not
sufficient to have C = max{d ∈ D : d 6=∞}. For example, the minimal C is 4 years
if possible intervals include 0.5, 1, 2, and 4 years; whereas it is 6 years if possible
intervals include 0.5, 1, 2, and 3 years.
We define binary variable δfl,i to be 1 if screening interval is di ∈ D for cycle l ∈ L
in f -subpopulation, and 0 otherwise. We have the following constraints for screening
interval assignment in each cycle l:
y(l−1)C+j((f, h), a = E) ≥ δfl,i,
∀f ∈ F , h ∈H , j ∈Ji, i ∈ {1, · · · , |D |}, (3.19)
y(l−1)C+j((f, h), a = E) ≤ 1− δfl,i,
∀f ∈ F , h ∈H , j /∈Ji, i ∈ {1, · · · , |D |}, (3.20)
|D |∑
i=1
δfl,i = 1, ∀ f ∈ F , l ∈ L , (3.21)
δfl,i ∈ {0, 1}, ∀ f ∈ F , l ∈ L , i ∈ {1, · · · , |D |}. (3.22)
Constraints (3.19) and (3.20) ensure that, if interval di is selected for f -subpopulation
in cycle l (i.e., δfl,i = 1), periods of Ji in that cycle must have screening action (E),
and the other periods in that cycle have no screening (W). Both constraints will
become redundant if δfl,i = 0. Constraint (3.21) guarantees that one and only one
interval is selected for cycle l.
To determine whether the screening interval switches from cycle l to l+1, we only
need to check the values of δfl,i and δ
f

















l+1,i| only takes two values: it equals 1 if the screening
interval switches from cycle l to l+1, and 0 otherwise. When zl,f = 1 (i.e., surveillance
46







δfl+1,i| which is trivially true by the definition of wl,f ; when zl,f = 0, Constraint (3.23)
becomes redundant as stopping surveillance (i.e., switching to d =∞) is not counted
as a switch.
In addition to these constraints, as in the nested formulation, we also need Con-
straints (3.12)-(3.13) to determine whether surveillance is “empty” in the next period
l+1 for fibrosis state f , and Constraints (3.15)-(3.17) to bound the number of switches.
To sum up, the general formulation for M -switch policy without nested structure




NB(x) s.t. (3.2)− (3.9), (3.12)− (3.13),
(3.15)− (3.17), (3.19)− (3.23)
}
(3.24)
In Appendix B.2, we show that this general formulation can be reduced to the
nested-structure formulation presented in (3.18), when the nested structure in screen-
ing intervals exist.
Remark 3.2 Using our modeling framework, we can also formulate another class of
practical surveillance policies, interval-switching policies, by choosing a long switch-
ing cycle (e.g., 10 years or 20 years) and not specifying the limits on the number of
switches (i.e., by removing Constraint (3.12)-(3.17)). This class of structured policies
are suitable when policy-makers are interested in identifying age group-based surveil-
lance policies, such as determining the surveillance policies for patients of age 40-49,
50-59, and each subsequent 10-year age groups.
3.4 Analytical Results
In this section, we explore structural properties of the HCC surveillance problem,
which may provide useful insights for decision-makers in developing effective surveil-
lance policies. We have three main results: 1) we identify the sufficient conditions
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under which additional surveillance improves the cost-effectiveness of a policy (Propo-
sition 3.1); 2) we characterize when the surveillance policies should be adapted to
populations with different disease progressions (e.g., genotype 3 hepatitis C virus in-
fection has faster fibrosis progression than other genotypes, see Theorem 3.1); and 3)
we quantify the trade-off between decreasing HCC incidence and increasing treatment
outcomes (as is happening in current practice), and characterize their net effect on
the surveillance policies (Theorem 3.2). All proofs are provided in Appendix B.3.
We start with introducing additional notations which are used in our analytical
results. We first define augmented tumor states H = H ∪ {4} where state 4 repre-
sents all absorbing states as one aggregated state. Hence, the state space defined in
Section 3.3 is equivalent to S = F ×H . Throughout this section, we refer to h as
an augmented tumor state h ∈ H unless its range is explicitly specified. As before,
subscript k represents the time index in all of the following notations.
H = H ∪ {4} Augmented tumor states where state 4 represents all absorbing
states as one aggregated state
H + = {1, 2, 3} Cancer states, including small, medium, and large HCC tumors
Fk = [Fk(f
′|f)] Transition matrix for progression in fibrosis states
Hk(f) = [Hk(h
′|h, f)] Transition matrix for progression in augmented tumor states h ∈
H given the fibrosis state f
Rk(f, h) Lump-sum NB of HCC treatment for state (f, h), h ∈H +
Wk(f, h) Lump-sum NB for state (f, h), for h ∈H + if treatment is delayed
to the next period
∆Qk(f, h), ∆Ck(f, h) QALY and cost components in the incremental net benefit of
immediate treatment, respectively, i.e., Rk(f, h) − Wk(f, h) =
λ∆Qk(f, h)−∆Ck(f, h)
V πk (f, h) Value function of state (f, h) for given policy π
bk(f, h) State distribution over F ×H (i.e., percentage of population in
state (f, h))
ζ = sensssensd Probability that a cancer will be detected and diagnosed
∆t(f) Marginal surveillance benefit for f -subpopulation at period t
Several useful properties for some of the above quantities are presented in the
preliminaries in Appendix B.3.1, which are used in proving some key results in this
section.
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Throughout this section, we make the following reasonable assumptions, which
are in line with the evidence from the medical literature and our data analysis.
Assumption 3.1 The joint transition probability for natural progression
Pk((f
′, h′)|(f, h),W) is specified by Pk((f ′, h′)|(f, h),W) = Hk(h′|h, f)Fk(f ′|f), ∀f, f ′ ∈
F , h, h′ ∈H .
This assumption implies that tumor progression depends on fibrosis stage, but not
vice versa (144, 173).
Assumption 3.2 For each disease state (f, h) ∈ Sd and k = 1, · · · , N−1, treatment
NB Rk(f, h), intermediate NB rk((f, h),W), and terminal NBs rN(f, h) and RN(f, h)
have the following properties:
1. Non-negativity,
2. Monotonicity: decreasing in f ∈ F and h ∈H , and
3. Terminal values rN(f, 0) ≥ RN(f, h) ≥ rN(f, h) for all f ∈ F and h ∈H +.
In Assumption 3.2, the second condition implies that the worse the health state, the
lower the NB; and the last condition implies that for the same fibrosis state, the
terminal NB is highest in cancer-free state, followed by cancer state with treatment,
and is lowest in cancer state without treatment. Throughout the paper, we use
“decreasing” to refer to “non-increasing” for simplicity.
Assumption 3.3 For cancer patients with small and medium-sized tumors, NB of
immediate treatment is no worse than delaying the treatment until the next period.
For cancer patients with large tumors, the total NB of immediate treatment is at least
κ1
ζ
higher than that of delayed treatment. That is, for any f and k, (1) Rk(f, h) ≥
Wk(f, h), h = 1, 2 and (2) Rk(f, h) ≥ Wk(f, h) + κ1ζ , h = 3.
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In Assumption 3.3, the difference between the immediate and delayed treatment
(i.e., Rk(f, h) − Wk(f, h)) can be interpreted as the opportunity reward of timely
treatment for cancer patients. It is reasonable to assume that such opportunity
reward should be non-negative as there is no clinical benefit for delaying liver cancer
treatment. Especially for advanced stage liver cancer (i.e., h = 3), which is a fatal
condition when left untreated, liver-disease related mortality is very high. As such,
the opportunity reward is higher in such patients, and should be at least worth the
screening cost per detected cancer case (κ1/η) so that treatment benefit can offset
the “average” screening cost.
We remark that Screen action is clearly not always the better action for maximiz-
ing the cost-effectiveness, because additional surveillance tests will increase cost but
not necessarily health outcomes. Let πk(f) denote the decision for f -subpopulation
in period k where the dependency of policy π on the initial state distribution is
suppressed for simplicity of the notation. To examine the value of the additional
surveillance test for a specific f -subpopulation at period t, for any given policy π,
we can construct a pair of policies π1 and π2 such that π1 has Wait action and π2
has Screen action in period t for this given f -subpopulation, and actions in these two
policies are the same elsewhere, i.e.,
π1t (f) = W, π
2





′) if f ′ 6= f or k 6= t. (3.25)
We remark that the definitions of π1 and π2 depend on the specific time period
t and specific fibrosis state f at which the two policies differ. However, again for
simplicity of the notation, we drop these dependencies in the remainder of the analysis.






t (f, h)− V π
1
t (f, h)], (3.26)
which represents the expected incremental NB value by having a surveillance test com-
pared with no screening in the given f -subpopulation at period t. In Proposition 3.1,
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we provide a sufficient condition under which Screen is better than Wait action, i.e.,
an additional surveillance test improves the policy NB and thus the cost-effectiveness.
Proposition 3.1 Let π1 and π2 be two identical policies except that the action is
Wait in π1 and Screen in π2 for a specific f -subpopulation in period t, as defined in












h∈H + bt(f, h)∆Ct(f, h)∑
h∈H + bt(f, h)∆Qt(f, h)
≤ λ. (3.27)
A careful examination of (3.27) reveals that the left-hand-side indeed represents an
upper bound on the ICER for performing an additional surveillance in f -subpopulation.
In particular, the denominator represents the incremental QALYs for cancer patients
by having immediate treatment compared with delaying treatment by one period,
and the numerator represents the incremental costs, which consist of (1) expected
surveillance cost per treated HCC case (therefore scaled by the factor 1/ζ) and (2)
expected additional cost by immediate treatment. Thus, Proposition 3.1 can be in-
terpreted as follows: cancer patients can achieve higher QALYs by timely treatment,
which, however, is only possible by performing surveillance in all patients including
those who actually are cancer-free and will not benefit from treatment. Considering
such extra spending, if the overall ICER is still below the acceptable WTP value, per-
forming a surveillance test is indeed beneficial and provides a good value for money.
This condition further implies that the followings are the incentives for more frequent
surveillance: 1) improved treatment NB, 2) improved sensitivity for the surveillance
test, 3) increased cancer prevalence, and 4) reduced surveillance and diagnostic test
costs.
Next, we introduce a definition for comparing transition matrices, which is needed
in the following results.
51
Definition 3.2 Let P := [Q(j|i)] and Q := [Q(j|i)] be two n × n transition matri-
ces. We say that Q dominates P (or P is dominated by Q), denoted as P  Q, if∑
j≥k P (j|i) ≤
∑
j≥kQ(j|i), ∀i, k = 1, · · · , n.
Hereinafter, we make the following additional assumptions for the following re-
sults.
Assumption 3.4 Transition matrices {Fk,Hk(f)} have following properties:
1. (Irreversible disease) Fk(f
′|f) = 0 if f ′ < f and Hk(h′|h, f) = 0 if h′ < h,
2. (Accelerated progression) Fk(f
′|f) ≤ Fk(f ′|f+1) for f+1 ≤ f ′ and Hk(h′|h, f) ≤
Hk(h
′|h+ 1, f) for h+ 1 ≤ h′, and
3. Hk(f)  Hk(f ′) for f ′ ≥ f in any period k.
In Assumption 3.4, the first condition implies that the disease progression under
natural history is irreversible, i.e., patients cannot regress to a healthier state spon-
taneously without treatment. The second condition implies that patients in a worse
health state are more likely to further progress to even worse states. We remark
that the first two conditions imply a more general structure commonly assumed in
medical decision making, known as the increasing failure rate (IFR) property (cf.
(46, 18, 6, 243, 187)), which implies that disease progression accelerates as the dis-
ease condition worsens. Lastly, the third condition implies that tumor progression is
more aggressive in patients with a more advanced fibrosis stage.
Assumption 3.5 Sensitivity and specificity of surveillance test are greater than 50%.
Assumption 3.6 Let q′k(f, h), c
′
k(f, h), and ρk(f, h) respectively represent the ex-
pected QALYs, costs, and survival probabilities under treatment for a detected can-
cer state (f, h), f ∈ F , h ∈ H + in period k. At any period k and for any f -
subpopulation:
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1. Expected intermediate QALYs accumulated during treatment for small HCC is
no higher than that of cancer-free state (i.e., q′k(f, 1) ≤ qk((f, 0),W)),
2. Expected intermediate cost of treatment for small HCC is no lower than ex-
pected intermediate cost in cancer-free state plus the test costs (i.e., c′k(f, 1) ≥
ck((f, 0),W) + κ0),
3. One period survival probability after treatment for small HCC is no higher than
the probability that a cancer-free patient will remain in cancer-free state during
the same period (i.e., ρk(f, 1) ≤ Pk((f, 0)|(f, 0),W)).
Assumption 3.6 implies that cancer-free state (i.e., h = 0) is better (in terms of
QALYs, costs, and disease progression) than small HCC state (i.e., h = 1) even under
treatment. Next, we present Proposition 3.2, where we show that for any policy π,
the value function decreases as disease progression becomes more aggressive, which
we use in proving Theorem 3.1.
Proposition 3.2 For a given policy π, let V 1k and V
2
k be the value functions associ-
ated with disease progression parameters {F1k,H1k(f)} and {F2k,H2k(f)}, respectively.
If F1n  F2n and H1n(f)  H2n(f) ∀f ∈ F and n ≥ k, then V 1k (f, h) ≥ V 2k (f, h),∀f ∈
F , h ∈H .
Next, in Theorem 3.1, we analyze the effect of disease progression on the value
of surveillance test. We show that a surveillance test leads to a higher marginal
benefit in population with a faster disease progression, which implies that surveil-
lance should be more frequent in such a population. Given the heterogeneity in liver
disease progression, such as accelerated fibrosis progression in patients infected with
genotype 3 hepatitis C virus (26), this result provides practical insights about how
a surveillance policy should be adjusted for certain subpopulation with a different
disease progression rate.
53
Theorem 3.1 As before, let π1 and π2 be two identical policies except that the action
is Wait in π1 and Screen in π2 for f -subpopulation in period t. Let ∆t(f) represent
the marginal surveillance benefit for f -subpopulation in period t, as defined in (3.26).
Suppose two populations are associated with disease progressions {F1k,H1k(f)} and
{F2k,H2k(f)}, respectively, and corresponding marginal surveillance benefits ∆1t (f) and
∆2t (f), respectively. Given the same state distribution {bt(f, h)} in period t, if F1n 
F2n and H
1
n(f)  H2n(f) ∀f ∈ F , and n ≥ t, then ∆1t (f) ≤ ∆2t (f), ∀f ∈ F .
The recent highly effective direct-acting antivirals (DAAs) have significantly changed
the disease prognosis and the landscape in hepatitis C treatment. In that regard, it is
interesting to analyze the effect of such advanced treatment options on the liver cancer
surveillance. On one hand, these new DAAs effectively lower liver cancer risk, which,
by Theorem 3.1, suggests less frequent HCC surveillance. On the other hand, DAAs
also improve survival outcomes of HCC treatment, for example, by reducing the risk of
HCC recurrence after liver transplant and thus improving the post-transplant survival
(53). Hence, such improved treatment benefit motivates more frequent screenings. As
a result, there is a trade-off and the net effect of improved hepatitis C treatment on
optimal HCC surveillance policy is unclear.To examine this trade-off, in Theorem 3.2,
we present a set of sufficient conditions which ensure that surveillance should be no
more frequent as the risk of HCC decreases, while treatment outcomes improve.
Theorem 3.2 For a given f -subpopulation, let ∆1t (f) and {b1k} respectively represent
the marginal surveillance benefit and state distribution for the base case, and ∆2t (f)
and {b2k} respectively represent the corresponding values for the case with reduced
HCC risk and improved treatment outcome. Assume the same initial distributions
b11 = b
2
1 and that the total NB of HCC treatment increases by ∆Rk(f, h) for tumor
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state h ∈H + and k ∈ N . Then, ∆1t (f) ≥ ∆2t (f) if:
a) Rt(f, h)−Rt(f, h+ 1) ≥
(
rt((f, h),W)− rt((f, h+ 1),W)
)













Condition (3.28) implies that early stage HCC has higher treatment NB than a
later stage HCC, and the difference, interpreted as the loss of treatment NB due
to one-stage more advanced HCC, should be at least as high as the difference of
intermediate NBs between the two state (h and h + 1) plus the treatment NB after
a potential progression to a higher state (h+ 1) in the next period. Condition (3.29)
characterizes the trade-off between the treatment benefit for a small group (i.e., cancer
patients) and the surveillance costs for the entire population, whether with cancer or
not. In the right-hand-side of (3.29), the numerator κ0(b
2
t (f, 0)− b1t (f, 0)) represents
the incremental surveillance cost for cancer-free patients as the HCC risk is reduced,
and the denominator represents the number of detected cancer patients—the small
subgroup that will actually benefit from the surveillance. Then, Condition (3.29)
implies that if the incremental treatment benefit is no higher than the incremental
surveillance cost per detected cancer patient, there is no reason to perform more
frequent surveillance.
3.5 Computational Study
In this section, we provide an overview of our parameter estimations, and present our
numerical results for the optimal policies and policy comparisons. All computations
are performed on a workstation with Intel Xeon 2.33 GHz processor and 12 GB RAM,
and MIPs are solved using IBM ILOG CPLEX version 12.6 (Armonk, NY).
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3.5.1 Parameter estimations
We estimate our model parameters using a variety of data sources, including the Hep-
atitis C Antiviral Long-term Treatment against Cirrhosis (HALT-C) trial data (144),
the United Network of Organ Sharing (UNOS) data (168), a previously validated
hepatitis C disease burden simulation model (HEP-SIM) that projects the changing
prevalence of hepatitis C in the US (110), and several published studies. Model pa-
rameters, their base values, and corresponding sources are listed in Tables 3.2 and 3.3.
Below, we provide an overview of our parameter estimations. Details of parameter
estimations and model validations can be found in Appendix B.5.
Study population: In our base case analysis, we study a population starting surveil-
lance at age 40. We do not consider patients below age 40 because the prevalence of
both hepatitis C and HCC is very low before the age 40 (144). We used the HEP-SIM
model (110) to estimate the initial distribution of fibrosis stages and HCC prevalence
in the population (the HEP-SIM model did not consider natural history of HCC,
health utility, and cost, so these parameters are estimated as described below).
Transition probabilities: Transition probabilities in our model depend on disease
progression risks, mortality rates, and test accuracy values. Estimates of progression
risks in non-tumor and tumor states are based on the best available evidence from the
medical literature (217, 73, 144, 173). Excess mortality risks from disease state (f, h)
due to liver disease are estimated from clinical observational studies (54, 91) and
background mortalities for each age group are based on US life tables (15). Lastly,
sensitivity/specificity of surveillance and diagnostic tests are estimated based on the
results in the published literature (13, 182, 50).
We calibrate transition probabilities from cancer-free (h = 0) to small HCC state
(h = 1) based on data from a large clinical trial, the HALT-C trial (144, 60). We
remark that the available estimates of HCC incidences from the literature cannot be
directly used in our model because these estimates are based only on detected HCC
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Table 3.2: Model parameter values
Variables Base value Reference
Natural history parameters
Annual progression risk in F
F3 to CC 0.116 (217)
CC to DC 0.039 (73)
Annual risk of developing small HCC
From F3 0.008 Calibrated based on HALT-C trial
From CC 0.016 Calibrated based on HALT-C trial
From DC 0.078 Calibrated based on HALT-C trial, (173)
Monthly progression risk in H
Small to medium 0.056 (51)




Large HCC 0.750 (91, 13)
Mortality from other causes life tables (15)
Annual transplant probability 0.023 (47)
for DC patients
Test accuracices
Surveillance test: sensitivity 0.75 (13, 143)
Surveillance test: specificity 0.94 (203)
Diagnostic tests: sensitivity 0.90 (50, 182)
Diagnostic tests: specificity 1.00 Model assumption
Quality of life

















CC, compensated cirrhosis; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma.
cases, which are lower than the actual number of new HCC cases. In calibration, we
use the existing incidence estimates as the base values for the corresponding transition
57
Table 3.3: Survivals, utilities, and costs of HCC treatment
Variables Base value Reference
Treatment effectiveness
Liver transplantation
Mean waiting time for transplant
Within the Milan Criteria 158.7 days UNOS data
Outside the Milan Criteria 205.6 days UNOS data
1-year/5-year OS 0.887/0.738 (232)





CC, small HCC 0.69 (140)
CC, medium HCC 0.61 (132)
DC, small /medium HCC 0.31 (132)
Palliative treatment (2-year OS) 0.41 (141)
Quality of life (first/subsequent years)
Liver transplantation 0.69/0.73 (179)





Liver transplantation (first/subsequent years) $95,971/$25,208 (47)
Resection $44,929 (125)
Ablation $20,214 (125)
Palliative treatment $18,539 (125)
OS, overall survival; HCC, hepatocellular carcinoma; CC, compensated cirrhosis;
DC, decompensated cirrhosis; QOL, quality of life.
probabilities, and then increase the values until the percentages of detected HCC cases
evaluated by the model (under similar surveillance strategies as in HALT-C trial) fall
within 95% confidence interval of the estimates from the trial data.
Intermediate NB: To estimate intermediate QALYs, we adjust life years in each
period by fibrosis stage- and age-specific quality of life (QOL), estimated from (49) and
(97). Health-related costs associated with each fibrosis stage are estimated from (47)
and costs of surveillance and diagnostic tests from (13). We adjust the intermediate
NB by half-cycle correction to account for the fact that transitions among states occur
continuously and not necessarily in the beginning or the end of a period (205).
58
Total NB of HCC treatment for each disease state is estimated by taking the
weighted average of NBs for four major types of treatment: resection, liver transplan-
tation, local ablation, and palliative treatment. For each treatment, total QALYs and
costs are evaluated by a separate Markov model (details of which can be found in
Appendix B.5.3), where survival rates and post-treatment QOLs are extracted from
a series of published clinical studies (Table 3.3), and treatment costs are estimated
from a population study using Medicare data (125). The weight for each treatment
(i.e., the treatment distribution) is determined based on the best evidence available
from US population-based studies (13, 70) and expert opinions.
Lastly, in our base case analysis, we consider a switching cycle of 4 years, and
a WTP value of $50,000/QALY to calculate corresponding NB based on QALYs
and costs, which is in line with existing US-based cost-effectiveness studies in HCC
surveillance (14, 13). We conduct extensive sensitivity analyses in Section 3.5.4 and
Appendix B.4.
3.5.2 Optimal policies
In this section, we examine optimal surveillance policies and their implications. In
particular, we seek answers to the following health policy questions: In which fibrosis
stages is surveillance cost-effective? Should surveillance interval depend on fibrosis
stage? What is the overall benefit of fibrosis stage-dependent surveillance policies?
To what extent can dynamic surveillance policies improve cost-effectiveness compared
with routine surveillance policies? Should the surveillance stop in older patients, and
if so, what is the optimal age to terminate surveillance? We evaluate these questions
by presenting the results for different classes of policies considered.
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3.5.2.1 Fully dynamic policy
Figure 3.4 depicts the near-optimal fully dynamic policy (with 0.52% optimality gap
after running the HS model for 16 hours). The dark area represents Screen ac-
tion in each f -subpopulation, and white area represents Wait action. As expected,
surveillance intervals are irregular throughout the planning horizon because we do
not impose any particular structure on this policy. Therefore, such a policy could be
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Figure 3.4: The optimal fully dynamic policy.
Note: Each row represents the policy for one subpopulation.
The optimal fully dynamic policy, however, provides several initial insights. First,
we observe that HCC surveillance is recommended in F3 patients and would be cost-
effective. This is an important clinical finding, because to our knowledge, the cost-
effectiveness of surveillance in this patient cohort has not been evaluated before.
Second, the fully dynamic policy suggests that surveillance intervals should not nec-
essarily be identical in all patients. Instead, different f -subpopulations may need
different surveillance frequencies. For example, surveillance is less frequent in early
stages of hepatitis C (e.g., in F3 patients) and more frequent in advanced stages (e.g.,
in DC patients). Such a stratification by fibrosis stage is meaningful from a clini-
cal perspective, because each f -subpopulation has distinctive clinical features (e.g.,
risk of cancer and disease progression, treatment eligibility and prognosis). Third,
reducing the frequency of surveillance as patients age and ultimately terminating
surveillance at a certain age (depending on the fibrosis stage) is more cost-effective
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than continuing surveillance throughout patients’ lifetimes.
3.5.2.2 M-switch policies
While the optimal fully dynamic policy provides useful insights, we acknowledge that
it may not be practical for implementation. Therefore, we next focus on structured
policies which have more practical appeal. In particular, we present the results of
M-switch policies for various M values (0, 1, and 2) as described in Section 3.3.3.
We first present 0-switch (i.e., stratified) policies, where interval lengths are fixed
(i.e., do not change with age) but could be different for each f -subpopulation (i.e.,
stratified by fibrosis stage). As presented in Figure 3.5, the optimal stratified pol-
icy recommends annual surveillance in F3 and CC subpopulations, and semiannual
surveillance in DC subpopulation. Furthermore, the policy recommends terminating
surveillance earlier in F3 subpopulation, compared with CC and DC subpopulations.
These results further corroborate our findings from the fully dynamic policy that ex-
panding HCC surveillance to F3 patients is cost-effective, but the surveillance should
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Figure 3.5: Optimal 0-switch (stratified) policy.
Note. The area shaded in different colors in each row represents different surveillance
intervals over a certain age range for each subpopulation.
Figure 3.6 presents the optimal 1-switch and 2-switch policies. Compared with the
0-switch policy, these policies recommend more frequent surveillance at earlier ages.
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Figure 3.6: Optimal M-switch policies.
extend surveillance to a higher terminating age. This aging effect is mainly driven by
the decreasing life expectancy in the aging population. These findings also imply that
when more flexibility is allowed in the policy structure, it is reasonable to allocate
more clinical resources for prevention and treatment to younger patients, as early
intervention achieves larger long-term treatment benefit in younger patients.
3.5.3 Policy comparisons
We compare the performance of our proposed surveillance policies against the cur-
rently recommended policies with respect to total expected net benefits, QALYs, LYs,
costs, expected number of surveillance tests, number of HCC detected at each stage,
and number of deaths due to liver disease. We further examine the incremental cost-
effectiveness of each policy. In evaluating routine policies, we first assume that only
cirrhotic patients undergo surveillance tests, as this is the current common clinical
practice (33, 143). Later in Section 3.5.3.2, we also analyze the effect of expanding
surveillance to F3 patients in routine policies.
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3.5.3.1 Comparisons of the M-switch policies
Table 3.4 compares the performances of M-switch policies against no surveillance and
fully dynamic policy. Among all policies considered, as expected, the fully dynamic
policy is the most cost-effective policy. While we acknowledge that such a policy is
impractical, we remark that the results from the optimal fully dynamic policy provide
the maximum NB that can be achieved, which can be used as a benchmark metric
for interpreting our results.
Table 3.4: Policy comparisons
Surveillance
policy
NB QALY LY Cost
# per 1,000 patients
# Tests # HCC detected
DLD
Small Medium Large
No surveillance 336,525 7.398 9.492 33,353 0.0 0 0 0 669
Fully dynamic 347,529 7.794 10.137 42,160 11.6 127 39 7 515
M-switch
0-switch 347,352 7.782 10.119 41,759 10.0 120 42 8 518
1-switch 347,425 7.791 10.133 42,139 11.7 125 39 7 516
2-switch 347,426 7.791 10.133 42,125 11.7 125 39 7 516
NB, net benefit; QALY, quality-adjusted life year; LY, life year; HCC, hepatocellular carcinoma; DLD,
death due to liver disease.
Interestingly, our results show that the NBs of optimal M-switch policies are very
close to that of the optimal fully dynamic policy (Table 3.4). Further, with respect to
all other measures, optimal M-switch policies perform similarly to the fully dynamic
policy. Another interesting finding is that having more than one switch in surveillance
intervals does not substantially improve the outcomes (results of policies with more
than two switches are presented in Appendix B.4.1). This finding implies that 1-
switch policy indeed is clinically very appealing: it achieves desirable performance
close to the optimal fully dynamic policy; yet, unlike the fully dynamic policy, it
has a simple structure and hence is practical for implementation. Therefore, in the
remainder of our analysis, we do not consider policies with more than one switch.
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3.5.3.2 Comparisons with currently recommended policies
Table 3.5: Routine policy comparisons for cirrhotic patients.
Surveillance
policy
NB QALY LY Cost
# per 1,000 patients
# Tests # HCC detected
DLD
Small Medium Large
No surveillance 336,525 7.398 9.492 33,353 0.0 0 0 0 669
Routine policies (cirrhotic patients)
24-month 344,470 7.661 9.923 38,573 3.7 65 42 12 562
12-month 346,323 7.731 10.037 40,225 7.0 96 42 9 537
6-month* 346,538 7.773 10.106 42,133 13.6 125 33 5 524
3-month 344,331 7.794 10.140 45,391 26.6 147 21 3 517
NB, net benefit; QALY, quality-adjusted life year; LY, life year; HCC, hepatocellular cancer; DLD,
death due to liver disease; * : currently recommended policy.
Most current HCC management guidelines recommend every 6-month surveillance
in cirrhotic (i.e., CC and DC) patients, and remain uncertain about the surveillance
frequency in non-cirrhotic (F3) patients (33, 143). Compared with the recommended
6-month surveillance for cirrhotic patients (which appears as the most cost-effective
routine policy when surveillance is offered to only cirrhotic patients), M-switch policies
recommend fewer number of surveillance tests while improving health outcomes (see
Tables 3.4 and 3.5). For example, compared with the 6-month surveillance policy,
1-switch policy saves about 1.9 tests per person. Given that there are about 82,000
hepatitis C patients at risk of HCC in the 40-45 year-old group (110), this leads to
156,000 fewer tests only for this age group. This finding implies that M-switch policies
can utilize limited surveillance and treatment resources in a more efficient way, and
improve cost-effectiveness of HCC surveillance.
We next examine the effect of expanding surveillance to F3 subpopulation in rou-
tine surveillance policies (Table 3.6). This analysis reveals three important findings.
First, expanding surveillance to F3 patients improves the cost-effectiveness in most
policies (compare NB in Tables 3.5 and 3.6). However, this is not always true. In
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Table 3.6: Routine policy comparisons when surveillance is expanded to F3 patients.
Surveillance
policy
NB QALY LY Cost
# per 1,000 patients
# Tests # HCC detected
DLD
Small Medium Large
Routine policies (F3+cirrhotic patients)
24-month 345,348 7.694 9.975 39,348 5.0 75 45 12 550
12-month 347,131 7.768 10.095 41,264 9.4 109 44 9 524
6-month 346,912 7.811 10.166 43,650 18.0 141 33 4 511
3-month 343,662 7.832 10.200 47,933 35.3 165 20 1 505
NB, net benefit; QALY, quality-adjusted life year; LY, life year; HCC, hepatocellular cancer; DLD,
death due to liver disease.
particular, with the expanded surveillance, excessive surveillance such as every 3-
month policy becomes less cost-effective. This is because in F3 patients have much
lower risks of HCC, and thus, the limited benefits by surveillance cannot offset the
costs of excessive surveillance. Second, when surveillance is expanded to F3 patients,
among the routine policies, every 12-month (rather than every 6-month) surveillance
becomes the most cost-effective policy. Third, expanding surveillance to F3 patients
in routine policies is not sufficient to achieve a similar level of NB compared with M-
switch policies (compare Tables 3.4 and 3.6). This further corroborates our findings
that M-switch policies can lead to more efficient use of health care resources.
3.5.3.3 Incremental cost-effectiveness analysis
Incremental cost-effectiveness analysis can help decision-makers determine if they are
willing to pay additional cost for improved health outcomes. We analyze the incre-
mental cost-effectiveness of the policies considered by following a standard approach
used in health economic evaluation (85, 64). In particular, we first order policies
from the least to the most effective (i.e., from the lowest to the highest QALYs), and
eliminate the dominated policies (i.e., policies with lower QALYs but higher costs).
Then, for each successive non-dominated policy, we calculate ICER by dividing the
incremental costs by the incremental QALYs.
Table 3.7 presents ICERs for the surveillance policies considered and Figure 3.7
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Table 3.7: Incremental cost-effectiveness ratios (ICERs).
Policy QALY Cost ($) ICER=∆Cost/∆QALY
No surveillance 7.398 33,353 -
24-month (cirrhotic) 7.661 38,573 19,826
24-month (F3+cirrhotic) 7.694 39,348 23,450
12-month (cirrhotic) 7.731 40,225 23,666
12-month (F3+cirrhotic) 7.768 41,264 28,126
6-month (cirrhotic) 7.773 42,133 (dominated)
0-switch 7.782 41,759 34,594
1-switch 7.791 42,139 41,936
3-month (cirrhotic) 7.794 45,391 (dominated)
6-month (F3+cirrhotic) 7.811 43,650 75,673
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Figure 3.7: Cost and effectiveness of surveillance policies.
presents the corresponding efficiency frontier. As shown in Table 3.7, 0-switch and 1-
switch policies have acceptable ICERs well below the WTP threshold of $50,000/QALY.
Compared with M-switch policies, routine policies are either less effective with lower
QALYs or are more effective but too costly with unacceptable ICERs (i.e. ICER
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>$50,000/QALY). As shown in Figure 3.7, M-switch policies are on the efficiency
frontier and are more effective (i.e., have higher QALYs) than other policies with
ICERs below the baseline WTP. Every 3- and 6-month surveillance in F3 and cir-
rhotic patients can further improve the health outcome but at substantially higher
costs, leading to unacceptable ICERs.
3.5.4 Robustness checks and probabilistic sensitivity analysis
We conduct a series of sensitivity analyses to assess the robustness of our results.
In the following, we present the probabilistic sensitivity analysis (PSA), and more
extended analyses can be found in Appendices B.4.2 and B.4.3.
In the PSA, we account for uncertainty in model inputs by randomly sampling the
value of all parameters simultaneously using the recommended statistical distributions
(31). For each distribution, we assume the coefficient of variation to be 10%. We
repeat the sampling 10,000 times, and for each sampled set of parameters we evaluate
the policies and calculate ICERs.
Figure 3.8 presents the cost-effectiveness acceptability curves for the optimal strat-
ified and 1-switch policies, which represent the probability that each policy is cost-
effective (i.e., with ICERs below a given WTP value) in comparison with the current
common practice, i.e., every 6-month surveillance in cirrhotic patients. These results
show that 0-switch and 1-switch policies are cost-effective with high confidence, at
least 87% and 97% at the baseline WTP value of $50,000/QALY, respectively. Fur-
thermore, they are also cost-saving (i.e., have higher QALYs with less cost) in about
62% and 37% of PSA samples, respectively (denoted by vertical intercepts in Fig-
ure 3.8). Thus, PSA implies that our model results are fairly robust, which further
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Figure 3.8: Cost-effectiveness acceptability curves (CEACs) for 0-switch and 1-switch
policies compared withevery 6-month surveillance in cirrhotic patients, the current
common practice.
Note. A CEAC represents the probability that the estimated ICERs are below the
given WTP value.
3.6 Discussion
With the rising burden of liver cancer in the US, there is an imperative need to
diagnose HCC in early stages by regular surveillance in high-risk patients. Even
though HCC surveillance has a potential to reduce the disease burden, its current
practice is substandard because of several reasons including lack of clinical trials and
confusion over the optimal frequency. Under such situations, mathematical models
can provide important clinical insights that otherwise are not feasible to obtain. In
this work, we develop a general modeling framework to systematically evaluate the
health and economic benefits of HCC surveillance policies in hepatitis C patients.
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Unlike previous sequential medical decision making models, our proposed mod-
eling framework permits explicit formulation of structured policies (i.e., M-switch
policies) that achieve high performance but are at the same time also practical for
implementation. Our modeling framework also effectively captures the condition that
the disease progression is jointly characterized by observable and unobservable states,
but intervention policies explicitly depend on only observable states. Although in this
study we focus on HCC surveillance, our modeling framework is general and could
be applied to many other diseases with or without precursor/comorbid conditions.
For instance, our modeling framework could be applied to coronary disease surveil-
lance with electron-beam CT which can depend on patients’ hypertension status or
other risk factors (90); breast cancer screening with mammogram or other imaging
techniques which can be tailored by patients’ pre-diabetic/diabetic state (126); and
esophageal cancer surveillance with endoscopy which can be adjusted based on pa-
tients’ precancerous dysplasia conditions (106).
Our findings unravel the complex links between disease progression, mortality,
test accuracy, health outcomes, costs, and frequency of surveillance policies. First,
unlike the current guidelines, we find that surveillance should be stratified by fibrosis
stage. Second, we find that expanding surveillance to F3 patients improves the over-
all cost-effectiveness of surveillance; however, F3 and CC patients should have less
frequent surveillance than the currently recommended every 6-month policy. This is
an important finding filling the gap in the literature about the cost-effectiveness of
HCC surveillance for F3 patients. Third, we find that surveillance should become less
frequent as patients age, and terminate after a certain age.
Our study has limitations. Complex model parameterization is based on published
estimates from multiple sources and different study cohorts. We also calibrate several
parameters to the HALT-C trial cohort. Due to lack of population-based estimates,
our model parameters may suffer from potential biases by specific study cohort. To
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assess the impact of parameters on model results and ameliorate this potential bias, we
conduct extensive probabilistic sensitivity analyses which have shown that the cost-
effectiveness results of our base case policies are robust against parameter variabilities.
This study can be extended in several ways. One is to incorporate other screening
modalities in HCC surveillance, such as CT and MRI. They are more accurate tests
but are also more costly. Screening with alternate modalities has been proposed to
improve the accuracy of surveillance, but the cost-effectiveness of such strategies has
not been addressed yet. In addition, we may investigate the effect of low utilization
and adherence in practice on the outcomes of surveillance (204, 201). Patients may be
less likely to follow very frequent surveillance (e.g., every 3-month screening), and thus
the structure of optimal policy can be different. Lastly, given the recent availability
of highly-effective hepatitis C treatments, the landscape of HCC surveillance could
change in future. In that regard, our modeling framework can be used to evaluate




FOR HEPATITIS C ELIMINATION
4.1 Introduction
The burden of hepatitis C virus (HCV) infection continues to rise globally. More than
185 million people, 2.8% of the world population, are infected with hepatitis C (165).
HCV infection can cause a series of life-threatening complications, such as cirrhosis,
liver failure, and liver cancer. In the US, the mortality rate due to HCV has already
surpassed that due to HIV infections (145).
In the last few years, significant breakthrough has been made in hepatitis C treat-
ment. The modern antiviral agents can achieve cure rates higher than 90% within
only 8-12 weeks, compared with the previous regimens with low cure rates of only
60%, long treatment duration, and significant side effects (189). The advent of highly
effective treatments not only makes it possible to cure hepatitis C in individuals, but
also shows the potential to eliminate the disease in a population. In other words,
it is possible to reduce the incidence of new infections (close) to zero in a defined
geographic area through deliberate intervention efforts (63).
Recently, several efforts and global movement have been dedicated to preventing,
diagnosing, treating, and developing national programs to ultimately eliminate viral
hepatitis as a public health problem. The World Health Assembly recently adopted
the first “Global Health Sector Strategy on Viral Hepatitis, 2016-2021” developed
by the World Health Organization (WHO, (169)). This strategy sets the elimination
target for hepatitis C by the year 2030: to reduce new infections by 90%, and to
reduce deaths due to viral hepatitis by 65%, as well as other targets for screening and
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treatment coverage. With the global momentum of hepatitis C elimination, many
countries have started taking actions to address the epidemic of hepatitis C, especially
in those places with high disease prevalence such as Egypt, Georgia, Mongolia, and
certain regions of India like Punjab.
However, meeting HCV elimination targets faces several challenges. First, many
infected individuals are not aware of their infection status, which could become the
bottleneck for achieving the disease elimination—availability of efficacious HCV treat-
ment won’t be of much use if patients are not aware of their infection. In addition,
unawareness of HCV infection also fuels ongoing HCV transmission. Therefore, it
is critical to identify the infected patients who can then be treated with available
therapies.
Second, limited resources and budget for scaling-up screening and treatment to
eliminate HCV can become a barrier. Both screening and treatment at a population
level could be costly and unaffordable. Unfortunately, the current level of funding
for HCV interventions is severely insufficient. For example, while HCV prevalence is
3-4 times higher than that of HIV, the appropriation for HCV is only less than 2%
of resources for HIV control (66). Hence, in such a situation with limited resources,
an efficient resource allocation strategy becomes even more critical.
In this chapter, we study a resource allocation problem for hepatitis C elimination.
In particular, we consider two types of intervention, screening and treatment. The
objective is to determine the optimal screening and treatment rates over the next 15
years (2015-2030) in a target population. We consider two different model setups:
(1) minimize the total cost of screening and treatment to achieve certain epidemic
reductions in line with the WHO targets; and (2) minimize the disease burden, the
cumulative number of infected patients, subject to a constant budget rate.
Our contributions of this chapter are twofold. From a theoretical viewpoint, we
show the asymptotic stability behavior of the hepatitis C transmission model, and
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characterize the structure of the optimal policies for two optimal control problems
which are nonlinear, non-convex, and may suffer from singular solutions. From a
practical viewpoint, both analytical and numerical results lead to important and
practical policy implications. In particular, we find that for the cost minimization
problem, a simple policy structure with a constant screening rate represents a good
balance between model tractability, policy performance and practicality. Among
such a class of policies, a minimal constant screening rate with 100% (or maximum)
treatment rate is found optimal. Lastly, for the fixed budget allocation problem, we
find that the optimal policy is to prioritize treatment first, and then to allocate the
remaining budget, if any left, for screening.
The remainder of this section is organized as follows. In Section 4.2, we review
the relevant literature in infectious disease modeling and the resource allocation prob-
lems in epidemic control. In Section 4.3, we introduce a system dynamic model for
hepatitis C transmission, and theoretically analyze the reproduction number and the
equilibrium stability. In Sections 4.4 and 4.5, we respectively present the two optimal
control problems: (1) minimize the total screening and treatment cost subject to the
final prevalence target constraint, and (2) minimize total disease burden subject to
the budget constraint. For each problem, we examine the structure of the optimal
policy, conduct extensive numerical analyses, and identify the policy implications
from both analytical and numerical results. Finally, we discuss the limitations and
future extensions of this study and conclude in Section 4.6.
4.2 Literature Review
We categorize the relevant literature to our study into the following two groups. First,
we review the classic infectious disease modeling and the mathematical epidemiology
literature, and particularly existing studies on HCV transmission models. Second,
we review the resource allocation optimization problems in the context of epidemic
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control.
4.2.1 Infectious disease modeling
The literature of mathematical epidemiology have experienced a rapid growth starting
from the middle of 20th century. Many compartment models have been developed
to analyze various aspects of infectious disease such as vertical transmission, mix-
ing population, vaccination, quarantine, treatment (29). The set of compartments
depends on the characteristics of the disease and the study objective, which may
include, but is not limited to, class M with passive immunity, susceptible class S,
exposed class E, infective class I, and recovered class R. These compartments can be
assembled in many ways to capture the key dynamics of the problem, such as the
classic SI, SIS, SIR, and SIRS models, and the more extended versions like SEIRS,
MSEIR models (102). These modeling studies typically focus on the analysis of
the basic reproduction number (101, 58, 59), local and global stability analysis of
disease-free equilibrium and epidemic equilibrium (162, 122, 226). Excellent reviews
of mathematical epidemiology models and analyses can be found in (9, 152).
A number of mathematical models have been developed for HCV transmission in
the dynamic modeling literature (52). Martin and colleagues develop a compartment
model of HCV transmission among injection drug users (IDUs) to assess the effect
of antiviral therapies on the prevalence reduction in the UK setting (155). The
model is later extended by incorporating the status of risk reduction intervention
among IDUs in addition to their HCV infection states. They find that scaling up
the risk reduction intervention results in modest prevalence reduction (227), whereas
scaling-up treatment could have a major preventive impact (156). The model is also
used to examine the joint impact of treatment and risk reduction interventions on
the prevalence among IDUs (153). Echevarria et al. modify the model for IDUs
in metropolitan Chicago and analyze the effect of scaling-up treatment among such
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population (65). Elabasha explicitly models the reinfection after previous successful
treatment as separate compartments (71), shows local and global stability results of
the model equilibrium, and presents the numerical results for IDU population in the
US.
As another class of modeling method, simulation modelings exhibit greater flexi-
bility in capturing finer details in disease dynamics. For example, in addition to the
dynamics of disease transmission at a population level, a simulation model can also
capture the progression of disease stages at an individual patient level. Hahn and
colleagues construct a stochastic individual-based simulation model based on inject-
ing behavior data collected from young IDUs in San Francisco to project the short-
and long-term effects of potential HCV vaccine (94). To evaluate the impact of im-
perfect follow-up during the HCV cascade of care, Linas and colleagues develop a
state-transition simulation model of disease progression and care delivery, and use it
to identify the intervention strategies to be prioritized along the cascade of care (138).
He et al. develop an agent-based simulation to model the transmission and progres-
sion of HCV inside and outside the US prison, and find that universal screening in
prisons is highly cost-effective and can also reduces disease burden in the outside
community (100).
4.2.2 Resource allocation and optimal control in epidemics
Resource allocation problems for epidemic control have been studied for many infec-
tious diseases, and most extensively for HIV control in a variety of settings. Alistar
et al. minimizes the reproduction number subject to a budget constraint to opti-
mize the budget allocation of prevention and treatment for HIV epidemic control
(8). Kok et al. determine the optimal allocation of HIV test among targeted and
routine programs to minimize the new infections in a dynamic model (120). An op-
timal portfolio problem raises when there exist multiple intervention options with
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different effects and costs. For a given budget, the optimal intervention portfolio is
determined for interacting populations (240, 7), for multiple independent populations
(28), and when the combination is allowed to change over the planning horizon (241).
For multi-level resource allocation problems which is commonly encountered in HIV
prevention practice, Lasry et al. solve the optimal budget allocation at two levels and
compare with equity-based heuristic allocation policies (127), and Malvankar-Mehta
and Xie identify the optimal incentives provided to decision makers at different lev-
els to maximize the total infections averted (149). Deo et al. formulate a planning
problem for screening and care of HIV as a non-linear mixed integer program, and
solve the optimal screening rate and the staffing level subject to budget and capacity
constraints using integer programming (56). Khademi et al. develop a Markov deci-
sion process (MDP) formulation for the optimal allocation of scarce HIV treatment
resources which allows early discontinuation of treatment, and employ the approxi-
mate dynamic programming approach to lower bound the price of nonabandonment
by comparing with the standard life-long treatment policy (116).
Optimal control theory, which has been extensively used in engineering and eco-
nomic applications (118, 190, 191, 82), is also a commonly utilized methodology in
analyzing optimal epidemic control problems. The Pontrayagin maximum principle
provides a set of necessary optimality conditions for optimal control problems, which
can be used to obtain analytical solutions of the optimal policies in some cases. Op-
timal treatment policy is studied for the spread of crop disease over regional scale in
a contact-process model (80). Rowthorn and Toxvaerd fully characterize the optimal
prevention and treatment policy in a classic SIS epidemic model (183). There exists
abundant body of literature on the optimal intervention policies in classic epidemic
models (e.g., SIR model), such as vaccination plus treatment (129), pulse vaccination
(195), intervention with time delay (239, 30), and educational campaign plus treat-
ment (22). In particular, Martin et al. examine the optimal hepatitis C treatment
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policy in IDU population with respect to various objectives and budget constraints
(154). Hansen and Day show the structure of the optimal prioritization of vaccination
and isolation in an SIR model with budget constraints (98). Optimal allocation of lim-
ited total budget for two coupled subpopulations are analyzed in SIRS model (160),
and in SIS model with quarantine (184) or heterogeneous populations symmetric and
asymmetric transmission (159).
In addition to infectious disease control problems, dynamic modeling and optimal
control theory have also been applied in a broad set of health care problems, such
as liver transplant prioritization policy (5), dialysis delivery design subject to budget
and capacity constraints (242), and cancer treatment design (128, 62, 109).
4.3 Disease Transmission Model
We consider the HCV transmission dynamics in an open population with new births.
The population are partitioned into four compartments by their hepatitis C infection
status (Figure 4.1): (1) Compartment S for the susceptibles, who have never been
infected with HCV, (2) Compartment I for the infected but undiagnosed, who are
currently infected with HCV but unaware of their infection, (3) Compartment D
for the diagnosed infections, who are aware of their infection awaiting treatment,
and (4) Compartment R for the recovered, who are cured (i.e., sustainable virologic
response [SVR] achieved) by successful treatment. The susceptible population (i.e.,
compartment S) can become infected by contacting with infected patients including
both undiagnosed and diagnosed cases (i.e., compartment I and D). Infected patients
can be diagnosed only through HCV screenings. Obviously, only diagnosed patients
are eligible for treatment. Those who failed treatment remain in compartment D and
can be retreated later. Although current direct antiviral agents have high cure rate,
recovered patients are still at risk of reinfection, especially in high risk population
like IDUs.
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Figure 4.1: Dynamic model for HCV transmission.
We define the state variable x(t) = (S(t), I(t), D(t), R(t)) to represent the popu-
lation size of each corresponding compartment at time t, and N(t) = S(t) + I(t) +
D(t)+R(t) to represent the size of the total population at time t. While state variable
depends on time t in principle, we suppress the dependency of time t in the notation
for simplicity, unless absolutely necessary.
We consider the standard incidence αS(I+D)
N
for new infections and βR(I+D)
N
for
reinfections, where α and β represent the infection rate for the susceptible population
and the treated patients, respectively. The rationale of standard incidence formulation
is that an uninfected individual has limited contact with the infected population, and





, respectively) is proportional to the fraction of the infected population in the
population. The uninfected population (compartments S and R) have a per capita
death rate of the background mortality µ, and the infected population (compartments
I and D) have higher mortality rate m > µ to represent the excess liver-related
mortality due to the infection. We assume a constant total birth rate Λ of the
susceptible population.
Remark 4.1 In the epidemic modeling literature, another commonly used incidence
formulation is the mass action incidence, defined as αS(I+D) and βR(I+D) accord-
ingly in our model setup, which, however, is deemed not suitable for modeling HCV
transmission. This is because it has an infection force proportional to the absolute
number of infections, implying that the contact between the uninfected people and the
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infected population can increase indefinitely as the infected population grow. On the
other hand, it could be more suitable for studying infectious diseases like influenza
and SARS (152).
We consider two different types of interventions: screening and treatment for hep-
atitis C. We denote the control variable u(t) = (v(t), w(t)), v(t), u(t) ∈ [0, 1] to repre-
sent screening rate and treatment rate at time t, respectively. Screening is applied to
all population except the diagnosed patients in compartment D, whereas treatment
is only available to diagnosed patients. Since currently available screening tests for
hepatitis C are highly accurate with the sensitivity and specificity close to 99% (194),
we assume perfect screening test, and thus the transition rate from compartment I to
D is simply the screening rate v. We denote η as the SVR rate of treatment, which
implies the transition rate to be wη from compartment D to R. Mathematically, the
above-described population dynamics are presented using a set of nonlinear ordinary
differential equations as follows. We use the notation ẋ := dx
dt
to represent the time
derivative of variable x. Then,
Ṡ =Λ− αS I +D
N
− µS (4.1)
İ =(αS + βR)
I +D
N
−mI − vI (4.2)
Ḋ =vI −mD − wηD (4.3)
Ṙ =wηD − βRI +D
N
− µR, (4.4)
N =S + I +D +R. (4.5)
The initial condition is determined by a given population profile (S0, I0, D0, R0):
(S(0), I(0), D(0), R(0)) = (S0, I0, D0, R0). (4.6)
All variables and parameters are summarized in Table 4.1.
79
Table 4.1: List of variables and parameters.
State variables: x(t) = (S(t), I(t), D(t), R(t))
S(t) Number of suspectible (uninfected) persons
I(t) Number of infected but undiagnosed patients
D(t) Number of infected and diagnosed patients, waiting for treatment
R(t) Number of recovered patients (cured from previous hepatitis C treat-
ment), but at risk of reinfection
Control variables: u(t) = (v(t), w(t))
v(t) Screening rate in S, I, and R population
w(t) Treatment rate in D population
Transmission model parameters:
Λ Birth (Arrival) rate of the population
α Infection rate for new infections in susceptible population
β Infection rate for reinfections in treated patients
µ Background mortality
m Mortality rate of the infected population (including the liver-related
mortality)
η Sustainable virologic response (SVR) rate of hepatitis C treatment
Cost parameters:
cas Cost of HCV antibody screening test
crs Cost of HCV RNA test
cd Cost of antiviral treatment
B Budget for screening and treatment per year
It is safe to assume that reinfection rate should be no higher than that of new
infections, as a study has found that persons who have previously cleared HCV have
lower odds of developing infections (89) (also see the parameter estimation in Section
4.4.3). Also, it is reasonable to assume that the infection rate α is higher than mortal-
ity rate m for the infected population. This is because when there is no intervention,






(I +D); if α < m, then İ + Ḋ < 0. That is, in this case, the
disease transmission is so slow that the disease is not self-sustaining and will extinct
even without any extra intervention efforts, which is not true in the context of HCV
epidemics. We formally state these assumptions below.
Assumption 4.1 α ≥ β, α > m.
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Lastly, we remark on the particular choice of the compartment model for this
problem in comparison with the model formulated in Chapter 3. Although both of
Chapter 3 and this chapter are related to the disease modeling for hepatitis C, the
research questions are at different levels and thus the models differ by their defini-
tions of states or the compartments. In particular, Chapter 3 focuses on the cancer
screening policy for the population who have already infected with hepatitis C. Since
the stages of infection affect the disease progression dynamics (e.g., changing cancer
risks, mortality risks) and subsequently influence the screening policy, a model that
explicitly captures the disease stages is deemed necessary.
In this chapter, the intervention policies target at a broader population including
not only hepatitis C-infected but also uninfected population. The main focus is to
study the intervention policy that controls disease transmission in the population.
Thus, a model is deemed necessary if it at least distinguishes the subgroups of the
population by their infection status. We choose a minimal set of compartments
as defined in (4.1)-(4.4) to reflect the major differences of infection status in the
population. Since intervention policy will not be tailored by disease stages in our
basic problem setting, we do not further stratify the compartments by the stages of
hepatitis C infections. The simple representation of the dynamic system also makes it
analytical tractable to derive policy structures from the optimal control formulations
as presented in the following sections.
We acknowledge the limitation that the compartment model (4.1)-(4.4) cannot
capture the exact natural history because of the aggregation of the disease stages.
For example, it has only one overall mortality m for infected population (in com-
partments I and D), which ignores the differences in the liver-related mortality by
specific stage of HCV infection: the excess mortality is negligible for asymptomatic
patients in early stage (i.e., F0-F3 fibrosis stages), but is very high for patients with
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advanced liver disease (e.g., F4 stage fibrosis, decompensated cirrhosis, liver can-
cer). However, since the majority of the population in our model are uninfected and
newly infected population, such a simplification is unlikely to significantly skew the
population dynamics and alter the policy implications.
4.3.1 Reproduction number and stability analysis
In the following theoretical analyses of the HCV transmission model (4.1)-(4.4), we
will calculate the reproduction number Rc and examine asymptotic behavior of the
epidemic dynamics.
Before the analyses, we first check the boundedness of the system. Define the
feasible set as




Proposition 4.1 The closed set X is positively invariant with respect to the model
(4.1)-(4.4). That is, all solutions with initial conditions in set X will remain in X
for any admissible control u(t) for t ≥ 0, i.e., x0 ∈X =⇒ x(t) ∈X , ∀t > 0.
Proposition 4.1 implies that the system (4.1)-(4.4) is always bounded for any given
initial population N0. Therefore, no particular state space will be excluded from the
following qualitative analyses.
In the infectious disease modeling literature, the basic reproduction number R0 is
a fundamental measure, which quantifies the severity of an epidemic, and is defined
as the average number of new secondary infections caused by an index case during
his life time when introduced to a susceptible population, in the absence of any
prevention or intervention (58). In our analyses, we are interested in the effects of
interventions on the epidemics, and thus our analyses instead focus on a counterpart
of R0 in the presence of intervention, the control reproduction number denoted by Rc.
For simplicity, we refer to the control reproduction number Rc as the reproduction
number throughout the remainder of this chapter.
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Proposition 4.2 The reproduction number Rc for the HCV transmission model (4.1)-
(4.4) is given by:
Rc(v, w) =
α(v + ηw +m)
(v +m)(ηw +m)
(4.8)
The mathematical representation of the reproduction number Rc is indeed in
line with its definition. Consider the following process. One infected individual—
the index case—starts in compartment I and stays in compartment I for an average
time of 1
v+m
; during this period of time, he will infect αS(I+D)
N
= α persons in the
susceptible population per time unit (note that S
N
= 1 and I = 1 as this infected
individual enters a population with all susceptible population). Then he moves to
compartment D with probability v
v+m
, stays in compartment D for an average time of
1
wη+m
, and causes α new infections per time unit. After moving to compartment R,
he will neither infect any susceptible population, nor get reinfected because all other
population are susceptible. Thus, total number of new infections that one infected











which is exactly the value of Rc in (4.8).
Next, we show that the reproduction number Rc is a threshold quantity for asymp-
totic stability properties at the equilibrium points of the epidemic population.
Proposition 4.3 The HCV transmission model (4.1)-(4.4) has a unique disease-free




, 0, 0, 0
)
. The disease-free equilibrium E is locally and
globally asymptotically stable if Rc < 1.
Proposition 4.4 There exists a unique endemic equilibrium (EE) if Rc > 1, and no
EE exists if Rc < 1.
Propositions 4.3 and 4.4 imply that Rc = 1 is the critical value: the epidemic
will eventually be eliminated only when Rc < 1 with sufficient intervention efforts;
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if Rc > 1, the epidemic could converge to a positive endemic equilibrium. From
the calculation of reproduction number Rc, we observe that neither treatment nor
screening alone can achieve the disease elimination in long run. This is because in








as α > m (Assumption 4.1). By letting Rc < 1, we obtain simple lower bounds for
constant screening rate v > α −m and treatment rate w > α−m
η
to achieve disease
elimination in long term.
From Propositions 4.3 and 4.4, we know that the system equilibrium changes with
the value of reproduction number Rc, and such a phenomenon is called bifurcation
(117). Moreover, with the base case parameter assumption α ≥ β (Assumption 4.1),
the bifurcation is forward at the bifurcation point Rc = 1; that is, the equilibrium
changes if Rc increases from 1. Of theoretical interest, in the following corollary,
we remark that a backward bifurcation is possible if reinfection rate is higher than
infection rate, i.e., the equilibrium changes if R decreases from 1, implying that there
could exist at least one nontrivial endemic equilibria for Rc < 1.
Corollary 4.1 A necessary and sufficient condition for backward bifurcation is




We remark that analyses of the critical value Rc and asymptotic stability proper-
ties provide qualitative insights and help us understand how quickly disease prevalence
can be decreased and eliminated eventually in infinite time horizon. However, it has
limited value of guiding specific actions to achieve certain hepatitis C elimination
target while considering other important factors such as limited resources in finite
time horizon. In the following sections, we turn to the optimal intervention problems
that trade-off between the epidemic control and limited resources. We present the op-
timization problem formulations, discuss the optimal intervention policy structures,
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showcase the numerical results, and discuss the policy implications in practice.
4.4 Optimal Resource Allocation: Final Prevalence Target
Constraint
In the first global health sector strategy on viral hepatitis proposed by the WHO
(169), the target is to eliminate viral hepatitis as a major public health problem by
2030. The strategy defines a set of quantitative targets for the next 15 years. In
particular, the impact targets include 90% reduction in new incidences, and 65%
reduction in liver-related mortality by 2030 compared with 2015; coverage targets
include that 90% infected cases are diagnosed and that 80% of treatment-eligible
patients are treated.
Motivated by the above targets stated in WHO strategy, we aim to solve the
following optimization question: In order to achieve a target disease prevalence (i.e.,
the number of total infected population), what is the optimal screening and treatment
policy for 2015-2030 which has the minimum total cost? Mathematically, we refer
to the screening and treatment policy as the trajectories of v(t) and w(t) over time,
respectively.
We let cas denote the cost of HCV antibody test used for the screening in the
general population. For those who show positive infection in the antibody test will
undergo HCV RNA test for diagnosis at the testing cost of crs. Let cd represent the





[cas · (S + I +R) · v + crs · I · v + cd ·D · w] dt (4.10)
s.t. (4.1)− (4.6),
I(tf ) +D(tf ) ≤ ρf , (4.11)
v(t), w(t) ∈ [0, 1], ∀t ∈ [0, tf ],
where ρf represents the target prevalence level to meet at the final time tf .
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Although the final prevalence is not explicitly stated as a target in the WHO
strategy, we highlight that prevalence is indeed in line with the two impact target
measures defined by the WHO—the numbers of liver-related deaths and new infec-
tions. In particular, given the setup of our HCV transmission model (4.1)-(4.4),
the number of liver-related deaths is given by (m − µ)(I + D), which is simply
proportional to prevalence (I + D) by a constant factor. Moreover, the number
of new infections ϕ = (αS+βR)(I+D)
N
is highly sensitive to the prevalence (I +D) when
the I+D
N

























, and observe that ∂ϕ
∂(I+D)










< 10% as in most realistic HCV epidemic settings.
Thus, we consider the final prevalence constraint in the optimal control problem (4.10)
as a reasonable representation of the WHO targets. In the next result, we show the
existence of optimal intervention policies to this formulation.
Proposition 4.5 There exists an optimal control for problem P-MinC (4.10).
4.4.1 Structure of optimal control policies
In this section, we analytically examine the structure of the optimal intervention
policies to the problem P-MinC (4.10) using the Pontryagin’s Maximum Principle,
which is a powerful mechanism used to establish the optimality conditions for optimal
control problems (118, 190, 218).
For the convenience of following analyses, we formulate the problem in the form
of Mayer-type problem; that is, we only minimize a terminal reward at the final time
without the running cost during planning horizon [0, tf ]. This can be easily achieved
with the expansion of state (S, I,D,R) by an additional state variable Z(t), which
captures the total cost at time t with the dynamics Ż = cas(I+D+R)v+c
a
sIv+cdDw
and the initial condition Z(0) = 0.
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Then we have the following reformulation of (4.10) in the Mayer form with state




s.t. ẋ = f(x) + g1(x)v + g2(x)w (4.13)
x0 = (0, S0, I0, D0, R0)



































Define the Hamiltonian H = H(x, u, λ, t) as
H = 〈λ, (f(x) + g1(x)v + g2(x)w)〉, (4.15)
where λ = (λ0, λ1, · · · , λ4) ∈ R5 are the costates (also referred to as “adjoint vari-
ables”) associated with system dynamics (4.13).
First order necessary conditions of optimal control u∗(t) are given by the Pontrya-
gin’s Maximum Principle (Theorem 2.2 and 3.3 in (190)) as follows. Let (x∗(t), u∗(t))
be an optimal pair, there exists a continuous and piecewise continuously differentiable
vector function λ(t) = (λ0(t), · · · , λ4(t)) satisfying the following:






















λ0(tf ) = 1, λ1(tf ) = λ4(tf ) = 0,
λ2(tf ) = λ3(tf ) = k, for some k ≥ 0 and k = 0 if I∗(tf ) +D∗(tf ) < ρtarget,
(4.17)
(3) u∗(t) minimizes H(x∗(t), u, λ(t), t) for any time t over the compact interval
U = [0, 1]× [0, 1]. That is,
H(x∗(t), u∗(t), λ(t), t) ≤ H(x∗(t), u(t), λ(t), t) for all u ∈ U.
Note that the Hamiltonian H is linear in control u = (v, w) in our formulation,
which implies that minimum H can be attained at the boundary values of control u
depending on the sign of gradient of ∂H
∂u
. In particular, the optimal control u∗(t) is
characterized in the following proposition.
Proposition 4.6 Let (x∗(t), u∗(t)) be an optimal pair. Costates λ(t) is determined




0 if Φ1(t) > 0
undetermined if Φ1(t) = 0
1 if Φ1(t) < 0
, w∗(t) =

0 if Φ2(t) > 0
undetermined if Φ2(t) = 0
1 if Φ2(t) < 0
(4.18)




∗ + I∗ +R∗) + casI
∗ + (λ3 − λ2)I∗,
Φ2(t) =cdD
∗ + (λ4 − λ3)ηD∗.
Conditions in (4.18) shed some lights on the basic policy structure. Most of
the time, optimal control is at the boundary value, and can switch to the opposite
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boundary at some critical time τ , for example, from 1 to 0 when the switching function
Φi(τ) across the value 0 from negative to positive. Controls switching between the
minimum and maximum values are called the bang-bang policy.
However, the optimal controls are not directly determined by condition (4.18) if
the switching functions vanish over an open interval, i.e., Φi(τ) = 0, τ ∈ [τ1, τ2], for
some τ2 > τ1. In this case, on [τ1, τ2],
∂2H
∂u2
≡ 0 which is singular and renders the first-
order optimality condition (i.e., the maximum principle) informative. As such, the
problem is called singular. To determine the singular controls, additional necessary
conditions are needed to fully characterize the optimal control. For example, one
can utilize the facts Φ̇i ≡ 0, Φ̈i ≡ 0, . . . ,Φ(2k)i ≡ 0 for some k ≥ 1, and check the








≥ 0, known as the generalized
Legendre-Clebsch condition (34).
On the other hand, conditions in (4.18) only indicate that there may exist singular
arcs, but do not guarantee the existence of singular arcs. The existence of singular
solutions could also depend on specific parameter values or the initial condition of
the problem (c.f., (158)).
We remark that if the cost function has quadratic terms with respect to control
variable u such as ((S + I + R) · v)2 and (D · w)2, the singularity issues can be
completely resolved. However, it could be more difficult to interpret a quadratic
monetary value in our problem context, and could be also more difficult to obtain
practically meaningful estimates of the coefficients for the quadratic terms. We shall
discuss more on the forms of objective functions in our numerical result section.
To summarize, because the cost function and the system dynamics are both linear
in control u in the problem P-MinCost (4.12), the optimal control admits a generalized
bang-bang policy, possibly in combination with singular arcs.
In the following proposition, we explore the possibility of singular controls in two
special cases of our problem.
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Proposition 4.7 Control v and w cannot be singular simultaneously in the following
cases:
(1) In a simplified model without the Recovered compartment. That is, no reinfec-
tion is considered.
(2) In the full model (4.12) when α = β. That is, reinfection rate is as high as the
infection rates for the susceptible population.
Analytical solutions to singular controls are in general challenging and intractable.
By Proposition 4.7, we can only rule out the simultaneous singularity of optimal
screening and treatment policies in two cases with either negligible reinfections or
very high reinfection rates; singular arcs for either intervention may still exist in the
original problem. In fact, in our computational experiments, we fail to solve the
problem (4.10) using the numerical solver, which fundamentally relies on the first-
order optimality conditions for general non-linear optimization problems. Thus, we
conjecture that singular arcs exist for the problem (4.10), which also renders numerical
solutions intractable.
4.4.2 Fixed (and constant) screening rate
Instead of investigating the exact singular solutions of theoretical interest which could
be highly dynamic and complex, in this section, we focus on a class of policies with
a simpler structure, which can be more practical for implementation, and may also
possibly circumvent the singularity issues.
To simplify the optimal control problem, we keep only one type of intervention as
the control variable in the model, and set the other at a given value. Specifically, we
choose treatment as the control variable to be optimized and set screening at a fixed
rate. Considering that the target population of screening has a much larger scale
than that of treatment, we believe it is more practical to first fix the screening policy
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with a simple and practical structure (e.g., constant rate, or piece-wise constant rate
for several phases), and then determine the corresponding optimal treatment strategy
possibly with a more flexible structure focusing on only a smaller patient group.
For a given screening rate v◦(t), problem (4.12) is reduced to the following. For




s.t. ẋ = f(x) + g(x) · w (4.20)
x0 = (0, S0, I0, D0, R0)




cas(I + S +R)v
◦ + crsIv
◦
Λ− µS − αS I+D
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In Proposition 4.8, we show that fixing screening rate at a given value v◦(t), not
necessarily a constant value, indeed excludes the existence of the singular arcs for
the treatment policy. That is, for a given screening policy, the optimal treatment
policy is always a pure bang-bang policy, meaning either no treatment at all (at the
minimum rate w(t) = 0) or treating all existing diagnosed patients (at the maximum
rate w(t) = 1). This simple policy structure is appealing form an implementation
perspective as well, as the decision now becomes when to start or stop treatment for
all diagnosed patients.
Proposition 4.8 For any given screening rate v◦(t) 6≡ 0 for all time t, the optimal
treatment rate u∗(t) is a pure bang-bang policy without singular arcs.
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Next, we consider a simple screening policy with a constant screening rate v◦(t) ≡
vc. Recall that the optimal control problem is subject to the target constraint of
the final prevalence. Clearly, all constant screening rates vc are not admissible to
the problem (4.19). To characterize the feasible range of vc, we first show that,
given the constant screening rate, the minimum final prevalence one can achieve is
nonincreasing in vc in Proposition 4.9. Then it follows that there exists a minimal
screening rate vc such that the final prevalence constraint (4.11) is satisfied (Corollary
4.2). Moreover, we can show that, in Proposition 4.10, more treatment efforts lead
to lower prevalence, with under certain simplification conditions. As a result, a full
treatment policy, i.e., w(t) = 1 for all time t, becomes the only feasible and thus the
optimal treatment policy given the minimal screening rate vc to achieve the prevalence
target (Corollary 4.3). Indeed, as shown in our numerical results, the intervention
policy with screening v(t) ≡ vc and treatment w(t) ≡ 1 is optimal with the lowest
cost among all policies with a constant screening rate.
Proposition 4.9 Consider the following optimal control problem to minimize final
prevalence under the given constant screening rate vc ∈ [0, 1]:
J∗(vc) = min
w(t)∈[0,1]
{J(vc) := I(tf ) +D(tf ) : (4.1)− (4.6)} . (4.22)
The optimal terminal prevalence J∗(vc) is nonincreasing in screening rate vc.
Corollary 4.2 Consider problem (4.19) with a constant screening rate, i.e., v◦(t) ≡
vc for all time t for some vc > 0. There exists a minimum constant screening rate
vc to achieve the terminal prevalence target. That is, problem (4.19) with constant
screening rate vc is feasible only for vc ∈ [vc, 1].
Proposition 4.10 Consider a stationary population by assuming Λ = µN0 and
m = µ. Let two state trajectories xi(t) = (Si(t), Ii(t), Di(t), Ri(t)) determined by
the control ui(t) = (v(t), wi(t)) for i = 1, 2. If w1(t)D1(t) ≤ w2(t)D2(t), then
S1(t) ≤ S2(t), R1(t) ≤ R2(t), and I1(t) +D1(t) ≥ I2(t) +D2(t).
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Corollary 4.3 Given the minimal constant screening rate vc, treatment rate w∗(t) ≡
1 is the optimal and only feasible treatment policy to achieve the final prevalence target.
4.4.3 Parameter estimation
In our numerical analyses, we consider the HCV epidemic in India population. HCV
elimination in India is an interesting study case because the disease burden in India
is high (with over 6 million people infected with chronic HCV), and effective oral
therapies are available at reduced costs (216). India government has started working
with the WHO to develop intervention plans for HCV elimination. Motivated by
such a realistic policy-making problem, we parameterize our model base on the India
setting (e.g., epidemic population profile, intervention costs), numerically solve the
optimal control problem, and obtain managerial insights on the intervention strategies
from the optimal policies.
Population profile. Since the model is scalable with the compartment sizes, we
run the results for N0 =1 million initial population. Although the overall nation-wide
prevalence rate is low (0.68%) as diluted by the large Indian population, the epidemic
is very severe in certain regions, like Punjab with a high prevalence rate of 5.2% (206).
Our analyses will focus on such targeted area and population. Awareness of infection
is low in India; it is estimated that only 5% of infected people are diagnosed (228).
As we do not differentiate the compartments by age groups, we use the crude death
rate estimate for overall Indian population as the background mortality µ (214).
To estimate an aggregated excess mortality due to HCV infection (i.e., for I and D
compartments), we use the weighted average of liver-related mortality by liver disease
stage with respect to their distribution in India population. We assume a constant
birth rate Λ = µN0.
Screening and treatment. HCV screening includes anti-HCV antibody test at
a cost of $5, and RNA test at a cost of $50 in India (as per communication with
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practitioners in India). The cost of DAA treatment in India has now reduced to $300
for 12-week treatment (as per communication with WHO-India). The new DAA has
shown very high efficacy with >95% SVR rate for all fibrosis stages and genotypes
(238). Considering the sub-optimal uses and adherence to treatment in actual clinical
practice, we use η = 0.9 as a conservative SVR estimate in our model.
Table 4.2: Parameter values.
Parameter Variable Value Reference
Total population N0 1,000,000
Initial prevalence 5.2% (206)
Initial awareness % 5% (99)
Current intervention
Annual screening rate 0.6% (99)
Annual treatment rate 0.2% (99)
Mortality (annual)
Background mortality µ 0.73% (214)
Excess mortality m− µ 0.8% weighted average of liver-related
mortality by liver disease stages1
Screening cost
Antibody test cas $5 per communication with clinicians in India
RNA test crs $50 per communication with clinicians in India
DAA treatment cost cd $300 per communication with WHO-India
SVR rate η 0.9 (238)
Infection rate α 0.0167 Estimated through calibration
Relative susceptibility κr 30% (100, 89)
of treated patients
1 No liver-related mortality for F0-F3 fibrosis stages, annual mortality 0.051 for F4 (6.89%
of the total hepatitis C-infected population), 0.265 for decompensated cirrhosis (1.43%) (54),
and 0.427 for liver cancer (0.18%) (100).
Calibration of infection rate. As the direct estimate of infection rates α and
β are not available from the literature, we use Martin’s approach (157) to calibrate
the parameters as follows. We assume a 70%(= 1− κr) reduction of reinfection rate
for those who have been successfully treated compared with the new infections (i.e.,
β = κrα) as in (100), in line with the findings from clinical studies that treated
patients are about 4 times less likely to develop infection than those infected for
the first time (89). Using the number of newly diagnosed infections and treatment
estimated in (99), we calculate the status quo annual screening rate to be 0.6% and
annual treatment rate 0.2%. Then we run the transmission model with the status quo
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intervention levels for long enough until the equilibrium state is reached for any given
infection rate α value, and calibrate the α value such that the equilibrium prevalence
rate under the status quo interventions is inline with the current prevalence estimate
(5.2%) in India.
Figure 4.2 shows the relation between the equilibrium prevalence and infection
rate α. In line with our results in Propositions 4.3 and 4.4, when α is smaller than
the critical value α0 = 0.0158 so that the reproduction number Rc < 1, the dynamic
system will eventually converge to a disease-free equilibrium. An endemic equilibrium
bifurcates forwardly at α = α0 and Rc = 1. That is, the endemic equilibrium
prevalence will increase with α value when α > α0 and Rc > 1.




















Figure 4.2: Calibration of infection rate α.
Note. The red dashed-line represents the calibration target prevalence. The intersec-
tion point with the solid curve represents the base case value of infection rate α used
in our numerical analyses.
We remark that the infection rate α is a sensitive parameter affecting the equi-
librium prevalence, disease transmission dynamics, and corresponding intervention
policies. Our estimate of α from the calibration serves as an initial basis for the
following analyses of the optimal intervention policy in HCV elimination; a more
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accurate estimate of α is possible if more data on the epidemic (e.g., longitudinal
incidence and prevalence statistics) can also be utilized in the calibration. We will
examine the effect of variability of α values on the policy structure in more details in
our numerical results.
4.4.4 Numerical results
The WHO 2016-2021 global health sector strategy on viral hepatitis (215) presents a
set of targets to achieve by 2030, including 65% reduction of liver related mortality
and 90% reduction of new incidences. As the number of the infected patients is the
major quantity driving both mortality and new incidence (see discussion in Section
4.4), in our base case results we set the target of reducing the number of infected
patients by 65% at 2030 compared with the initial number of the infected at 2015 as
the final state constraint (4.11) in the model.
Optimal screening and treatment policies are numerically solved using the MAT-
LAB package GPOPS-II (172). GPOPS-II employs the direct method for solving opti-
mal control problems, i.e., discretize-then-optimize, in contrast to the indirect method
which first derives the optimality conditions and then iterates the solutions in discrete
time until the optimality conditions are satisfied, i.e., optimize-then-discretize, such
as the multiple-shooting method (178). In particular, it approximates the continuous-
time optimal control as sparse non-linear programming (NLP) using different collo-
cation schemes, and then solves the NLP with NLP solvers. Computation time for
all problem instances are less than one minute.
4.4.4.1 Fixed constant screening rate
As the base case result, we choose a constant annual screening rate vc = 8% through-
out 2015-2030 and solve the optimal treatment policy accordingly. That is, screening
covers 8% of all population every year except those who have been diagnosed with
HCV infection (i.e., compartment D). This particular choice of screening rate is made
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for the purpose of exploring and presenting the underlying rationales of the optimal
treatment policy. Figure 4.3 presents the optimal treatment policy and the corre-
sponding state trajectory over time. The markers shown in the figure represent the
discretization points for time discretization which are adaptively determined by the
solver (e.g., smaller discretization in the region with more rapid changes of state or
control values). We observe that optimal treatment is indeed a pure bang-bang policy
without singular arcs, which numerically verifies our result in Proposition 4.8.
Figure 4.3 shows that given the constant screening rate, the number of the un-
diagnosed infections (compartment I) is decreasing steadily. The treatment rate af-
fects the number of diagnosed infections and those recovered differently in three time
phases: (1) before the year 2024, treatment at the maximum rate 100% strives to
move the diagnosed infections to the recovered state (i.e., from compartment D to
R), and maintain the number of diagnosed infections under control; (2) during the
years 2024-2028, treatment pauses, and the number of diagnosed infections increases
as more infections continue to be diagnosed but no treatment is available during this
period; and (3) after the year 2028, treatment resumes at the maximum rate 100%
and successfully reduces the prevalence to the targeted level at the end of 2030.
Interestingly, the optimal treatment policy exhibits an on-off-on structure to min-
imize the total screening and treatment cost. To understand the underlying reason
of such a policy structure, we first highlight the multiple effects of treatment. On
the one hand, treatment immediately reduces the disease prevalence, and the reduced
prevalence in turn results in fewer new infections in long term; on the other hand,
since the treated and recovered people also constitute a part of screening target pop-
ulation, the growing number of recovered people could increase the total screening
cost. Then, the optimal treatment policy (Figure 4.3A) can be interpreted as follows.
The early treatment in the first “on”-segment can be considered as the “treatment
as prevention”. That is, it helps reduce future new infections by reducing prevalence
97





























(A) Screening rate and the optimal treatment rate.





























(I) Infected and undetected
(D) Infected and detected
(R) Recovered
(B) State trajectory.
Figure 4.3: Optimal treatment policy and the state trajectory at a fixed annual
screening rate of 8%.
in early periods and leads to potential savings of treatment cost in future. When
such preventive benefits are offset by the increasing screening cost as the screening
target population grows, treatment becomes less attractive, or even stops. Delaying
treatment is feasible only if it is still possible to meet the final prevalence target
by implementing the maximum treatment rate—the second “on”-segment—later and
throughout the remaining time. As such, the three stages of the on-off-on structure
can be interpreted as the preventive treatment, feasible delay, and target-approaching
treatment stages, respectively.
However, it is not guaranteed that the optimal treatment policy of the bang-bang
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policy type always consists of such three stages. For different model parameter set-
tings, other switching structures, such as on-off or off-on structures, are also feasible.
In the following, we perform a series of sensitivity analyses and discuss the effects of
several major model parameters on the switching structure of the optimal treatment
policy.
• Effect of infection rate α (compared to mortality m). From earlier discussion
on reproduction number Rc, in the absence of treatment, we know that Rc
reduces to α
m
. A lower infection rate α results in a smaller reproduction number
Rc which is closer to 1, implying a slow spread of the disease; in this case,
treatment may not exhibit a strong preventive value on the epidemic control,
which indicates that early treatment is not necessarily optimal. As shown in
Figure 4.4, when infection rate α is low (the upper panel), optimal treatment
policy is to delay the treatment until necessary for reaching the final prevalence
target; when infection rate α is high with a faster disease transmission (the
lower panel), upfront and non-stop treatment could be more efficient to prevent
the new infections, and also more economical to achieve the final prevalence
target.








, = 0.016 (Low) 








, = 0.018 (High)
Figure 4.4: Effect of infection rate α on the optimal treatment policy.
• Effect of antibody testing cost cas for general screening target population.
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Figure 4.5 shows the optimal treatment policies under various values of anti-
body testing cost cas . It presents a clear pattern: a higher antibody testing cost
favors later rather than early treatment. With a higher antibody testing cost,
early treatment is not favored because it increases the screening target popula-
tion in early periods, which will contribute to higher screening cost throughout
the horizon. Then the potential savings of the preventive treatment is coun-
terbalanced by such an increase of total screening cost. Therefore, it would be
better to maintain less early treatment as the antibody testing cost increases.
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Figure 4.5: Effect of antibody testing cost cas on the optimal treatment policy.
• Effect of RNA testing cost crs for detected infections. RNA testing cost crs
shows an opposite effect on results compared to the antibody testing cost cas
in Figure 4.6. Unlike the HCV antibody testing for general population, RNA
tests are only performed on those who have a positive antibody test. In other
words, RNA test costs are only attributed to the detected v(t) · I(t) cases, and
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can be considered as an additional penalty cost to the number of the infected
I(t) in the cost function. To achieve a lower value of I(t), i.e., a smaller size
of compartment I, it is critical to reduce the incoming flow—new infections or
reinfections—to the compartment I, which indeed strengthens the preventive
value of early treatment. Therefore, more early treatment would be expected
when RNA testing cost becomes higher.
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Figure 4.6: Effect of RNA testing cost crs on the optimal treatment policy.
• Discounted cost. Many economic analyses consider time discounting of future
cost. To account for time discounting in the optimal policy, the only change







[cas(S(t) + I(t) +R(t))v
◦ + crsI(t)v
◦ + cdD(t)w(t)] dt,
where r represents the annual discount rate. Since lower weights are now placed
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on the costs that are incurred in future, treatment efforts are shifting towards
later periods (Figure 4.7). For a small discount rate of 0.03% per year, early
treatment is still needed in the optimal policy; whereas for a commonly used
discount rate of 3% per year, early treatment is no longer desirable and all
treatment efforts shift towards later periods.
























Figure 4.7: Effect of time discounting factor on the treatment policy.
4.4.4.2 Minimal screening rate
As we discussed in Section 4.4.4.1, the feasible delay stage is possible only if imple-
menting the maximum treatment rate throughout the remaining time can bring the
prevalence down to the target value. In other words, the feasibility question reduces
to whether the screening has detected sufficiently many patients for treatment. If the
screening rate is too low, many infected people still remain undiagnosed and do not
have access to treatment. In such a case, treatment at the maximum rate cannot
reduce the total prevalence to the target level. On the other hand, if screening at a
higher rate is able to detect more infected patients than needed, the optimal treat-
ment will only cover the exact amount that is needed to reduce the prevalence to the
target level, resulting in the delay periods of treatment as we observed earlier.






















































Target prevalence level: Reduction by 65%
(B) Prevalence
Figure 4.8: Optimal treatment policy and prevalence for different constant screening
rates.
screening rate decreases. When the screening rate decreases to a critical value vc, the
minimal screening rate, there is no delaying periods and the optimal treatment policy
is to simply treat every diagnosed patients with the maximum rate wmax = 100%
all the time. As such, the prevalence continues decreasing from the beginning until
reaching to the final target prevalence at the end of the horizon (Figure 4.8B).
More interestingly, we find that the minimal screening rate vc with the maximum
treatment rate wmax indeed results in the lowest total cost. Figure 4.9 shows that the
total cost increases with the screening rate, for different prevalence reduction targets.
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The dashed line indicates that the target prevalence cannot be achieved given that
screening rate value. These results imply that any constant screening rate higher than
vc (corresponding to the leftmost point of each solid curve) is deemed unnecessary.
The high screening rate could lead to more diagnosed cases than needed to achieve
the prevalence target. That is, the extra spending on screening has no contribution
in achieving the target prevalence. Thus, maintaining screening rate at the minimum
but necessary level is deemed the most efficient way of utilizing resources to achieve
the prevalence reduction target.


































Figure 4.9: Total cost for screening and treatment by constant screening rate for
different prevalence reduction targets.
Comparisons of results across different prevalence reduction targets (in Figure 4.9)
also highlight the importance of screening on the HCV elimination. To achieve 90%
reduction of prevalence, the minimal screening rate needs to be more than twice as
high as that for 65% reduction. The minimal screening rate is not simply linearly
scaled with the target prevalence reduction, because when the prevalence becomes
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lower, it is more difficult to detect new infected cases unless screening more aggres-
sively. From the comparisons, we also find that the total cost increment is largely
attributed to the increased screening rate.
4.4.4.3 Treatment capacity
While treatment rate remains constant at the maximum rate of 100% whenever the
treatment is not delayed, obviously the actual number of people receiving treatment
is not stationary over time due to the dynamic size of the diagnosed population
in compartment D. In practice, treatment capacity may not always meet the surge
of high treatment volume. To capture such a constraint, we include the following
constraint to the problem formulation P-MinC (4.10):
w(t)D(t) ≤ TC, ∀t, (4.23)
where TC represents the treatment capacity as a given parameter.
For a given constant screening rate vc, we solve the problem with treatment ca-
pacity TC = γ ·TC with varies value of γ < 1 (e.g., γ = 90%, 80%) and TC defined as
the maximum value of D∗(t) when the problem is solved without treatment capacity
constraint (4.23).
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(B) vc = vc for 65% prevalence reduction
Figure 4.10: Number of treatment under various treatment capacities.
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When screening rate is above the minimal rate (for the problem with unlimited
treatment), i.e., vc > vc , a large amount of patients are treated at the beginning of the
target-approaching treatment stage (Figure 4.10A). Such a big surge of the treatment
volume is smoothed out by the treatment capacity constraint. With limited treatment
capacity, treatment is extended for longer periods such that the final prevalence target
is still achievable.
When the minimal screening rate vc is chosen, the additional treatment capacity
constraint could render the problem infeasible, because w∗(t) = wmax is the only
feasible treatment policy in this case. Thus it would be interesting to investigate the
trade-off between the practical treatment capacity constraint and the final prevalence
target constraint. We evaluate the treatment policies w(t) = min{ TC
D(t)
, 1} with various
treatment capacity TC (illustrated in Figure 4.10B). Table 4.3 shows that reducing
treatment capacity to 75%·TC results in a less than 0.5% gap from the 65% prevalence
reduction target. For a higher reduction target of 90%, the final prevalence is more
robust against the treatment capacity: a similar feasibility gap can be achieved by a
treatment capacity 65% · TC.
4.4.4.4 Alternative formulations of cost functions
Quadratic cost structure. In many economic and engineering applications, quadratic
cost structure is a popular choice for the objective cost function of optimal control
models (118). Quadratic cost function has two appealing features. From an empirical
perspective, quadratic cost with respect to control variables represents a scaling-up
cost for increasing the control efforts. It makes sense in the context of disease screen-
ing: cost for screening 10% of the population is likely to be higher than twice of
the cost for screening 5% of the population, as increasing the coverage would require
extra manpower and resources in addition to the cost of tests themselves.
From the mathematical perspective, quadratic cost function is smooth and convex
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65% reduction1 100% 3,489 65.0% 18.6
95% 3,316 65.0% 18.6
90% 3,141 65.0% 18.6
85% 2,967 64.9% 18.6
80% 2,792 64.7% 18.5
75% 2,618 64.4% 18.5
70% 2,443 62.8% 18.2
65% 2,269 58.3% 17.4
60% 2,094 53.7% 16.6
55% 1,920 49.2% 15.8
50% 1,745 44.6% 15.0
90% reduction2 100% 6,613 90.0% 30.4
95% 6,282 90.0% 30.4
90% 5,952 90.0% 30.4
85% 5,621 90.0% 30.4
80% 5,290 90.0% 30.4
75% 4,960 89.9% 30.4
70% 4,629 89.8% 30.4
65% 4,298 89.6% 30.4
60% 3,968 89.3% 30.3
55% 3,637 88.5% 30.2
50% 3,307 85.1% 29.6
1 At minimal constant screening rate vc = 7.4%.
2 At minimal constant screening rate vc = 16.7%.
which has many desirable properties. In particular, in our optimal control problem,
a quadratic cost function will rule out the singularity issue, which makes it possible
to directly compute the optimal screening and treatment policy at the same time.
However, one challenge in implementing the quadratic cost function in our problem
is the lack of realistic estimates for the coefficient of the quadratic terms.
In the following, we present the optimal policy with quadratic cost function based
on assumed values for the scaling-up costs, and discuss the policy insights from the
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qs[(S + I +R)v]







where qs and qd represent the scaling-up costs ($ per person-squared) for screening
and treatment, respectively. To determine scaling-up costs for numerical analysis, we
calculate the base value of qs such that, with the initial population size, the quadratic
cost qs[(S + I + R)v]
2 is comparable to and has a similar order of magnitude as the
linear cost term cas(S+I+R)v+c
r
sIv. The same method is applied for calculating the
treatment scaling-up cost qd. In the following numerical results, we use q
0
s = 5× 10−5
and q0d = 5 × 10−2 as the baseline values, and vary the value by an order of 100







as the low values,
and 100qs and 100qd as the high values. In Figure 4.11, the upper panels show the
optimal rate, and the lower panels show the corresponding numbers of screening and
treatment, respectively.
With moderate baseline scaling-up costs (middle panels), the optimal policy reallo-
cates the intervention efforts over time in a smooth and steady way, as the quadratic
cost structure could lead to significant penalties if the numbers of treatment and
screening have dramatic changes over time. In particular, a relative stable number
of patients, not necessarily all the diagnosed patients, receive treatment during the
first 10 years. By comparing the results across different settings of qs and qd, we find
that a higher scaling up cost results in a smoother intervention efforts throughout the
horizon. When scaling-up cost is low for screening but high for treatment, the number
of treatment remains steady over time, whereas the number of screening is adjusted
dynamically to supply proper amount of diagnosed patients to be treated. When
scaling-up cost is high for screening but low for treatment, screening tends to stay
stationary, whereas the number of treatment follows the dynamic size of diagnosed
population with a maximum treatment rate of 100%.
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Figure 4.11: Optimal treatment and screening rates with quadratic cost functions.
Consideration of Health Outcomes for Infected People. Policy makers
may also consider other possible alternatives of cost functions to seek to balance
the cost with health outcomes. For example, to balance the number of liver-related





[(cas(S + I +R)v + c
r
sIv + cdDw) + cm(m− µ)(I +D)]dt;
or to balance the total cost with the total quality adjusted life years of the population,





{π(eSS + eII + eDD + eRR)− [cas(S + I +R)v + crsIv + cdDw]} dt,
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where π represents the willingness-to-pay value, eS, eI , eD, and eR represent the qual-
ity of life for each compartment, respectively.
We remark that as long as the health outcome terms added to the objective
functions are linear with respect to the control variables, the structure of the optimal
control policy will not change: singular arcs may exist when both screening and
treatment are control variables, and the optimal treatment policy is a pure bang-
bang policy when the screening rate is fixed.
4.4.5 Constant screening rate assumption revisited
We close this section by revisiting the assumption of the constant screening rate. Our
previous results have shown that the constant screening rate assumption makes the
problem tractable, and also lead to the simple structure of the optimal treatment
policy. Of course, such a simplifying assumption comes at the price of a suboptimal
cost compared to the optimal solution without the assumption. In the following, we
attempt to numerically characterize how much we may lose by assuming the constant
screening rate.
Since the ideal benchmark for comparison—the exact optimal policy to the original
problem (4.10)—is not available, we instead use a series of feasible solutions that
allow certain changes of screening rate over time in our comparisons (Table 4.4). In
particular, we obtain (1) the optimal screening and treatment policies for quadratic
cost functions with various scaling-up cost values, and (2) the optimal treatment
policy with a piece-wise constant screening rate where different screening rates are
fixed for the first and the second half of time horizon, respectively (all combinations
of a grid search for values from 0 to 15% by every 1% increment are evaluated).
The lowest total cost is attained with the optimal solution to quadratic cost func-






). We use this best available policy
as the baseline for comparisons. Minimal constant screening rate policy results in a
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Table 4.4: Comparisons of policies with dynamic screening rates.
Policy Total cost ($ Million) Gap
Quadratic cost function with scaling-up cost (qs, qd)
(Low, Low)1 18.14 –
(Low, Mid) 18.34 1.1%
(Low, High) 18.82 3.8%
(Mid, Low) 18.27 0.7%
(Mid, Mid) 18.36 1.2%
(Mid, High) 18.88 4.1%
(High, Low) 18.37 1.3%
(High, Mid) 18.37 1.3%
(High, High) 18.50 2.0%












vc = vc = 7.4% 18.58 2.4%
1 We use the low, medium, and high values for scaling-up costs de-
fined in Section 4.4.4.4.
2.4% gap compared with the baseline policy. Most policies with quadratic scaling-up
costs outperform the constant screening rate policy, which take the advantage of a
fully dynamic structure of the controls. Among the piece-wise constant screening
policies as a class of more practical policies, the minimal constant screening rate pol-
icy is outperformed by only two piece-wise policies with a small gap, implying that a
simple relaxation on the constant screening assumption will not significantly improve
the outcomes.
A common feature among the policies with lower cost is that screening tends to
be at a higher rate in early periods and reduces to a lower level or even stops later,
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which indicates a simple structure of screening rate for potential improvements if the
implementation is possible in practice.
To summarize, our comparisons imply that the assumption of constant screen-
ing rate does not result in a significant loss of performance. The minimal constant
screening rate policy performs well and close to the best available policy with both
dynamic screening and treatment rates.
4.5 Optimal Resource Allocation: Budget Constraint
In this section, we aim to address a different policy question in HCV elimination:
for a given amount of budget per year, what is the optimal allocation for screening
and treatment to minimize the disease burden? In particular, we refer to the disease
burden as the cumulative number of infected people, or the cumulative prevalence.







cas(S + I +R)v + c
r
sIv + cdDw ≤ B (4.26)
v(t), w(t) ∈ [0, 1], ∀t ∈ [0, tf ],
where B represents the annual budget which is assumed to be constant over time.
In addition to the switched roles of disease burden (prevalence) and the cost for the
objective function and constraint in the formulation, the budget allocation problem
(4.25) differs from the cost minimization problem (4.10) in the way how resources
are allocated over time. Cost-minimizing policy employs a dynamic allocation of
resources in screening and treatment, which is informed by the optimal solution but
not policy makers; whereas in the budget allocation problem, the total resources
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spent for screening and treatment is limited to an upper bound, which can be pre-
determined and planned by policy makers. As such, the budget allocation model is
suitable for the cases where there is a central planner designing the HCV epidemic
control program under certain budget limit.
The following proposition shows the structure of the optimal allocation strategy
when a stationary size of total population is considered—a simplifying assumption
for the convenience of analyses. We believe such an assumption is not restrictive as
the demographic dynamics (e.g., the change of the total number of the population)
are presenting limited changes compared to the epidemic dynamics (e.g., the change
of the number of infected, diagnosed, or the new infections).
Proposition 4.11 (Treatment-first policy) Consider a population with a station-
ary size by assuming Λ = µN0 and m = µ. The optimal budget allocation policy always
prioritizes treatment; when there are remaining budget after covering the treatment
for all diagnosed patients, allocate the remaining budget for screening.
The treatment-first allocation policy structure is intuitive. Recall the objective
is to reduce the number of the infected people, including the undiagnosed and the
diagnosed, over time. Treatment directly reduces the number of infections; whereas
screening takes effect in an indirect way: it redistributes the undiagnosed and the
diagnosed patients within the infected population, which only matters when the bud-
get is able to treat more patients than all the currently diagnosed patients. Without
screening, excessive treatment capacity cannot reach the infected but undiagnosed
population. In other words, the role of screening is intermediary by making treatment
possible but not direct, and the optimal strategy is to allocate budget for screening
such that number of treatment is always maximized.
Remark 4.2 The treatment-first policy structure also holds true if the objective func-




In this section, we present the numerical analyses of the budget allocation problem.
We apply the same parameter values that are described earlier in Section 4.4.3 in all
our numerical analyses. In the following, we will first present the optimal treatment
and screening policies (solved by the GPOPS-II solver) under various annual budget,
and compare the optimal allocation policy with a set of heuristic allocation policies.
We also evaluate the effect of budget on the WHO targets. Finally, we explore a
specific setting where the treatment-first policy might fail, and highlight the the
effect of awareness of infection on the budget allocation.
4.5.1.1 Prioritize treatment
Figure 4.12 presents the optimal treatment and screening rates under various annual
budget levels. The solutions clearly demonstrate a common“treatment-first” policy:
allocate budget for treatment as the first priority; whenever there is remaining budget,
allocate them for screening. In particular, when the annual budget is very tight (e.g.,
B = $30, 000), all efforts are devoted into treatment (Figure 4.13). When there
are more budget available (e.g., B = $0.1 ∼ 0.5M), all budget will be first spent
on treatment in early periods, but not all diagnosed patients can be treated at this
stage (i.e., w(t) < 1); as treatment continues, there will be less diagnosed patients
waiting, and then the budget is able to cover all these patients at a treatment rate
w(t) = 1, and utilizes the remaining budget for screening. For example, in Figure
4.13, with annual budget B = $0.1M , screening is available only in the second half
of the planning horizon. When a higher budget is available, it is the best to treat the
existing diagnosed patients as much as one can, and in the mean time to screen the





















































































B=$30,000 B=$100,000 B=$200,000 B=$500,000
Figure 4.13: Fraction of budget allocated to screening and treatment.
4.5.1.2 Comparison of different budget allocation policies
From a practical viewpoint, a natural question for the optimal treatment-first policy
is that how much would the model outcomes depend on such a prioritization scheme?
In other words, we are interested in investigating what if the prioritization is relaxed
in the resource allocation. In the following, we compare the treatment-first policy
with a set of heuristic policies to seek answers to the above questions.
We define a class of policies denoted as “Scr-x policies” as follows. First allocate
the screening fraction, x%, of budget for screening, and (100− x)% for treatment; if
treatment budget is sufficiently large to cover all diagnosed patients, the remaining
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budget will be allocated for screening. That is, Scr-0 policy is synonymous with the
optimal treatment-first policy. With a high budget, Scr-x policies with different value
of x may represent the same policy. For example, when B = $2M , Scr-0 and Scr-30
represent the same allocation policy since 70% of the budget is always sufficient to
cover all the existing diagnosed patients with a treatment rate 100%.













Low budget level ($0.5M/year)
Scr-0 (treatment-first) 6.63 71% 3% 93%
Scr-10 6.63 71% 3% 93%
Scr-20 6.64 71% 3% 93%
Scr-25 6.64 71% 3% 93%
Scr-30 6.66 71% 3% 93%
Scr-35 6.74 73% 7% 83%
Scr-40 6.82 75% 14% 70%
Scr-50 6.99 79% 26% 50%
Scr-60 7.16 83% 37% 35%
Scr-70 7.33 88% 45% 24%
High budget level ($2M/year)
Scr-30 (treatment-first)2 3.93 12% 28% 96%
Scr-35 3.94 12% 28% 96%
Scr-40 4.00 12% 28% 96%
Scr-45 4.18 12% 28% 96%
Scr-50 4.47 14% 39% 94%
Scr-55 4.80 23% 68% 83%
Scr-60 5.14 31% 80% 72%
Scr-65 5.47 40% 86% 62%
Scr-70 5.81 49% 90% 53%
1 Similar results for number of new infections. 2 Identical to all Scr-x policies with x ≤ 30.
Table 4.5 summarizes the performance of the optimal treatment-first policy and
the heuristic Scr-x policies. Figure 4.14 presents the fractions of budget that are
actually spent on screening in a selected subset of the policies for comparison. We find
that there exists a range of screening fractions that are insensitive to the performance
outcomes, such as screening fractions ≤ 25% for a low budget B = $0.5M and
screening fractions ≤ 40% for a high budget B = $2M . From Figure 4.14, we observe
that in these policies, since screening initially takes up certain share of budget from
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(B) Annual budget of $2M
Figure 4.14: Fraction of budget spent on screening by different allocation policies.
treatment, treatment needs longer time but is still able to reduce the number of
diagnosed patients to a “full coverage”, and then continues with maximum treatment
rate 100%. Thus, diverting budget to screening within certain amount and in early
periods has limited effects on the cumulative disease burden and the final outcomes,
as long as the resources for treatment are able to cover all diagnosed patients in later
periods. However, when too much share of budget is allocated for screening, treatment
may never catch up with all diagnosed patients, leading to a poorer performance
outcomes.
4.5.1.3 Budget and WHO targets
To evaluate the effect of budget on the actual epidemic control impact, we calculate
the four metrics in the WHO target (215) (number of new infections, number of liver-
related deaths, diagnosis rate, and treatment rate in treatment-eligible patients) for
the optimal allocation policies with various budget levels.
Figure 4.15A shows the outcomes of the impact targets: the number of new infec-
tions and liver-related deaths at the final time compared with the initial values. We
use the number of the infected patients (I(t) + D(t)) as the surrogate of number of
liver-related deaths ((m−µ)(I(t)+D(t))) as the two quantities have the same results
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when scaled by the initial value at t = 0. We find that the reductions in the number
of the infected and the number of new infections mostly overlap. This is because
new infections (αS + βR) I+D
N
is very sensitive to the number of the infected (I +D)
when the prevalence is low (e.g., <5%). Annual budget of $1.3 million reduces the
number of infections by 65% of the initial value, whereas it needs a higher budget
of $2.1 million annual budget to achieve the 90% target reduction of the number of
new infections. We remark that a more detailed model that considers disease natural
history may better differentiate the results in the number of deaths from that of new
infections; yet the approximate overall estimates projected from our model are still
useful to show the major impact of interventions at various budget levels.
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(B) Coverage targets
Figure 4.15: Impact of annual budget on the WHO impact and coverage targets.
Figure 4.15B shows the coverage of diagnosis (D) among the infected (I+D) and
the coverage of treatment (R) among the treatment-eligible patients (D + R). Since
budget allocation always prioritizes treatment, the treatment coverage remains high
at all annual budget. On the other hand, screening is limited or even not available
under very low annual budget. With annual budget of $2 million, diagnosis rate can
only be as high as 28%. We remark that although diagnosis rate tends to increase
with the annual budget, the diagnosis rate estimate becomes less informative given
118
the high budget (e.g, >$3 million), as the total number of the infected is already very
low (see Figure 4.15A).
The above observations imply that if all the four WHO targets for HCV elimina-
tion are considered as constraints, these constraints may not be binding at the same
time at the optimal solution. Given the low priority of screening in the optimal bud-
get allocation policy, diagnosis rate target is difficult to achieve. Policy makers must
make trade-offs between this target and the others performance measures related to
disease burden (e.g., prevalence) as in the impact targets.
4.5.1.4 Budget allocation when awareness matters
As discussed earlier in Section 4.5.1.1, screening does not directly contribute to re-
ducing disease prevalence. Its contribution is indirect, by identifying more patients
eligible for treatment, especially when budget for treatment is capable of treating
more diagnosed patients.
We remark that such an interpretation is subject to our current model formula-
tion. The infection force is defined as α · I+D
N
(and similarly β · I+D
N
for reinfections),
implying that the numbers of the undiagnosed (in compartment I) and the diagnosed
population (in compartment D) have the same effect. In other words, awareness of
infection does not affect the infectivity of diagnosed patients. On the other hand, in
many realistic cases of epidemic control, it is possible to reduce the chance of trans-
mitting the disease from those who are aware of their infections through preventive
interventions such as education or risk reduction programs. As such, by increasing the
diagnosis rate among the infected patients, screening can reduce the infection force
and thus also directly contributes to reducing the total disease burden. To capture





for reinfections), where κd represents the relative infectivity of the diagnosed
patients.
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We solve the model with the new definition of the infection force using the base
case parameter settings (for India population profile), and find that κd varying from
0.1 to 0.9 has no effect on the optimal policy. This is possibly because the benefit
of screening is still limited given that the prevalence and infection rate are not high
enough such that the screening can make a difference. We next experiment several
parameter settings with higher prevalence and infection rate. Figure 4.16 shows the
optimal policies of allocating annual budget B = $2M for a population with an initial
prevalence rate of 10%, a high infection rate α = 0.05, and decreasing κd values. In
such a high risk population, when awareness of infection reduces the infectivity by
70% (κd = 0.3), screening shows its effects: it is optimal to start with spending all
budget in screening rather than treatment. The lower the κd value is, the greater
benefits the screening will have, and thus the longer the time periods for prioritizing
screening will last for. This way, the initial investment in screening reduces the
infection force, which will also decrease the number of future infections as a long
term benefit. Following the upfront screening periods, the optimal budget allocation
resumes the treatment-first policy through the rest of time horizon.

















































Globally, 130-170 million people are chronically infected with HCV, and more than
350,000 people die from HCV every year. The recent availability of highly-efficacious
therapies provide a hope to eliminate HCV by 2030 (35). However, several barriers
exist before HCV can be eliminated worldwide. Our study aims to identify optimal
screening and treatment policies under constrained budgetary resources, and provide
insights to tackle the ongoing HCV epidemic.
In this study, we develop an epidemic model for HCV transmission. Building
upon this dynamic system, we formulate two optimal control problems to identify
the optimal screening and treatment policies for HCV elimination. In particular,
in the first problem, we consider a cost minimization problem subject to a target
prevalence constraint. We analytically show that the optimal treatment is a pure
bang-bang policy without singular arcs for any given screening rate. The policy with
the minimal screening rate and non-stopping treatment at the maximum treatment
rate is deemed an appealing strategy, which performs closely well compared with
other policies with more dynamic structures. In the meantime, it maintains a simple
policy structure which is straightforward for implementation. In the second problem,
we consider a budget allocation problem that aims to minimize the disease burden
subject to a fixed budget constraint. We show that optimal allocation policy follows
a simple treatment-first rule in both analytical and numerical results.
Our study has limitations. First, in our formulation, we do not consider behav-
ioral and preventive interventions that could reduce HCV transmission such as harm
reduction programs for high risk population (e.g., needle exchange programs, opiate
substitute treatment (227)), mainly because of the lack of data to quantify the re-
lations between the cost and effect (e.g., reduction in the infection rate). On the
other hand, if the costs and effects of such interventions are available for a particular
population or in a specific region, our model can be used to determine the optimal
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screening and treatment strategies for the given level of such preventive intervention.
Second, our model has limited details in modeling HCV natural history. We
choose to keep the model parsimonious to maintain the basic disease transmission
structure, at the price of losing certain details of disease progression. As a result, our
model may oversimplify the evaluation of the number of liver-related deaths as one
WHO target measure, which could be dependent on specific stage of liver disease.
Incorporating the information of age-groups and quality of life are also limited by
this type of compartment models.
Although we present the numerical analyses as a case study for HCV epidemic
elimination in India, our work can be easily extended to other countries or different
HCV epidemic settings. Decision support tools can be built on the analytical policy
structure and numerical solutions for policy makers to design intervention plans for
HCV elimination. Recommended policies can be evaluated in a separate model so that
a more comprehensive set of outcomes (e.g., deaths by liver disease stage, disability-
adjusted life years for measuring disease burden) could also be provided to policy
makers for a better planning.
122
APPENDIX A
APPENDIX FOR CHAPTER 2
A.1 Estimates of Annual CLL Incidences in the Base Case
In the simulation model, the annual incidence of CLL between 2000–2011 were ob-
tained through model calibration (see Appendix A.2), and the annual incidence be-
tween 2011-2014 were obtained from published sources (196, 198, 199, 197). From
2015 onwards, we assumed stationary annual incidences in our base case results, i.e.,
a constant annual incidence as the same as the 2014 estimate (Table A.1). In the
sensitivity analysis, we adjusted for increase in the annual CLL incidence because of
the aging of US population (see Appendices A.6 and A.7.3).
Table A.1: Annual incidence estimates.
Year Annual incidence























We developed a microsimulation model, simCLL (simulation model of CLL manage-
ment), that simulated the clinical practice of chronic lymphocytic leukemia (CLL)
management in the US from 2011 to 2025. Model components included population
characteristics, incidence of CLL, survival outcomes using existing and emerging ther-
apies, cost of treatment and disease management, and quality of life associated with
CLL.
We started the simCLL from year 2000 and matched simulation outcomes with
Surveillance, Epidemiology, and End Results (SEER) data until 2010. The period
from 2000-2010 was used as warm-up phase in our simulation model. The purpose
of the warm-up phase was to generate a reasonable population profile that closely
matched the observation data from SEER so that the base case simulation will start
with this baseline population from 2011. In the warm-up phase, if the simulation
outcomes did not match with SEER data, we calibrated (i.e., adjusted) model input
parameters until the model outcomes and SEER data matched closely.
In particular, during the 2000-2010 warm-up period, the simulation model started
from an empty population in 2000, generated new incidences for each 5-year age
group (i.e., 30-34, 35-39, etc.) in each model cycle according to the SEER incidence
data (211). The following input parameters were calibrated: time-to-treatment prob-
ability, progression and mortality risks for fit and unfit patients, mortality risks for
relapsed patients. The primary calibration target was 11-year CLL prevalence and
the age distribution in 2011 (i.e., at the end of warm-up period). We identified 100
best combinations of calibration parameters by grid search, and used their averages
as the calibrated values. Figure A.1 shows the comparison of CLL prevalence in
2011 between the simulated population and the SEER data (Figure A.1-A), and age
distributions of CLL patients in 2011 (Figure A.1-B). Therefore, with the calibrated
parameters, we obtained the population characteristics (i.e., joint distribution of age
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and health states) in 2011, which was used as the initial population for our base case
results (Figure A.2).
Note that the SEER data does not fully cover the US population. To recover the
total disease population in the US, we scaled up the number of new CLL incidences
during 2000-2011 in our simulation model such that the total number of CLL patients
in the simulation is close to the national estimates of 126,299 cases in 2011 (210).
Figure A.1: Model calibration results.
(A) Comparison of limited-duration prevalence from SEER and simulation by year.
(B) Comparison of age distribution at the end of calibration phase.
Figure A.2: Calibrated population distribution by age and health states in 2011.
125
A.3 Survival Model Fittings, State Transition Probability
Estimation and Validation
Our microsimulation model, simCLL, included four health states: watchful waiting,
first-line treatment, relapse, and dead (Figure A.3). The transition probabilities be-
tween the health states were estimated from survival distribution from the published
survival curves. In particular,
• Transition probabilities from watchful waiting to first-line treatment were based
on time-to-treatment results from a large clinical study (171);
• Transition probabilities from first-line treatment to relapse and death states
were based on the progression-free survival (PFS) and overall survival (OS) dis-
tributions for the specific first-line treatment option and patient characteristics;
• Transition probabilities from relapse to death were based on the OS distribution
of treatment for relapsed patients.
Figure A.3: Clinical pathways of CLL patients in microsimulation model.
A.3.1 Fitting of survival distributions
We first digitized the Kaplan-Meier curves from published studies (1), and fitted the
extracted data points with parametric survival models. We considered the following
commonly used parametric survival models in survival analysis:
• Exponential distribution: S(t) = exp(−λt) (shape parameter λ).
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• Weibull distribution: S(t) = exp((−λt)p) (shape parameter λ, scale parameter
p).
• Log-logistic distribution: S(t) = 1
1+(λt)1/γ
(shape parameter λ, scale parameter
γ).
• Log-normal distribution: S(t) = 1−Φ( ln t−µ
σ
) (shape parameter µ, scale param-
eter σ, the cumulative distribution function Φ of the standard normal distribu-
tion).
• Gompertz distribution: S(t) = exp (−λγ−1(exp(γt)− 1)) (shape parameter λ,
scale parameter γ).
The best fitted parametric survival distributions were selected based on the goodness-
of-fit metrics (e.g., Akaike information criterion, Bayesian information criteria), as
well as visual inspections for a reasonable extrapolation beyond the limited follow-up
periods (151). Parameters of the fitted distribution for each survival model are pro-
vided in Table A.2, and comparisons of goodness-of-fit between survival distributions
are provided in Table A.3.
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Table A.2: Fitted survival distributions and parameters.
Treatment Survival Survival model Shape parameter Scale parameter
Time to treatment
Age ≥ 55 yr weibull 0.011 0.742
Age < 55 yr weibull 0.014 0.708
First-line
FCR, fit OS weibull 0.006 1.202
FCR, fit PFS weibull 0.015 1.349
FCR, del17p OS log-normal 3.452 0.824
FCR, del17p PFS log-normal 2.53 0.629
Clb, unfit OS weibull 0.01 1.164
Clb, unfit PFS gompertz 0.047 -0.013
Clb, del17p OS weibull Extrapolateda
Clb, del17p PFS gompertz Extrapolateda
GClb, unfit OS weibull 0.012 1.751
GClb, unfit PFS weibull 0.031 1.959
GClb, del17p OS weibull Extrapolateda
GClb, del17p PFS weibull Extrapolateda
Ibrutinib, fit/unfit OS log-normal Extrapolatedb
Ibrutinib, fit/unfit PFS log-normal 4.377 1.229
Ibrutinib, del(17p) OS exponential 0.007
Ibrutinib, del(17p) PFS exponential 0.004
Relapse
FCR OS weibull 0.015 0.852
BR OS weibull 0.023 1.451
Idelalisib+R OS weibull 0.004 0.867
Ofatumumab OS log-logistic 0.071 0.745
Ibrutinib OS log-normal 5.039 2.006
HSCT OS log-normal 4.069 2.224
a: For patients with del(17p), PFS and OS outcomes for Clb treatment were extrapolated by applying the
hazard ratio (HR) associated with del(17p) (i.e., HR=9.3 for OS, and 7.3 for PFS) observed in CLL8 trial (95).
b: Due to limited events observed in the ibrutinib arm of RESONATE2 trial, we did not directly fit
the survival model to the Kaplan-Meier estimates of ibrutinib arm; we first fitted the survival model to the Clb
arm (with a log-normal distribution with a shape parameter 5.119 and a scale parameter 1.938) and then applied
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A.3.2 Conversion to transition probabilities
We converted the fitted survival distribution to the transition probabilities for each
model cycle (i.e., 4 weeks in our microsimulation) using the Bayes’ Formula: given
the survival function S(t) for the random survival time T , the transition probability
m(t) for model cycle t is calculated by
m(t) =
P(t ≤ T < t+ 1)





A.3.3 Mortality and progression risk
Mortality risk determined transition from any state to the “death” state, which was
defined as the maximum value of cause-specific mortality and other-cause mortality
in each cycle. The cause-specific mortality for each cycle was estimated based on OS
data of each specific treatment (Table 3.3) following the above described procedure;
other-cause mortality is age-dependent and was estimated from the US life tables
(16). For watchful waiting state, we assigned only the background mortality.
Progression risks determined transitions from the first-line treatment state to re-
lapse state. By definition, PFS accounted for both progression and death events
during the follow-up time. Thus, to obtain the risk for progression only, we sub-
tracted the estimated mortality risks from the transition probabilities estimated from
the PFS curves.
A.3.4 Validation of model-projected survival
To validate that the simulation model predicted the survival results in line with the
observed survival data of each specific treatment, we collected the progression-free
time for first-line patient and the survival time (after progression) for relapse patient.
For those who were alive at the end of the simulation, their progression-free time
or survival time were considered as censored. Then we obtained the Kaplan-Meier
estimates of the simulation survival results. In each of the following figure, we plotted
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the observed survival curves obtained from published trials (in red), fitted survival
curves as the model input (in blue), and the simulated survival result (in black).
Figure A.4 shows reasonable matches between the model outputs and observed
survival from clinical studies. In a few relapse treatment settings, the simulated sur-
vival curves were lower than the observed survival in very late periods; this is mainly
because these patients are typically in old ages where the age-specific background
mortality could dominate the mortality risk extrapolated from the fitted survival
curve. Overall, these results represent a good validation of our simulation model.











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































A.5 Out-of-pocket Cost Calculation for Medicare Patients
Unlike chemotherapies which are covered by Medicare Part B, oral targeted therapies
are covered in Medicare Part D. Patients in Medicare Part D would need to pay out-
of-pocket expenses for these drugs. In particular, after spending the initial coverage
limit, patients enter the coverage gap (known as the “donut hole”). Although the
Affordable Care Act (ACA) has started to gradually lower the cost share for patients
in the coverage gap to reduce the total out-of-pocket costs (expected to reduce to 25%
cost sharing by 2020, see Table A.6), CLL patients may still face high out-of-pocket
costs in the oral targeted agents. We considered the reducing coverage gapes when
we estimated the average lifetime out-of-pocket drug costs for CLL patients.
















2011 310 2840 6447.5 0.5 0.93
2012 320 2930 6657.5 0.5 0.86
2013 325 2970 6733.5 0.475 0.79
2014 310 2850 6455 0.475 0.72
2015 320 2960 6680 0.45 0.65
2016 360 3310 7062.5 0.45 0.58
2017 b 360 3310 7062.5 0.4 0.51
2018 360 3310 7062.5 0.35 0.44
2019 360 3310 7062.5 0.3 0.37
2020 onwards 360 3310 7062.5 0.25 0.25
Note: Adapted from http://www.q1medicare.com/PartD-The-MedicarePartDOutlookAllYears.php
a: Catastrophic coverage starts after this point.
b: Assume the deductible and initial coverage limit in 2017 and onwards to be the same as those in 2016.
The out-of-pocket cost was calculated as follows (213). Patients first pay all drug
spending within the deductible (e.g., $320 in 2015 plan), and have 25% cost sharing
until the total drug spending has reached the initial coverage limit (e.g., $2960 in 2015
plan). Then patients enter the coverage gap, where they are responsible for a large
share of drug cost (the exact share depends on the plan of a specific year, see Table
A.6), until the patients’ cumulative total out-of-pocket costs of this year have reached
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the total out-of-pocket spending limit (e.g., $6680 in 2015 plan). The rest of drug
cost will be covered by the catastrophic coverage with a 5% cost share. We provided
two working examples for calculating the annual out-of-pocket costs for ibrutinib for
2015 and 2020 plan, respectively (Table A.7).
Given the annual total cost of $130,000 for ibrutinib, the annual out-of-pocket
costs of ibrutinib was estimated as $10,400-$10,600, which were not affected substan-
tially by the reducing coverage gap with ACA, because majority of the ibrutinib cost

































































































































































































































































































































































































































































































































































A.6 Adjustment of Annual CLL Incidence with Aging US
Population
In the base case, we assumed a stationary annual CLL incidences from 2015 onwards
(Appendix A.1). In the sensitivity analysis, we considered an increase in CLL in-
cidence because of the aging of US population (Table A.8). Thus, we adjusted the
annual incidence of CLL with the US population projection data as follows.
1. We obtained age distribution of CLL incidences in 2012 from the most recently
released SEER data;
2. Given the estimate of total CLL incidences in the US in 2012 (198), we calcu-
lated the number of CLL incidences by age groups in the US in 2012.
3. Based on the 2012 US population data from US Census Bureau (223), we esti-
mated the age group-specific incidence rates (e.g., # per 100,000 persons in age
group 60-64 year-old)
4. We applied the estimated age group-specific incidence rates to the US popula-
tion projection data (224) (the population projection data is available for every
5 years from 2010, so we interpolate the estimates within each 5 years).
Table A.8: Increase of population in old age groups compared with 2015 population.
Age 2020 2025 2030 2035 2040 2045 2050
60-64 11.0% 12.3% 4.5% 1.7% 4.3% 12.2% 17.2%
65-69 12.5% 25.2% 27.1% 18.6% 15.8% 19.1% 28.4%
70-74 29.1% 45.8% 63.0% 66.1% 55.8% 52.6% 57.6%
75-79 21.7% 58.2% 79.9% 102.4% 107.4% 95.8% 92.8%
80-84 9.5% 34.9% 77.2% 103.5% 131.0% 138.9% 127.7%
85-89 4.7% 14.6% 37.9% 79.9% 122.1% 164.6% 195.0%
65 16.6% 35.4% 52.1% 62.7% 69.1% 74.2% 80.8%
75 12.8% 37.7% 65.8% 95.6% 118.8% 130.0% 135.2%
Based on population projection data from US Census Bureau (224).
Following the above-described approach, we obtained the incidence estimates ac-
counting for the aging of the US population (Table A.9). We also calculated the
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percentages of new CLL incidences with age >70 and >65 by year (Table A.9), which
clearly shows the aging trend in the CLL incidences in the next few decades.
Table A.9: Annual incidence estimates adjusted for aging US population.
Year Annual incidence % age >70 % age >65
2000-2010 SEER incidence rescaled
in calibration
- -
2011 14,570 51.1% 65.4%
2012 16,060 51.5% 67.0%
2013 16,228 51.8% 67.5%
2014 16,569 51.7% 67.7%
2015 16,912 51.5% 68.0%
2016 17,312 52.1% 68.5%
2017 17,707 52.6% 69.1%
2018 18,105 53.0% 69.6%
2019 18,505 53.5% 70.0%
2020 18,902 53.9% 70.5%
2021 19,340 54.7% 71.3%
2022 19,777 55.4% 72.0%
2023 20,216 56.1% 72.7%
2024 20,653 56.8% 73.4%
2025 21,094 57.5% 74.0%
2026 21,516 58.4% 74.6%
2027 21,938 59.3% 75.2%
2028 22,364 60.1% 75.8%
2029 22,787 60.9% 76.4%
2030 23,210 61.7% 77.0%
A.7 Results of Sensitivity Analyses
A.7.1 Analysis of drug cost discount
We used 26% discount off average wholesale price (AWP) as our base case estimates
of drug cost. In sensitivity analyses, we considered different AWP discount estimates.
We applied the 37% discount of AWP as lower limits of drug costs, suggested by an-
other study by congressional budget office which estimated that the “lowest price paid
by any private-sector purchaser for the drug product” (including discounts, rebates,
chargebacks, and other pricing adjustments) to be 37% lower than AWP (104, 139).
In addition, we performed the analyses with full AWPs as upper limits of drug costs
for comparisons. Table A.10 presents the major change of the model results compared
with our base case results.
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The ICER of oral-targeted therapies remained greater than $160,000/QALY given
the range of AWP discounts, which is still above a reasonable range of willingness-
to-pay ($50,000/QALY–$150,000/QALY). These results show that even using the
expected discounted drug price, these therapies will not be deemed cost-effective.





Change Full AWP Change
Annual cost of CLL management
CIT
2011 743,062,907 649,620,128 -13% 914,519,232 23%
2014 948,972,374 827,749,057 -13% 1,192,129,412 26%
2016 994,163,585 867,002,274 -13% 1,248,639,494 26%
2020 1,137,790,265 991,094,998 -13% 1,425,418,922 25%
2025 1,116,012,859 972,161,578 -13% 1,398,157,351 25%
OTT
2011 743,062,907 649,620,128 -13% 914,519,232 23%
2014 917,874,069 802,374,898 -13% 1,148,186,659 25%
2016 1,657,380,404 1,427,638,370 -14% 2,159,133,619 30%
2020 4,238,284,439 3,621,650,816 -15% 5,680,660,839 34%
2025 5,130,373,316 4,381,990,566 -15% 6,892,176,447 34%
Cumulative cost 2011-2025
CIT 15,218,203,943 13,266,836,906 -13% 19,036,395,847 25%
OTT 44,395,963,354 38,031,694,677 -14% 59,021,379,222 33%
Increment 29,177,759,410 24,764,857,771 -15% 39,984,983,375 37%
Lifetime cost of OTT
2011 146,744 127,014 -13% 188,021 28%
2014 331,376 284,982 -14% 435,418 31%
2016 604,092 516,065 -15% 811,620 34%
Lifetime out-of-pocket cost of OTT
2011 9,246 8,412 -9% 11,236 22%
2014 27,416 25,315 -8% 32,339 18%
2016 56,560 52,150 -8% 66,944 18%
Incremental cost-effectiveness
Incremental total 20,167,080,889 17,121,161,329 -15% 27,366,527,123 36%
discounted cost
ICER ($/QALY) 189,226 160,646 -15% 256,778 36%
A.7.2 One-way sensitivity analysis
In the one-way sensitivity analysis, we ran the model with the upper and lower limits
of each parameter value. For some parameters that belong to the same category, we
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changed the values of these parameters in the same group. For example, we changed
the cost of all oral targeted agents by ±20% together (rather than changing the cost of
ibrutinib and idelalisib separately); we adjusted the survival distributions for all oral
targeted therapies with hazard ratios of 0.8 or 1.2 together (rather than adjusting the
survival distributions for one therapy at each time). Utility and oral targeted therapy
discountinuation probability were varied within their reported confidence interval,
We presented the sensitivity analysis results for four main model outcomes using
tornado diagrams (Figure A.5): (1) incremental annual cost of CLL management
of oral targeted therapies compared with chemoimmunotherapies in 2016, when oral
targeted therapies start to be used in first-line setting; (2) incremental cumulative
cost of oral targeted therapies from 2011–2025; (3) lifetime treatment cost of oral
targeted therapies for patients using oral targeted therapies as first-line treatment
after 2016. The tornado diagram for the incremental cost-effectiveness ratio of oral
targeted therapies for 2011-2025 was presented in Figure 2.5A in the main text.
Following tornado diagrams depict sensitive model parameters and their effects to
the model outputs.
A.7.3 Scenario analysis
We evaluated the model results under two scenarios considering (1) the CLL incidence
rates rising with aging population in the US (see Appendix A.6 for more details), and
(2) the gradual transition from CIT to oral targeted therapies for fit patients in the
first-line setting, where we assumed 25%, 50%, 75%, and 100% utilization of oral
targeted therapies in 2016, 2017, 2018, and 2019, respectively. We presented the
results and comparisons to the base case in Table A.11.
A.7.4 Probabilistic sensitivity analysis (PSA)
To define the sampling distribution for each parameter in the PSA, we assumed a
mean value of its baseline value, and a standard deviation of half width of its range
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Figure A.5: Tornado diagrams for one-way sensitivity analysis.
that is defined for one-way sensitivity analysis. We follow the recommended sta-
tistical distributions by the parameter types (31), which were defined by: gamma
distribution for cost parameters, binomial distribution for probability and utility pa-
rameters, lognormal distribution for hazard ratio parameters. We run the PSA for
1000 iterations.
Figure 2.5B presents the cost-effectiveness acceptability curve (CEAC) of the
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Table A.11: Scenario analysis results.
Base Aging population scenario Partialuptake scenario
Prevalence in 2025
CIT 161,740 189,303 (17.04%) -
Oral 199,228 229,286 (15.09%) 198,602 (-0.31%)
Annual cost of CLL management ($)
2014 CIT 948,972,374 955,479,699 (0.69%) -
2016 CIT 994,163,585 1,017,491,537 (2.35%) -
2014 Oral 917,874,069 926,149,191 (0.90%) 917,874,069 (0.00%)
2016 Oral 1,657,380,404 1,686,708,467 (1.77%) 1,634,837,050 (-1.36%)
2018 Oral 3,383,614,544 3,503,477,197 (3.54%) 3,161,858,594 (-6.55%)
2020 Oral 4,238,284,439 4,468,901,709 (5.44%) 4,066,862,129 (-4.04%)
2025 Oral 5,130,373,316 5,759,684,042 (12.27%) 5,080,468,797 (-0.97%)
Cumulative cost 2011-2025 ($)
CIT 15,218,203,943 16,204,937,328 (6.48%) -
Oral 44,395,963,354 47,328,146,113 (6.60%) 43,175,278,807 (-2.75%)
Lifetime treatment cost ($)
CIT: 2016 cohort 115,762 115,754 (-0.01%) -
Oral: 2016 cohort 604,071 603,962 (-0.02%) 525,350 (-13.03%)
Oral: 2020 cohort 601,294 602,865 (0.26%) 602,138 (0.14%)
Lifetime out-of-pocket cost ($)
CIT: 2016 cohort 650 651 (0.30%) -
Oral: 2016 cohort 56,560 56,641 (0.14%) 48,421 (-14.39%)
Oral: 2020 cohort 55,332 55,471 (0.25%) 55,406 (0.13%)
Cost-effectiveness (total discounted values for 2011-2025)
Cost ($): CIT 5,908,502,555 6,342,645,316 (7.35%) -
LY: CIT 2,043,997 2,154,196 (5.39%) -
QALY: CIT 1,743,135 1,838,279 (5.46%) -
Cost ($): Oral 26,075,583,444 28,185,211,686 (8.09%) 24,728,649,769 (-5.17%)
LY: Oral 2,192,509 2,308,518 (5.29%) 2,190,070 (-0.11%)
QALY: Oral 1,849,712 1,949,548 (5.40%) 1,847,635 (-0.11%)
ICER ($/QALY) 189,226 196,305 (3.74%) 180,098 (-4.82%)
ICER ($/LY) 135,795 141,539 (4.23%) 128,840 (-5.12%)
two treatment strategies considered. It clearly shows that oral targeted therapies
is deemed cost-effective with a very low probability even at a willingness-to-pay as
high as $150,000/QALY, which validates the robustness of the base case ICER esti-
mate and our findings that oral targeted therapies is deemed not cost-effective.
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APPENDIX B
APPENDIX FOR CHAPTER 3
B.1 POMDP Formulation
B.1.1 Continuous state DP
In the following, we present the continuous state dynamic program formulation for
the liver cancer surveillance problem, which will be shown to be equivalent to a special
case of a POMDP model later.
• S = Sd∪Se: Core state space, including the disease states Sd := {(f, h) : f ∈
F , h ∈ H } (where F := {0, 1, 2} and H := {0, 1, 2, 3}) and absorbing states
Se := {PTX,DLD,DOC} (the same definitions as in our original manuscript).
• B = {[b(s)] :
∑
s∈S b(s) = 1; 0 ≤ b(s) ≤ 1,∀s ∈ S }: State distribution over
the core states S . For example,
b = (0.1, 0.05, 0.05, 0︸ ︷︷ ︸
F3-subpopulation
, 0.3, 0.05, 0.05, 0︸ ︷︷ ︸
CC-subpopulation
, 0.2, 0.1, 0.1, 0︸ ︷︷ ︸
DC-subpopulation
, 0, 0, 0︸ ︷︷ ︸
absorbing states
)
representing the distribution probability of state (0, 0), (0, 1), (0, 2), (0, 3), (1, 0),
· · · , (2, 2), (2, 3), PTX,DLD, and DOC.
• A = {(a0, a1, a2) : af ∈ {E,W},∀f ∈ F}: Action space. Because the screening
actions can be different across f -subpopulations and that we require them to be
the same within a given f -subpopulation, a single action (i.e., either screen or
not) is not sufficient to define the decisions for the entire population. Instead,
a proper action a ∈ A needs to be a triplet where the each element represents
the action in the corresponding f -subpopulation. For example, a = (E,W,W)
means screening action (E) in F3-subpopulation (f = 0), and no screening (W)
in CC and DC-subpopulations (f = 1, 2).
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• P (a0,a1,a2)(s′|s): Core state transition probability. For s = (f, h), the state tran-
sition probability is determined by the action af in triplet a = (a0, a1, a2). In
particular, if af = W, the transition probability follows the natural progression
probability; if af = E, after the screening test, some patients are diagnosed
with cancer and initiate treatment (i.e., s′ = PTX), and the others follow the
natural progression. For example, for F3-subpopulation (f = 0), the connection
between the transition probabilities with actions a0 = E and W is formalized as
follows:
P (E,a1,a2)(s′|(f = 0, h)) =

sensssensd, if h 6= 0 and s′ = PTX,




• rk(s, a): Expected net benefit reward accumulated in period k when the state
is s and the action is a.
• rN(s): Expected terminal net benefit reward at the end of planning horizon for
the state s.
• T [b, a]: Updated state distribution, given the past distribution b and the ac-
tion a. Let T [b, a](s′) denote the component for state s′ in the updated state
distribution T [b, a]. It is obvious that




Let V ∗k (b) present the maximum net benefit that the population can attain in period k
and onwards given the state distribution b in period k. Then the optimality equation
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is:













A special case POMDP model
The above continuous state DP model is indeed a special case of POMDP models.
The updated state distribution T [b, a] in (B.1), which only depends on the state
transition probability and the previous distribution, can be viewed as a Bayesian
update of the belief state in a standard POMDP model with the observation space
Θ = S and a non-informative observation matrix Ka , i.e., Ka(o|s) = 1|S | for all
o ∈ Θ, s ∈ S , a ∈ A .
Then we define the belief state updates τ [b, a, o] given current belief state b,
action a ∈ A and observations o ∈ Θ. Let τ [b, a, o](s′) be the component for state
s′ in the updated belief τ [b, a, o], i.e., τ [b, a, o](s′) = P(s′|b, a, o).



























which is indeed reduced to the state distribution update T [b, a] in (B.1).
Next, we check the equivalence of the optimality equations of the POMDP model
and the Equations (B.2)-(B.3). In the POMDP model, we use U∗k (b) to present
the maximum net benefit for period k and onwards given the belief state b. The
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optimality equations for the POMDP are as follows:






































b(s)rk(s, a) + U
∗
k+1(τ [b, a, o])
}





where Equation (B.4) holds for arbitrary observation o ∈ Θ since τ [b, a, o] is inde-
pendent of the choice of observation o in Equation (B.1).
Therefore, the continuous state DP formulation (B.2)-(B.3) is reduced to a POMDP
formulation (B.4)-(B.5), implying that we could apply the existing POMDP algo-
rithms for solving the continuous state DP model.
B.1.2 POMDP formulation for M-switch policies
To formulate M-switch policies, we need to impose additional constraints to the above
POMDP model. Since such constraints define the correlations of decisions across
different decision periods, they will break down the principle of optimality (see more
detailed explanations in our responses to comment #5), which is essential for solving
a DP in a recursive manner. An alternative is to modify the POMDP formulation
by augmenting the state space with the screening interval and switch information
and modifying the action space accordingly, such that the Markov structure and the
principle of optimality will preserve. Obviously, this modification comes at a further
computational cost, so the resulting formulation is hopeless to solve computationally.
However, we still present it to show that technically it is possible to formulate this
problem as a POMDP. The corresponding formulation is presented as follows.
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• State space. An augmented state s̄ = (b,d,g,w) ∈ S̄ consisting of belief
state b and “tracker states” (d,g,w). In particular,
– b(s), s ∈ S : Distribution over core states S .
– df ∈ D , f ∈ F : Current screening interval in f -subpopulation, where D is
the set of possible screening intervals. For example, D = {3M, 6M, 12M, 18M}
representing screening every 3-month, 6-month, 12-month, and 18-month.
– gf ∈ N , f ∈ F : Number of periods since the last switch of intervals in
f -subpopulation. The initial value is 0 at period k = 1.
– wf ∈ {0, 1, · · · ,M}, f ∈ F : Number of remaining interval switches in f -
subpopulation. The initial value is M (= the predefined maximum number
of interval switches for each subpopulation) at period k = 1.
• Action space. The action space is modified accordingly as follows. Actions
are no longer “whether screen or not” decisions; instead, the actions are defined
to assign screening intervals: ā ∈ Ās̄ = {(ā0, ā1, ā2) : āf ∈ Ā fs̄ , f ∈ F}, where
Ā fs̄ =

D if wf ≥ 1, and gf = ndf for some n = 0, 1, · · · ,
{df} if wf = 0, and gf = ndf for some n = 0, 1, · · · ,
{NA} if gf 6= ndf for any n = 0, 1, · · · ,
where gf = ndf for some nonnegative integer n indicates the period where the
current screening interval is completed and one can determine the next screening
interval (either same or different, subject to the number of remaining possible
switches wf ), and the action NA is a dummy action for any other period where
the screening interval is not allowed to change.
• State transitions.
– Transitions of state distribution b: The “whether screen or not” decisions
(i.e., a = (af )f∈F ) for each f -subpopulation are now determined by state
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gf and df :
af =

E if gf = ndf for some n = 0, 1, · · · ,
W otherwise.
(B.6)
The state distribution b is then updated following the Equation (B.1) with
action a.






f represent the states in
the next period, which are determined as follows:
1. If action āf 6= NA, i.e., a decision of screening interval is made,
d′f = āf ,
(a) If āf 6= df , i.e., a different screening interval is assigned,
g′f = 1, (reset the number of periods since the last interval switch)
w′f = wf − 1. (count down the remaining number of switches by 1)
(b) if āf = df ,
g′f = gf + 1,
w′f = wf .
2. If action āf = NA, i.e., no change in screening interval is made,
d′f = df ,
g′f = gf + 1,
w′f = wf
• Reward functions. The intermediate net benefit reward r̄(s̄, ā) accrued in
each period can be defined as follows:




where reward r(s, a) is defined in Section B.1.1, and action a is determined by
Equation (B.6).
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B.1.3 Computational results of POMDP formulations
We implemented the POMDP model for fully dynamic policy (without M-switch
structures) following the above formulation and attempted to solve it numerically,
using the pomdp-solve package, a widely used computational package for POMDPs
(see http://www.pomdp.org/). We remark that considering M-switch policies would
require further expansion of the space space and hence computational time for the
fully dynamic policy would serve as a lower bound for solving the M-switch policies.
We tested the model on the Linux operating system with an Intel Xeon 2.30GHz
CPU and 62Gb RAM. The algorithm was able to only proceed for 3 periods with
fast growing number of alpha vectors, and exploded afterwards (see the results in
the table below). Note that the POMDP formulation for M-switch policies consists
of an even larger state space with a more complex structure (a mixture of discrete
“tracker” states and continuous belief states in the augmented state space, see Section
B.1.2). Thus, solving the POMDP model for identifying the optimal M-switch would
be computationally even more demanding.





B.2 Reduction of HS-M-G to HS-M-NI Formulation
In the following, we will show that the formulation for nested screening interval in
our original manuscript can be derived from the above-introduced generalized formu-
lation. In particular, Constraints (3.10)-(3.11) in our manuscript can be derived from
Constraints (3.19)-(3.22) in this section given the nested interval structure.
First we have the following observations for the nested structure of screening
intervals:
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• J1 ⊃J2 ⊃ · · · ⊃J|D | = ∅.
• If screening interval di is selected, all screening periods Ji′ for interval di′ ,∀i′ ≥
i are “automatically” selected.
Due to the “overlapping” nature of nested intervals, we now implicitly allow “mul-
tiple” screening intervals to be selected together (e.g., J3,J4, and onwards), instead
of “one-and-only-one” is allowed as defined in Constraint (3.21). In particular, we
define φfl,i to be 1 if screening periods Ji are selected for cycle l in f -subpopulation,
and 0 otherwise. By this definition, we relpace constraints (3.19)-(3.20) with
y(l−1)C+j((f, h),E) = φ
f
l,i, ∀j ∈Ji, i = {1, · · · , |D |}, f ∈ F , h ∈H , l ∈ L , (B.7)
and the constraint (3.21) becomes trivially true and can be removed since we at least
have screenings in J|D | = ∅ (i.e., no screening).
Note that there are repeatedly defined equality constraints due to the overlapping
J ’s. That is, Constraint (B.7) for Ji+1 has been defined in the constraints for Ji.
Thus, it is sufficient to define the constraints for j ∈Ji\Ji+1 as follows:
y(l−1)C+j((f, h),E) = φ
f
l,i, ∀j ∈Ji\Ji+1, i = {1, · · · , |D |−1}, f ∈ F , h ∈H , l ∈ L .
(B.8)
Following the previous observations that all screening periods Ji′ for interval




l,i+1, ∀i = {1, · · · , |D | − 1}, f ∈ F , l ∈ L , (B.9)
By the change of variables using Constraint (B.7), Constraint (B.9) is as the same as
the follows:
y(l−1)C+j((f, h),E) ≤ y(l−1)C+j′((f, h),E),
∀j ∈Ji, j′ ∈Ji+1, i = {1, · · · , |D | − 1}, f ∈ F , h ∈H , l ∈ L , (B.10)
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which can be further simplified by removing the repeated definitions on Ji ∩Ji+1:
y(l−1)C+j((f, h),E) ≤ y(l−1)C+j′((f, h),E),
∀j ∈Ji\Ji+1, j′ ∈Ji+1, i = {1, · · · , |D | − 1}, f ∈ F , h ∈H , l ∈ L ,
(B.11)
To sum up, given the nested structure of screening intervals, the general formula-
tion can be simplified as Constraints (B.8) and (B.11). Given that variable φfl,i only
appear in Constraint (B.8), we can simply present Constraint (B.8) as
y(l−1)C+j((f, h),E) = y(l−1)C+j′((f, h),E),
∀j, j′ ∈Ji\Ji+1, i = {1, · · · , |D | − 1}, f ∈ F , h ∈H , l ∈ L . (B.12)
Finally, the general formulation is simplified to Constraints (B.8) and (B.12), which
are identical with the Constraints (3.10)-(3.11).
B.3 Appendix for Analytical Results
B.3.1 Preliminaries
We first establish several relations of quantities previously defined in Section 3.4. For
any given policy π, f ∈ F and h ∈H , value functions have the following backward
induction form:









(f ′, h′)|(f, h), πk(f)
)
V πk+1(f
′, h′), k = 1, · · · , N − 1,
V πN (f, h) = rN(f, h),
and for the augmented state h = 4, V πk (f, h = 4) = 0, ∀f ∈ F , k ∈ N , as no reward
is accumulated in absorbing states.
By the construction of policies π1 and π2 in Section 3.4 (identical everywhere






k in periods k ≥ t:
V π
2




t (f, h)− κ0, if h = 0,
ζRt(f, h) + (1− ζ)V π
1
t (f, h)− κ1, if h ∈H +,
V π
2
k (f̃ , h̃) =V
π1
k (f̃ , h̃), if k = t, f̃ 6= f ; or k ≥ t+ 1, ∀f̃ ∈ F , h̃ ∈H (B.13)
which indicates that for cancer-free patients, Screen action does not change the
outcomes except incurring additional test cost κ0; and for cancer patients, following
the Screen action with test cost κ1, ζ × 100% of these patients are diagnosed and
receive immediate treatment, while others are missed by the tests and continue the
natural progression until the next period.
Let q′k(f, h), c
′
k(f, h), and ρk(f, h) respectively represent the expected QALYs,
costs, and survival probabilities under treatment for a detected cancer state (f, h),
f ∈ F , h ∈ H + in period k. Then, given the terminal QALY q′N(f, h) and cost
c′N(f, h), the lump-sum treatment NB is calculated recursively as follows:
Rk(f, h) =
[
λq′k(f, h)− c′k(f, h)
]
+ γρk(f, h)Rk+1(f, h),
∀f ∈ F , h ∈H +, k = 1, · · · , N − 1, (B.14)
RN(f, h) = λq
′
N(f, h)− c′N(f, h), ∀f ∈ F , h ∈H +, and
Rk(f, h = 4) = 0, f ∈ F , k = 1, · · · , N. (B.15)
If the treatment is delayed by one period (i.e., a cancer patient does not have any
intervention at period k and receives treatment at period k + 1), the lump-sum NB
Wk(f, h) in state (f, h), h ∈H + at period k is calculated as:
Wk(f, h) =
[






′, h′)|(f, h),W)Rk+1(f ′, h′),
∀f ∈ F , h ∈H +, k = 1, · · · , N − 1,
We let QRk (f, h) and Q
W
k (f, h) denote the QALY components of Rk(f, h) and
Wk(f, h), and C
R
k (f, h) and C
W
k (f, h) denote the cost components, respectively. Then,
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the QALY and cost components of immediate treatment benefit (Rk(f, h)−Wk(f, h))
are defined respectively as follows:
∆Qk(f, h) =Q
R
k (f, h)−QWk (f, h) and (B.16)
∆Ck(f, h) =C
R
k (f, h)− CWk (f, h), ∀f ∈ F , h ∈H +, k = 1, · · · , N − 1. (B.17)
B.3.2 Proofs of theorems
Lemma B.1 (Fenwick et al. (2001)) If a policy π has the maximum NB, then π
is the most cost-effective policy.
Proof of Lemma B.1. We prove this by contradiction. Let π have the maximum NB.
Suppose there exists a policy π′ which is more cost-effective than π. By definition,
E(π′) > E(π) and C(π
′)−C(π)
E(π′)−E(π) < λ. Then, λE(π)−C(π) < λE(π
′)−C(π′), which is a
contradiction. 
Throughout the remainder of this appendix, we omit the superscript π in V πk+1
for simplicity, except where its inclusion is necessary to avoid ambiguity. Before
presenting the proof of Theorem 3.1, we first introduce a lemma where we characterize
several relationships between V πk (f, h), Rk(f, h), and Wk(f, h).
Lemma B.2 The followings hold for ∀f ∈ F , h ≥ 1, and period k = 1, 2, · · · , N−1:
1. V πk (f, h) ≤ Rk(f, h) for any policy π,
2. V πk (f, h) ≤ Wk(f, h) if πk(f) = W.
Proof of Lemma B.2.
Condition 1. By induction.
(1) It holds for n = N , because V πN (f, 4) = RN(f, 4) = 0, and V
π
N (f, h) = rN(f, h) ≤
RN(f, h) for f ∈ F , h ∈H + by Assumption 3.2.
(2) Suppose the statement holds for n = k + 1, i.e., for any policy π, V πk+1(f, h) ≤
Rk+1(f, h) for all f and h ≥ 1. Then, for n = k,
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a) For policy π1 where π1k(f) = W, ∀h ∈H +:
V π
1








′|h, f)V π1k+1(f ′, h′)








′|h, f)Rk+1(f ′, h′) (B.18)
= Wk(f, h) (B.19)
≤ Rk(f, h), (B.20)
where Inequality (B.18) follows from the induction hypothesis and (B.20) follows from
Assumption 3.3. We remark that (B.20) also holds for absorbing state h = 4 because
V πk (f, h = 4) = Rk(f, h = 4) = 0 for all k.
(b) For policy π2 where π2k(f) = E, we define policy π
1 as the policy identical to
π2 except that π1k(f) = W. Then by Equation (B.13), we have:
V π
2
k (f, h) = ζRk(f, h) + (1− ζ)V π
1
k (f, h)− κ1 ≤ Rk(f, h)− κ1 ≤ Rk(f, h),
where the first inequality follows from (B.20), which completes the proof.
Condition 2. This condition directly follows from (B.19), where we have shown
V πk (f, h) ≤ Wk(f, h) if πk(f) = W for all f and h ≥ 1 at any period k. 
Proof of Proposition 3.1. For the entire population, the difference of the expected NB
between the two policies π1 and π2 is
∑




1 (f̃ , h̃)− V π
1
1 (f̃ , h̃)
)
. Since the
actions in the two policies are different only in period t for the f -subpopulation, this
difference is reduced to the marginal surveillance benefit ∆t(f) for the f -subpopulation
in period t, i.e.,
∑




1 (f̃ , h̃)− V π
1


























t (f, 0)− κ0
)







ζRt(f, h) + (1− ζ)V π
1
t (f, h)− κ1
)
− V π1t (f, h)
]


























where the inequality follows from Lemma B.2. By the NB definitions of Rk(f, h)
and Wk(f, h),































bt(f, h)∆Ct(f, h) (B.22)
≥0, (B.23)
where (B.22) follows from the definitions of ∆Qt(f, h) and ∆Ct(f, h) given in (B.16)
and (B.17), respectively, and (B.23) follows from Condition (3.27), which completes
the proof. 
We now introduce two lemmas which are used in proving other statements.
Lemma B.3 Let y = [ys] represent a column vector and ys represent the s-th element
of the vector. If ys is decreasing in s, and transition matrix P is IFR, then (Py)s is
decreasing in s.
Proof of Lemma B.3. The proof follows from Lemma 4.7.2 in (175). 
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Lemma B.4 Let P and Q be two n × n transition matrices. If P  Q and vector
y = [ys] ∈ Rn is decreasing in s, then Py ≥ Qy component-wise, i.e., (Py)s ≥
(Qy)s, ∀s = 1, · · · , n.
Proof of Lemma B.4. The result immediately follows from Definition 3.2 and Lemma
4.7.2 in (175). 
Proposition B.1 (Monotonicity) For any given policy π, the value function V πk (f, h)
is decreasing in both f ∈ F and h ∈H .
Proof of Proposition B.1. First we show that for any given policy π, V πk (f, 0) ≥
Rk(f, 1) for any f -subpopulation and period k ∈ N . By induction,
(1) For n = N , VN(f, 0) = rN(f, 0) ≥ RN(f, 1) by Assumption 3.2.
(2) Assume V πn (f, 0) ≥ Rn(f, 1) holds for n = k+1, and let πk(f) represent the action
taken in period k for the f -subpopulation. Then, for h = 0 and n = k:






′, h′)|(f, 0),W)Vk+1(f ′, h′)
=
(








′, h′)|(f, 0),W)Vk+1(f ′, h′) (B.24)
≥
(
λqk((f, 0),W)− ck((f, 0),W)− 1{πk(f) = E}κ0
)
+ γPk((f, 0)|(f, 0),W)Vk+1(f, 0) (B.25)
≥(λq′k(f, 1)− c′k(f, 1)) + γρk(f, 1)Rk+1(f, 1) (B.26)
=Rk(f, 1), (B.27)
where 1{·} denotes the indicator function. Equation (B.24) follows from the definition
of intermediate NB rk(s, a), (B.25) follows by dropping other non-negative terms in
the summation, (B.26) follows from Assumption 3.6 and the inductive hypothesis,
and (B.27) follows from the definition of Rk(f, h) (B.14). Thus, V
π
k (f, 0) ≥ Rk(f, 1)
holds true for any fibrosis state f and all periods.
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Next, we prove the monotonicity results by induction.
(1) For n = N , this is true for any given f ∈ F and h ∈ H by Assumption 3.2.
Since VN(f, h) = rN(f, h) ≥ 0, ∀h ∈ H and VN(f, h = 4) = 0 for absorbing state
h = 4, it is also true for f ∈ F and h ∈H .
(2) Suppose the statement holds for n = k + 1. That is, for any policy π, V πk+1(f, h)
is decreasing in f∈ F and h∈H . Then, for n = k,
Case 1: The action in fibrosis state f in period k is Wait, i.e., the policy taken is π1













′|h, f)Vk+1(f ′, h′).
1. Fix fibrosis state f . We have that
∑
h′ Hk(h
′|h, f)Vk+1(f ′, h′) is decreasing in h







′|h, f)Vk+1(f ′, h′) with non-negative
coefficients Fk(f
′|f) is also decreasing in h. Since rk((f, h),W) is decreasing in
h by Assumption 3.2, V π
1
k is decreasing in h for any given fibrosis state f .
2. Fix tumor state h. For f̃ ≥ f , by the inductive hypothesis, Assumption 3.4, and
Lemma B.4, we have
∑
h′ Hk(h
′|h, f)Vk+1(f ′, h′) ≥
∑
h′ Hk(h
′|h, f̃)Vk+1(f ′, h′)

























′|h, f̃)Vk+1(f ′, h′),
where the last inequality follows from Assumption 3.4 and Lemma B.3. Since
rk((f, h),W) ≥ rk((f̃ , h),W) by Assumption 3.2 , we have for f ≤ f̃ ,
V π
1








′|h, f̃)Vk+1(f ′, h′) = V π
1
k (f̃ , h).
Thus, V π
1
k (f, h) is decreasing in f for any given tumor state h.
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Case 2: The action for fibrosis state f in period k is Screen, i.e., the policy taken is
π2 where π2k(f) = E, and let π
1 be the policy identical to π2 except that π1k(f) = W.
1. For a fixed f :
a) When h = 0, by the definition of value function V π2k given in (B.13),
V π
2
k (f, 0) =V
π1
k (f, 0)− κ0
≥ζRk(f, 1) + (1− ζ)V π
1
k (f, 0)− κ0
≥ζRk(f, 1) + (1− ζ)V π
1
k (f, 1)− κ1
=V π
2
k (f, 1) (B.28)
where the first inequality follows from (B.27), the second inequality follows
because V π
1
k (f, 0) ≥ V π
1
k (f, 1) by Case 1(1) and the fact that κ0 ≤ κ1 by
Assumption 3.5, and (B.28) follows again from the definition of V π
2
k in (B.13).
b) When h ∈H +, by (B.13), the value function is equal to:
V π
2
k (f, h) = ζRk(f, h) + (1− ζ)V π
1
k (f, h)− κ1.
Since both Rk(f, h) and V
π1
k (f, h) are decreasing in h by Assumption 3.2 and
Case 1, we have V π
2
k (f, h) is decreasing in h ∈ H +. To show that V π
2
k is
decreasing in h ∈H = H ∪ {4}, it is sufficient to show that V π2k (f, h) ≥ 0 for
any h ∈H + because V π2k (f, h = 4) = 0. Below we show that V π
2
k (f, h) ≥ 0 for
any h ∈H +.
V π
2
k (f, h) =V
π1
k (f, h) + ζ(Rk(f, h)− V π
1
k (f, h))− κ1
≥V π1k (f, h) + ζ(Rk(f, h)−Wk(f, h))− κ1 ≥ 0,
which follows from Lemma B.2 and Assumption 3.3. Therefore, V π
2
k (f, h) is
decreasing in h ∈H for a fixed fibrosis state f .
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2. For a fixed h, V π
2
k (f, h) is decreasing in f because both Rk(f, h) and V
π1
k (f, h)
in Equation (B.13) are decreasing in f by Assumption 3.2 and Case 1(2), which
completes the proof.

Proof of Proposition 3.2. By induction.
(1) As terminal rewards are the same, i.e., for any f ∈ F , V 1N(f, h) = V 2N(f, h) =
rN(f, h) for h ∈ H and V 1N(f, h = 4) = V 2N(f, h = 4) = 0 for absorbing state h = 4,
the assertion holds for n = N .
(2) Assume the assertion holds for n = k+1. That is, V 1k+1(f, h) ≥ V 2k+1(f, h),∀f ∈ F












′|f, h)V 2k+1(f ′, h′).
(B.29)
where the first inequality follows from Lemma B.4 with the given condition H1k(f) 
H2k(f) and the monotonicity of value function from Proposition B.1; the second in-
equality follows from the induction hypothesis that V 1k+1(f, h) ≥ V 2k+1(f, h),∀f ∈ F
and h ∈H .





′|f, h)V ik+1(f ′, h′)






















Now we show the statement holds for n = k. As before, let π1 and π2 be two
identical policies with the same actions, except that the action is Wait in π1 and
Screen in π2 for state f in period k. Recall that any policy can be presented as either
π1 and π2 because for any policy, the action taken for f -subpopulation in a particular
period t is either W or E. Let V π,ik represent the value function for policy π associated
with disease progressions {Fik,Hik(f)}.
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k (f, h) ≥ V
π1,2
k (f, h),∀f, h, which follows from (B.30).
2. For policy π2 where the action taken in state f in period k is Screen (i.e.,
π2k(f) = E), we let π
1 be the policy identical to π2 except that π1k(f) = W:
V π
2,1
k (f, 0)− V
π2,2
























k (f, h)− V
π2,2
k (f, h) =
(
ζRk(f, h) + (1− ζ)V π
1,1




ζRk(f, h) + (1− ζ)V π
1,2










≥ 0, ∀h ≥ 1,
where both results follow from the first case shown above, which completes the
proof. 
Proof of Theorem 3.1. Recall that by Equation (B.21):













, for i = 1, 2.
From Proposition 3.2, we know that V π
1,1
t (f, h) ≥ V
π1,2
t (f, h) for all f ∈ F and
h ∈ H . Therefore, it follows that Rt(f, h) − V π
1,1
t (f, h) ≤ Rt(f, h) − V
π1,2
t (f, h) for
all f ∈ F and h ∈H +. Thus, ∆1t (f) ≤ ∆2t (f) for all f , which completes the proof. 
Before proving Theorem 3.2, we present two more lemmas which are used in
proving this theorem.
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Lemma B.5 Let {b1k(f, h)} and {b2k(f, h)} represent two state distributions corre-
sponding to two HCC progression matrices {H1k(f)} and {H2k(f)} (with same fibrosis
progression matrices {Fk}), respectively, where H1k(f)  H2k(f) for all f and period
k. Suppose the initial distributions are the same, b11 = b
2
1. Then, for any given policy








k(f, h), ∀l ∈H .
Proof of Lemma B.5. By induction.









n(f, h) holds for n = k for all f ∈ F and
l ∈ H . Let FW and F E denote the fibrosis states which have Wait and Screen ac-
tions at period k, respectively. Then, transition probabilities Pk((f, h)|(f ′, h′),W) =
Hk(h|h′, f ′)Fk(f |f ′), ∀f ′ ∈ FW and Pk((f, h)|(f ′, h′),E) = Gk(h|h′, f ′)Fk(f |f ′), ∀f ′ ∈
F E, where transition matrix Gk(f) is defined based on Hk(f) as follows:
Gk(f) =

Hk(0|0, f) · · · Hk(3|0, f) Hk(4|0, f)
(1− ζ)Hk(0|1, f) · · · (1− ζ)Hk(3|1, f) (1− ζ)Hk(4|1, f) + ζ
(1− ζ)Hk(0|2, f) · · · (1− ζ)Hk(3|2, f) (1− ζ)Hk(4|2, f) + ζ




It is easy to verify that Gk(f) is also IFR. In addition, if H
1
k(f)  H2k(f), then
G1k(f)  G2k(f) for any period k, by Definition 3.2 and Equation (B.32).


































Gk(h|h′, f ′) (B.33)
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where the first inequality follows from the fact that H1k(f)  H2k(f), and the second





is increasing in h′ due to the IFR property (Assumption 3.4), and Lemma 4.7.2 in




















2) For f ′ ∈ F E, we can apply the same argument in Equation (B.34) since G1k and






























which completes the proof. 
Next, in the following lemma, we show that Rk(f, h)− V π
1
k (f, h) is decreasing in
h.
Lemma B.6 Suppose policy π1 has action Wait for fibrosis state f in period t, i.e.,
π1t (f) = W. For a fixed fibrosis state f and any tumor state h = 1, 2, if







Rt(f, h)− V π
1
t (f, h) ≥ Rt(f, h+ 1)− V π
1
t (f, h+ 1).
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Proof of Lemma B.6. Fix fibrosis state f ,
V πt (f, h)− V πt (f, h+ 1)








′|h, f)Vt+1(f ′, h′)
−
(





































′|f)Ht(h+ 1|h, f)Vt+1(f ′, h+ 1)




′|f)Ht(h+ 1|h, f)Rt+1(f ′, h+ 1) (B.38)






Ht(h+ 1|h, f)Rt+1(f, h+ 1) (B.39)
=r̃t(f, h) + γHt(h+ 1|h, f)Rt+1(f, h+ 1)
≤Rt(f, h)−Rt(f, h+ 1), (B.40)
where (B.36) and Ht(h
′|h, f) − Ht(h′|h + 1, f) ≤ 0 in (B.37) follow from Assump-
tion 3.4, (B.38) follows from the fact that Vt+1(f, h) ≤ Rt+1(f, h) by Lemma B.2,
(B.39) follows from that Rt(f, h) is decreasing in f by Assumption 3.2, and (B.40)
immediately follows from Condition (B.35). 
Proof of Theorem 3.2. Policy π1 represents a policy with the action Wait for f -
subpopulation in period t, i.e., π1t (f) = W. We define Ut(f, h) := Rt(f, h)−V π
1
t (f, h)
for h ∈ H + to represent the treatment benefit. Let ∆Rt(f, h), ∆Ut(f, h), and
∆V π
1
t (f, h) represent the change in Rt(f, h), Ut(f, h), and value function V
π1
t (f, h),
respectively, as the risk of developing HCC decreases and treatment NB increases.
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Then, by definition given in (3.26):






























Also, by the definition of Ut(f, h):

























b2t (f, h)ζ∆Ut(f, h)−
(





Let {H1k(f)} represent the HCC progression probability matrix for the base case,
and {H2k(f)} for the case with reduced HCC risk and improved treatment out-
come. Clearly, H1k(f)  H2k(f) for all f and period k. By Lemma B.5, we have∑
h≥l b
1




t (f, h), l ∈ H . In addition, we have that ζUt(f, h) − κ1 is
decreasing in h ∈ H + by Condition (3.28) and Lemma B.6, and is nonnegative by
Assumption 3.3. Thus, by Lemma 4.7.2 in (175),[
b2t (f, 1), b
2
t (f, 2), b
2








b1t (f, 1), b
1
t (f, 2), b
1


























t (f, h)ζ∆Ut(f, h).
Note that ∆V πt (f, h) ≥ 0 for h ∈ H +. This is because (1) when treatment
NB Rk(f, h) does not change, value function V
π
k (f, h) increases as HCC risk reduces
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by Proposition 3.2 and the fact that H1k(f)  H2k(f); and (2) when treatment NB
Rk(f, h) increases, value function V
π
k (f, h) will further increase if policy π has more
than one Screen actions after period t, which can be checked by the recursive form of
value functions and (B.13). Thus, ∆Ut(f, h) = ∆Rt(f, h) −∆V πt (f, h) ≤ ∆Rt(f, h),
which implies
∆2t (f)−∆1t (f) ≤− [b2t (f, 0)− b1t (f, 0)]κ0 +
∑
h∈H +
b2t (f, h)ζ∆Rt(f, h)









where the last inequality follows from Condition (3.29) in Theorem 3.2, which com-
pletes the proof.

B.4 Extended Sensitivity Analysis Results
B.4.1 Policies with more interval switches
To examine the effect of the possible number of switches (M), on the optimal M-switch
policies, we solve the HS-M problem with up to 5 switches of surveillance intervals.
Figure B.1 presents these optimal M-switch policies and Table B.1 summarizes the
performance of corresponding policies.
We observe that the increasing number of maximum possible switches does not
change the policy for CC and DC subpopulations at all, and has limited changes for F3
subpopulation. Also, the allowed additional switches do not translate into significant
improvement in policy performance. In Table B.1, we observe that the total NB has
only marginal improvement with the increasing number of switches, which implies
that more than one switch does not substantially improve the cost-effectiveness and
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Figure B.1: Sensitivity analysis for the number of switches.




# per 1,000 patients
# Tests # HCC detected
DLD
Small Medium Large
1-switch 347424.7 7.791 10.133 42139 11.7 125 39 7 516
2-switch 347426.1 7.791 10.133 42125 11.7 125 39 7 516
3-switch 347427.1 7.790 10.132 42091 11.5 125 39 7 516
4-switch 347427.1 7.790 10.132 42091 11.5 125 39 7 516
5-switch 347427.1 7.790 10.132 42091 11.5 125 39 7 516
B.4.2 Scenario analysis
We next examine the optimal surveillance policies under different settings of switching
cycle, initial population age, and WTP value. For each scenario, we present the results
for 1-switch policy, as it well represents the class of dynamic policies with a relatively
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(c) 1-switch policy for WTP=$100,000/QALY
Figure B.2: Sensitivity analysis for switching cycle length, initial age, and WTP.
We find that policy results are not very sensitive to the choice of the switching
cycle or the initial population age. When we use a longer switching cycle which
allows longer surveillance intervals, the model does not utilize any interval longer
than 4 years and leads to the same policy as in the base case results; when we reduce
the switching cycle to 2 years which enables quicker switches to different intervals, the
optimal 1-switch policy has only minimal changes in surveillance intervals compared
with the base case results (Figure B.2a). The optimal 1-switch policy for a population
with initial age 50 is also similar to the base case results (Figure B.2b).
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When WTP value is higher, the optimal 1-switch policy recommends more fre-
quent surveillance, as expected. For example, Figure B.2c presents the optimal 1-
switch policy with the WTP value of $100,000/QALY. This result also reflects the
tendency of utilizing more frequent surveillance in future, as higher WTP values are
more likely to be accepted by policy makers in future (166).
B.4.3 Probabilistic sensitivity analysis
In addition to the PSA results presented in Section 3.5.4, we also assessed the cost-
effectiveness acceptability curves (CEACs) by comparing stratified and 1-switch poli-
cies with the annual surveillance policy, the most cost-effective routine policy in F3
and cirrhotic patients (see Table 3.7). Figure B.3 shows that, compared with annual
surveillance policy, 0-switch and 1-switch policies also achieve very high confidence
of cost-effectiveness for a wide range of WTPs. Thus, the PSA results demonstrate






























Stratified policy 1-switch policy
Figure B.3: Cost-effectiveness acceptability curve for optimal stratified policies and
1-switch policy compared with every-12 month surveillance.
168
B.5 Parameter Estimation
B.5.1 Calibration of HCC risks based on HALT-C trial
Since existing HCC incidence estimates in the literature do not represent the tran-
sition probabilities from cancer-free state to the small HCC state in our model, we
calibrate such transition probabilities based on a recent clinical study, the HALT-C
trial (130). The HALT-C trial was designed to evaluate the long-term outcomes in
patients who had chronic hepatitis C infection with advanced fibrosis or compensated
cirrhosis and were not cured by previous hepatitis C treatment. Since it is the most
recent and the only study that has long-term follow-up for non-cirrhotic patients, the
HALT-C trial represents the best clinical data for our model calibration.
The HALT-C trial has a medium follow-up time of 6.5 years, in which 622 (59%)
patients are with advanced fibrosis (i.e., F3 stage) and 428 (41%) patients are with
cirrhosis at their enrollment with an average age of 50. We use the same initial pa-
tient characteristics in our model for the calibration. The primary goal of calibration
is to identify reasonable estimates for the transition probabilities such that the per-
centage of total detected HCC cases from the model will be similar to those from
the clinical data. Although the protocol of the HALT-C trial recommends ultrasound
surveillance every 12-month during the first 3.5 years and every 6 months during the
extended follow-up, only 68.9% patients have consistent screenings at least once per
year (201). Thus, we evaluate annual and biennial surveillance policies in our model
and use the weighted average of the results from the two policies (68.9% for the an-
nual surveillance) as the model output for the calibration. To search for reasonable
estimates of the transition probabilities, we use the incidence estimates from the lit-
erature as the initial value, and then increase the value until the model outputs fall
in the 95% confidence intervals of the estimates based on clinical data. Table B.2
shows the calibration results for the estimated probabilities of developing small HCC
that are selected as the base values (in Table 3.2).
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Table B.2: Calibration results for the risk of developing HCC
Performance measure
Estimates in HALT-C Model output (%)
% (95% CI) Weighted Annual/Biennial
HCC% at 3.5 years (144) 3.40 (2.35, 4.70) 2.36 2.77/1.44
HCC% at median follow-up (6.5 years) (144) 4.80 (3.54, 6.28) 3.59 3.79/3.14
Annual risk of death/transplant (F3) (60) 2.20 (1.20, 3.68) 1.98 1.96/2.02
Annual risk of death/transplant (CC) (60) 5.30 (3.38, 7.87) 6.43 6.38/6.54
HCC, hepatocellular carcinoma; CI, confidence interval; CC, compensated cirrhosis.
B.5.2 Transition probabilities
Transition probabilities in the model are derived from disease progression risks, mor-
tality risks, and test accuracy parameters. To estimate the transition matrix for nat-
ural progression [Pk(s
′|s,W)], we need to specify the transition matrices {Fk,Hk(f)}
(see Assumption 3.1).
In transition matrix Fk = [Fk(f
′|f)] for fibrosis states, we assume that in each
3-month (i.e., one period in our model), fibrosis stage can either progress to the
next advanced stage or remain unchanged. This is because the fibrosis progression is
usually slow, which typically takes about one decade to progress to the next advanced
stage (217). Estimates of annual risks from F3 to CC and from CC to DC are available
in published meta-analysis and systematic reviews (217, 173). We then convert the
annual risk into the risk for three months using the formula r′ = 1 − (1 − r)T ′/T as
suggested in (164), where r and r′ represent the risk for time horizon T=12 months
and T ′=3 months, respectively.
Transition matrix Hk(f) for tumor states is estimated based on the following
components:
• p1(f): Monthly risk of developing small HCC for each fibrosis state f , which is
obtained from the model calibration (see Section B.5.1).
• p2, p3: Monthly risks of HCC progression from small to medium, and medium
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to large HCC, respectively, which are estimated from (51).
• Ĥk(f) = [Ĥk(h′|h, f)]: 3-month transition matrix for HCC progression for each











• ml(f, h): Mortality from liver disease state (f, h). For the early stage HCC (i.e.,
h ≤ 2), we assume the tumor does not lead to the excess mortality. In this case,
the excess mortality only depends on the fibrosis state f , which is estimated
from the systematic review of clinical studies (54). For the late stage HCC
(i.e., h = 3), as it is deadly and usually leads to very poor prognosis (with a
median survival of 6 months), the excess mortality for large HCC is high for all
non-tumor fibrosis state f and is estimated based on the mortality of patients
undergoing best supportive care in a retrospective analysis (91).
• mok: Age-dependent mortality from other causes, which are estimated from the
US life tables (15).
• mk(f, h) := ml(f, h) +mok: Total mortality for state (f, h).











′|h, f) +mk(f, h) = 1, ∀f ∈ F , h ∈H , k = 1, · · · , N − 1.
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′|f)Hk(h′|h, f) if s′ = (f ′, h′) ∈ Sd,




Accuracy of surveillance and diagnostic tests are estimated from the literature.
For the surveillance ultrasound test, we use the sensitivity of 0.75 and specificity of
0.94 following Anderson et al. (13). For the HCC diagnosis, MRI and CT are the
commonly used diagnostic imaging tests. Note that sometimes in practice a second
imaging test may be needed if the first one is not conclusive. Thus, using the estimate
of a single test may underestimate the actual diagnostic accuracy. Considering this,
we estimate the diagnostic sensitivity as 0.9, which is in line with the range reported
in literature (182, 50).
B.5.3 Lump-sum treatment reward
Since no surveillance decisions are considered after HCC treatment, we assign a lump-
sum treatment reward in the absorbing state PTX in our model, which is calculated
from separate Markov models. In clinical practice, four main types of treatment are
commonly used: liver resection, liver transplant, ablation, and palliative treatment.
We estimate treatment distributions based on (13, 70), and expert opinion, which are
presented in Table B.3.
• Resection, ablation, and palliative treatment are usually delivered soon after the
HCC diagnosis. We use a simple 2-state Markov model (Figure B.4) to calculate
the total quality-adjusted survival time for each treatment separately. For each
treatment, post-treatment mortality is determined by the age-dependent back-
ground mortality (15) plus the treatment-specific mortality. Treatment-specific
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mortality, derived based on the survival estimates from clinical studies, depend
on f and h states. Quality of life (QOL) after each type of treatment is deter-
mined by the QOL at treatment initiation at disease state (f, h) (see Section
B.5.4) and the percentage change in QOL after the corresponding treatment as
estimated in (220) (converted to EQ5D utilities based on method in (45)). We
consider these treatments as one-time procedures without maintenance therapy
for a long-term follow-up, and thus use a fixed cost for each treatment estimated




Figure B.4: Two-state Markov model for estimating lump-sum rewards of liver resec-
tion, ablation, and palliative treatment.
• Liver transplant is different from other treatments in the sense that transplant-
eligible patients need to wait for additional time on the waiting list until an
available organ is available for the transplant. While waiting, patients may lose
their eligibility for transplant as they may progress outside the Milan criteria
meanwhile. In that case, they are managed by palliative treatment (see state
transitions in Figure B.5). We estimate the probability of transplant on the
waiting list in each period based on the average waiting time of transplant
recipients from the United Network for Organ Sharing (UNOS) data (168).
After transplant, patients have a long-term follow-up with maintenance costs in
subsequent years. Estimates for post-transplant survival, QOL, and treatment

























Figure B.5: Markov model for estimating lump-sum rewards of liver transplant.
Table B.3: Treatment distribution
Non-tumor state Tumor state RES OLT ABL PAL
F3/CC small HCC 35% 35% 30%
F3/CC medium HCC 28% 14% 28% 30%
F3/CC large HCC 13% 6% 81%
DC small/medium HCC 28% 42% 30%
DC large HCC 19% 81%
RES, resection; OLT, liver transplant; ABL, ablation; PAL, palliative treat-
ment; CC, compensated cirrhosis; DC, decompensated cirrhosis.
B.5.4 Intermediate QALY and cost
For health states (f, h), we assume any undetected HCC state h does not impair the
quality of life as the development and progression of HCC are usually silent with
rare clinical symptoms (51). That is, the utility for state (f, h) only depends on the
fibrosis state f , denoted as u(f). In addition, we adjust the utility by age to capture
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the aging effect (97). That is, the utility in state s ∈ S is given by:
uk(s) :=

u(f)ηk, if s = (f, h) ∈ Sd, ∀f ∈ F , h ∈H ,
0, if s ∈ Se.
where ηk represents the age-adjustment factor (97). The intermediate QALYs qk(s, a, s
′)







′)) if a = W, or a = E and s′ 6= PTX,
QRk (s) if a = E and s
′ = PTX,
0 otherwise,
where we take the average of uk(s) and uk+1(s
′) for the half-cycle correction, and
QRk (s) represents the lump-sum QALYs of treatment for state s ∈ Sd. Similarly, we
define the cost in state s ∈ S as:
ck(s) :=

c(f) if s = (f, h) ∈ Sd, ∀f ∈ F , h ∈H ,
0 if s ∈ Se,
where c(f) is the cost associated with the fibrosis state f for the routine care of
chronic hepatitis C. Then, we define the intermediate cost from state s to s′ with
action a as follows:


















′)) if s = (f, h), ∀f ∈ F , h ≥ 1, and s′ 6= PTX,
cs + cd + C
R
k (s) if s = (f, h), ∀f ∈ F , h ≥ 1, and s′ = PTX,
0 otherwise,
where CRk (s) represent the lump-sum cost of treatment for state s ∈ Sd.
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B.5.5 Initial HCC prevalence
The initial state distribution requires estimates of the prevalence of unobservable HCC
for each f -subpopulation. However, such estimates do not exist in the literature.
Therefore, to estimate initial prevalence, we use the prevalence of projected HCC
cases from a population-based simulation model (110). These estimates are stratified
for each 5-year age groups (see Table B.4). Since the simulation model does not
differentiate the HCC cases by the tumor size at diagnosis, we assume the simulation-
projected HCC prevalence corresponds to the the distribution of small HCC in our
base case result.
B.5.6 Model Validation
In addition to validating the clinical implications of our findings with domain experts,
to validate our model parameterization, we have cross-compared our model results
with a previously published and well-recognized cost-effectiveness study by Andersson
et al. (13). In particular, Anderson et al. assessed the cost-effectiveness of (routine)
screening policies with different fixed intervals for 50-year-old compensated cirrhosis
(CC) patients. To compare our model results to those in (13), we applied our model to
the same population profile and screening policies. Our model produced comparable




































































































































































































































































































































































































































































































































































































































APPENDIX FOR CHAPTER 4
C.1 Proofs of Propositions
Proof of Proposition 4.1. First observe that Ṅ = Λ − µ(S + R) −m(I + D) =
Λ−µN − (m−µ)(I +D) ≤ Λ−µN because m ≥ µ by definition. Let Ṁ = Λ−µM
with M(0) = M0 = Λ/µ. Then M(t) = Λ/µ for t ≥ 0. By the comparison theorem
(Theorem 1.5.2 in (124)), if N(0) = N0 ≤M0, then N(t) ≤M(t) = Λ/µ for t ≥ 0.
Next we consider the case N0 >
Λ
µ




λ − µN(τ) < 0 when N(τ) > Λ/µ for τ ∈ [0, t]. And thus N(t) < N0 holds true for
all time before N(t) = Λ/µ. If N(t′) = Λ/µ at some time t′, N(t) ≤ Λ/µ for t ≥ t′
by the previous argument. 
Proof of Proposition 4.2. We first determine the disease-free equilibrium (DFE)
by solving 
Ṡ = İ = Ḋ = Ṙ = 0
I = D = 0
=⇒

Ṡ = Λ− µS = 0
Ṙ = −µR = 0.




, 0, 0, 0
)
.
We employ the next-generation operator method (58) to calculate the reproduction
number Rc. For the infected compartments I and D, we define the new infections
matrix F and transfer matrix V :
F =
(αS + βR) I+DN
0
 , and V =
 (v +m)I
−vI + (m+ wη)D
 , (C.1)
where F−V = [ İ
Ḋ
] holds true. Then we calculate the corresponding Jacobian matrices
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α(v + wη +m)
(v +m)(wη +m)
,
as a function of intervention v and w. 
Proof of Proposition 4.3.
Local asymptotic stability: Throughout this proof, we let state x = (S, I,D,R)
represent the vector of compartment sizes, ẋ = f(x) represent the system of dynamics
(4.1)-(4.4), P = I+D
S+I+D+R
represent the prevalence rate (i.e., the fraction of infected
people among the total population), and PS =
∂P
∂S






−µ− αP − αSPS −αSPI −αSPD −αSPR
αP + (αS + βR)PS (αS + βR)PI −m− v (αS + βR)PD (αS + βR)PR + βP
0 v −m− wη 0
























At DFE x = E = (S∗ = Λ
µ



















−µ −α −α 0
0 α−m− v α 0
0 v −m− wη 0






x=E has eigenvalues λi, i = 1, · · · , 4: λ1 = λ4 = −µ, λ2 and λ3 are roots









Det(A) = −(α−m− v)(m+ wη)− αv = (m+ v)(m+ wη)(1−Rc), (C.7)
Tr(A) = α− v − wη − 2m. (C.8)
By Theorem 4.7 in (117), E is locally asymptotically stable if and only if real
part of all eigenvalues λi, i = 1, · · · , 4 are negative. By (C.6) it is equivalent to have
Det(A) > 0 and Tr(A) < 0, which reduces to Rc < 1 because Det(A) > 0 holds true
by (C.7), and Tr(A) < 0 holds true by the following:
Rc =
α(v + wη +m)
(v +m)(wη +m)
< 1 =⇒ α < v +m and α < wη +m (C.9)
=⇒ 2α < v + wη + 2m (C.10)
=⇒ Tr(A) = α− v − wη − 2m < −α < 0. (C.11)
This concludes the proof for the local stability.
Global asymptotic stability:
















where matrices F and V are defined in (C.2).
Next we can easily check the following properties of matrices F and V :
• F ≥ 0
• V has the form V = sI −B with B ≥ 0





By Lemmas 1 and 2 in (225), all eigenvalues of (F − V ) have negative real parts if
and only if Rc < 1. It implies that the linear ODE system ˙̃I
˙̃D




is globally stable when Rc < 1. Therefore, (Ĩ(t), D̃(t)) → (0, 0) as t → ∞. By
comparison principle (124), given the same initial condition (I0, D0), we have I(t) ≤
Ĩ(t), D(t) ≤ D̃(t),∀t ≥ 0, which implies that (I(t), D(t)) → (0, 0) as t → ∞ for the
nonlinear system (4.2)-(4.3). Substituting I = D = 0 to equations (4.1) and (4.4), we
have that S(t) → S∗ and R(t) → 0 as t → ∞. Therefore, (S(t), I(t), D(t), R(t)) →
E = (λ
µ
, 0, 0, 0) as t → ∞. That is, the disease-free equilibrium E is globally asymp-
totically stable if Rc < 1. 
Proof of Proposition 4.4: Let P = I+D
S+I+D+R



























Moreover, by plugging (C.16) and (C.17) to (C.15) we have




















Also note that P (S+I+D+R) = I+D; by plugging in the results of (C.14), (C.16),
(C.17), and (C.19), we have






























and then we get a quadratic equation of term P :
a2P
2 + a1P + a0 = 0, (C.22)
where
a2 =





Rc > 0 (C.23)
a1 = α
v + wη +m
vwη
(µ− β) + α + (v +m)(wη +m)
vwη
β − β
















. There exists endemic equilibrium if and only if
there exists only one root 0 < P ≤ 1.
(1) When Rc > 1. We know that a2 > 0 by (C.23) and a0 < 0 by (C.25). In this
case, there is always one positive root no matter whether a1 < 0 or a1 > 0 because√
a21 − 4a0a2 > |a1|. Then it is sufficient to check
a21 − 4a0a2 ≥ 0, and
− a1 +
√
a21 − 4a0a2 < 2a2 ⇐⇒ a0 + a1 + a2 > 0.
The former is trivial, and the latter can be verified as follows:
a0 + a1 + a2 =
(v +m)(wη +m)
vwη
[µ(1−Rc) + µRc + β(1−Rc)]






(µ+ β) + (α− β) > 0. (C.26)
Therefore, there exists a unique EE when Rc > 1.





are either negative real numbers or complex numbers with negative real parts; neither
case implies a meaningful solution of prevalence P at an EE. In other words, there
exists no EE in such a case. 
Proof of Corollary 4.1. Consider the equilibrium disease prevalence P = I+D
S+I+D+R
as a function of reproduction number Rc. A necessary and sufficient condition of






Recall that P is the root of equation (C.22). Taking the derivative with respect to
Rc at both sides, we have
da2
dRc






























< 0, it is equivalent to have a1 < 0, i.e.,





Proof of Proposition 4.5.
We can show that the optimal control exists for problem (4.10), and the existence can
be generalized for any cost function which is convex in control variable u. First we
modify the the formulation to the form that is suitable for applying Filippov-Cesari
Theorem (Theorem 2.8 in (190)) as follows.
We define an auxiliary state variable Y (t) = −(I(t) +D(t)). With the augmented





where f0(x, u, t) is assumed to be convex in control variable u,
System dynamics: ẋ = f(x, u) := (f1(x, u), f2(x, u), f3(x, u), f4(x, u), f5(x, u)),
where fi(x, u) for i = 1, 2, 3, 4 are defined in (4.1)-(4.4),
and f5(x, u) = −f2(x, u)− f3(x, u),
Initial conditions: x(0) = (S0, I0, D0, R0,−(I0 +D0))
Terminal conditions: xi(tf ) free for i = 1, 2, 3, 4;
x5(tf ) ≥ −ρtarget.
Now we are ready to apply the Filippov-Cesari Theorem, or Theorem 2.8 in (190).
Define the set
N(x, U, t) := {(−f0(x, u, t) + γ, f1(x, u, t), · · · , f5(x, u, t)) : γ ≤ 0, u ∈ U}.
It is sufficient to verify the following conditions:
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(i) N(x, U, t) is convex for each (x, t)
(ii) U is closed and bounded
(iii) There exists an admissible pair (x(t), u(t))
(iv) There exists a number b such that ‖x(t)‖ ≤ b for all t ∈ [0, tf ] and all admissible
pairs (x(t), u(t)).
(i) We first check the convexity of set N(x, U, t). Since (x, t) is given, we suppress
the dependency of x and t in the notation. We want to check the convexity of set
M(U) = {(g0(u)+γ, g1(u), · · · , g5(u)) : γ ≤ 0, u ∈ U} where g0(u) is concave (because
g0 = −f0), gi(u), i = 1, · · · , 5 are in u. Let y1 and y2 be two arbitrary points in set
Mx,t(U), i.e.,
y1 = (g0(u1) + γ1, g1(u1), g2(u1), g3(u1), g4(u1)), for some γ1 ≤ 0, u1 ∈ U,
y2 = (g0(u2) + γ2, g1(u2), g2(u2), g3(u2), g4(u2)), for some γ2 ≤ 0, u2 ∈ U,
Note that U = [0, 1]×[0, 1] and is convex. For any λ ∈ [0, 1], let u′ = λu1+(1−λ)u2 ∈
U , and
λy1 + (1− λ)y2
=(λ(g0(u1) + γ1) + (1− λ)(g0(u2) + γ2),
λg1(u1) + (1− λg1(u2)), · · · , λg5(u1) + (1− λg5(u2)))
=(λ(g0(u1) + γ1) + (1− λ)(g0(u2) + γ2), g1(u′), · · · , g5(u′))
where the second equation follows from the linearity of gi for i = 1, · · · , 4, and the
last inequality follows from the concavity of function g0 with respect to control u.
Note that
λg0(u1) + (1− λ)g0(u2) + λγ1 + (1− λ)γ2 ≤ g0(u′) + λγ1 + (1− λ)γ2
185
since g0 is concave in u. Then the left-hand-side can be rewritten as
λg0(u1)+(1−λ)g0(u2)+λγ1+(1−λ)γ2 = g0(u′)+γ′ for some γ′ ≤ λγ1+(1−λ)γ2 ≤ 0.
Thus, λy1 +(1−λ)y2 ∈ N(x, U, t) for any λ ∈ [0, 1], implying that N(x, U, t) is convex
for all choices of (x, t).
(ii) U = [0, 1]× [0, 1] and thus is closed and bounded.
(iii) Let x̂(t) be the solution to the system (4.1)-(4.6) with control û(t) ≡ 0 for all t.
(x̂, û) is an admissible pair.
(iv) As shown earlier in Proposition 4.1, the size the total population is always
bounded. An thus, let b = 2 max{Λ/µ,N0} and then we have ‖x(t)‖ ≤ |S(t)| +
|I(t)|+ |D(t)|+ |R(t)|+ |I(t) +D(t)| ≤ 2N(t) ≤ b, which completes the proof. 
Proof of Proposition 4.6. Calculate the gradient of Hamiltonian H(x∗, u, λ, t) with
respect to control variables:
∂H
∂v
=〈λ, g1(x∗)〉 = λ0(crs(S∗ + I∗ +R∗) + casI∗) + (λ3 − λ2)I∗
∂H
∂w
=〈λ, g2(x∗)〉 = λ0cdD∗ + (λ4 − λ3)ηD∗
Notice that variable Z does not contribute to the equations of system dynamics,
direct computation from (4.16) shows λ̇0 = 0; by the transversality condition, we







, which completes the proof. 
Proof of Proposition 4.7:
Case (1). Consider a simplified model with only S, I, and D compartments and the





























and N = S + I + D. Suppose there exists an singular arc on certain time interval
[t1, t2], and then switching functions vanish:
Φ1(t) = 〈λ, g1〉 ≡ 0, Φ2(t) = 〈λ, g2〉 ≡ 0, ∀t ∈ [t1, t2]. (C.27)
Moreover,
Φ̇1(t) = Φ̇2(t) = 0, ∀t ∈ [t1, t2].
To calculate these quantities, we use the mathematical tool called the Lie bracket of




g(x) · f(x)− d
dx
f(x) · g(x).
The properties of the lie bracket in the following lemma can be easily verified by
direct calculations (also see Proposition 2 in (129)).
Lemma C.1 The lie bracket [·, ·] has the following properties:
• [f, f ] = 0 and [f, g] = −[g, f ],
• Let λ be the co-state vector corresponding to the problem (4.12). Define function
Φ(t) = 〈λ, h〉. Then
Φ̇(t) = 〈λ, [f + g1v + g2w, h]〉.
By Lemma C.1, we have
Φ̇1(t) = 〈λ, [f + g1v + g2w, g1]〉 = 〈λ, [f, g1]〉+ 〈λ, [g2, g1]〉w = 0,































As g2 ∝ [g1, g2] and Φ2 = 〈λ, g2〉 ≡ 0, we have 〈λ, [g1, g2]〉 = 0. Then Φ̇1(t) and Φ̇2(t)
can be simplified to
Φ̇1(t) = 〈λ, [f, g1]〉 ≡ 0, and Φ̇2(t) = 〈λ, [f, g2]〉 ≡ 0. (C.28)
By (C.27) and (C.28) , λ has zero inner product with g1, g2, [f, g1], and [f, g2].
However, these four vectors are linear independent, which implies λ ≡ 0. But λ0 ≡ 1
as shown earlier. Therefore, control v and w cannot be simultaneously singular.
Case (2). Consider the full model (4.12) when α = β. Then compartments S and R
are indeed indifferent and can be combined as one compartment. As a result, the full
model is equivalent to the optimal control problem (C.27) as in Case (1) except for a
different g′2(x) = (cdD, ηD, 0,−ηD)>.

























g′2 − casηD(1, 0, 0, 0)> =
I
D
g′2 − casηD(k1g1 + k2[f, g1]) (C.29)















0 ≡Φ̇1 = 〈λ, [f, g1]〉+ 〈λ, [g′2, g1]〉w
=〈λ, [f, g1]〉 − 〈λ, g′2〉
I
D
+ 〈λ, g1〉csηDk1 + 〈λ, [f, g1]〉csηDk2
=〈λ, [f, g1]〉(1 + csηDk2) (C.31)
Clearly 1+csηDk2 6= 0 for k2 value that solves (C.30). Then (C.31) implies 〈λ, [f, g1]〉 ≡
0. Moreover, 〈λ, [g1, g′2]〉 ≡ 0 by (C.29), and thus Φ̇2(t) = 〈λ, [f, g′2]〉 ≡ 0. Therefore,
λ has zero inner product with g1, g
′
2, [f, g1], and [f, g
′
2], which are indeed linear in-
dependent. This implies λ ≡ 0, which contradicts with λ0 ≡ 1 and completes the
proof.

Proof of Proposition 4.8. For problem (4.19), Hamiltonian is defined as H =

















λ0(tf ) = 1, λ1(tf ) = λ4(tf ) = 0, λ2(tf ) = λ3(tf ) = k (C.33)
for some k ≥ 0 and k = 0 if I∗(tf ) +D∗(tf ) < ρtarget.





= 〈λ, g〉 = D∗(cd + η(λ4 − λ3)).
Suppose there exists a singular arc. Switching function Φ(t) vanishes on the singular
arc, i.e., Φ(t) ≡ 0. Since disease free equilibrium is not achieved, given v◦ 6≡ 0,
compartment I(t) and D(t) cannot remain 0 over a time interval. Thus, Φ(t) ≡ 0
implies






Φ̇ = 〈λ, [f, g]〉 ≡ 0 (C.35)
Φ̈ = 〈λ, [f, [f, g]]〉+ 〈λ, [g, [f, g]]〉w (C.36)
Direct calculation can show that
[f, g] =











− ((m− µ)D − v◦I)

,














+ (m− µ)D + v◦I













Thus, on the singular arc,
〈λ, [g, [f, g]]〉 =− η〈λ, [f, g]〉+ 2cdηv◦I +
2βη2D2
N


















where the second and the fourth equality holds true by (C.34). Next, we determine
the sign of λ2 − λ3 on the singular arc.







=− (cas + crs)v◦ + cdw + (m+ v◦)(λ2 − λ3) + ηw(λ4 − λ3)
=(m+ v◦)(λ2 − λ3)− (cas + crs)v◦ + wΦ
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with terminal condition λ2(tf )− λ3(tf ) = 0.
Consider a reverse process λ23(τ) = λ2(tf − τ) − λ3(tf − τ) with screening rate
v̄◦(τ) = v◦(tf − τ), for τ ∈ [0, tf ]. Then we have
˙λ23(τ) = −(m+ v)λ23(τ) + (cas + crs)v̄◦(τ)− w(tf − τ)Φ(tf − τ)
with initial condition λ23(0) = 0. Note that wΦ ≤ 0 always holds true because
w = 0 when Φ > 0 and w = 1 when Φ < 0. Therefore ˙λ23 ≥ −(m + v̄◦)λ23. Let
ẏ = −(m+ v̄◦)y with y(0) = 0. By comparison theorem (Theorem 1.5.2 in (124)), we
have λ23(t) ≥ y(t) = 0 for all t ∈ [0, tf ], which implies










= 〈λ, [g, [f, g]]〉 ≥ 2βηcdD2
N
> 0, which contradicts to the










excludes the existence of singular control arc. 
Proof of Proposition 4.9. The optimization problem is equivalent to
max
w(t)∈[0,1]
{−J(vc) : (4.1)− (4.6)} .
Define the Hamiltonian H = 〈λ, f(x) + g1(x)vc + g2(x)w〉 with the costate λ(t) =
(λ1(t), · · · , λ4(t)), where
f(x) =

Λ− µS − αS I+D
N






















We want to examine the effect of the constant screening rate vc on the objective value
−J(vc). The subderivative of objective value −J(·) at vc, denoted by h, is as follows











Note that costates λ(t) satisfy λ̇ = −∂H
∂x
with transversality conditions λ1(tf ) =
λ4(tf ) = 0, λ2(tf ) = λ3(tf ) = 1. By direct calculation,
λ̇3 − λ̇2 = (m+ vc)(λ3 − λ2)− wη(λ4 − λ3).
Note wη(λ4−λ3) ≥ 0 because w = 1 when switching function η(λ4−λ3) > 0 and w = 0
when η(λ4 − λ3) < 0. Thus λ̇3 − λ̇2 ≤ (m + v)(λ3 − λ2). Since λ3(tf ) − λ2(tf ) = 0,
by time reversion and the comparison theorem, we have λ3(t) − λ2(t) ≥ 0 for all




I(λ3 − λ2)dt ≥ 0,
which implies
−J(v) ≥ −J(vc) + h(v − vc) ≥ −J(vc), ∀v ≥ vc,
and therefore J(v) ≤ J(vc),∀v ≥ vc. 
Proof of Proposition 4.10. Since the total population N(t) remains a constant




state x(t) = (S(t), I(t), D(t), R(t) represents a population distribution which sums to
one. We also let w represent the actual number of treatment, i.e., w(t) = w(t)D(t),
w(t) ≤ D(t). Then the system dynamics are as follows:
Ṡ = µ− µS − αS(I +D) (C.38)
İ = (αS + βR)(I +D)− µI − vI (C.39)
Ḋ = vI − µD − ηw (C.40)
Ṙ = ηw − µR− βR(I +D) (C.41)
v ∈ [0, 1], w ≤ D
For the uninfected population (i.e., the susceptibles and the recovered), we define
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 µ− µS − αS(I +D)
ηw − µR− βR(I +D)
 =
 µ− µS − αS(1− S) + αSR
ηw − µR− βR(1−R) + βRS

(C.42)
where the second inequality follows from the fact that S + I +D +R = 1.
Next, we introduce the definition of quasimonotone nondecreasing property (124)
(also referred to as “cooperative” in the literature) that plays a key role in establishing
differential inequality results.
Definition C.1 (Quasimonotonicity, Laskshmikantham et al. (2015)) Function
g(t, x) : R+ ×Rn 7→ Rn is said to be quasimonotone nondecreasing if for any given t,
x ≤ y, xi = yi =⇒ fi(t, x) ≤ fi(t, y) (i = 1, · · · , n).
It is straightforward to check that hw(y) is indeed a quasimonotone nondecreasing
function. Also note that hw1(y) ≤ hw2(y) because w1 ≤ w2.
We are now ready to apply Theorem 1.5.4 of (124) to show the inequalities S1(t) ≤
S2(t) and R1(t) ≤ R2(t) as follows. Since state y(t) = (S(t), R(t)) is differentiable,
Dini derivative of y(t) at time t is the usual derivative ẏ = h. Given the same initial
condition y1(0) = y2(0), ẏi = hwi(yi) for i = 1, 2, and quasimonotone nondecreasing
function hw2 , by Theorem 1.5.4 of (124), hw1(t)(y) ≤ hw2(t)(y) implies that y1(t) ≤
y2(t) component-wisely for all t ≥ 0. That is, S1(t) ≤ S2(t), R1(t) ≤ R2(t), and thus
I1(t) +D1(t) ≥ I2(t) +D2(t) for all time t. 
Proof of Proposition 4.11. With the assumption of stationary population, we
consider the system dynamics (C.38)-(C.41) with the state x = (S, I,D,R) now rep-
resenting the population distribution. Budget B is scaled accordingly and represents
the annual budget per person.
Case (1). When B ≤ cdD, i.e., budget is not sufficient to treat all diagnosed patients.
By Proposition 4.10, more people receiving treatment (i.e., a higher value of w(t) =
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w(t)D(t)) always leads to lower I(t) + D(t), regardless of the value of screening
rate v(t). Therefore, in this case, it is optimal to increase treatment number to the
maximum possible value, i.e., by allocating all the budget to treatment and none for
screening.
Case (2). When B > cdD. By the result of Case (1), budgets are first allocated for
treatment until all diagnosed patients are covered. To show that the remaining budget
should be spent on screening, it is sufficient to show that at the treatment rate
w(t) = 1, increasing the number of screenings will reduce the prevalence I(t) +D(t).
Consider the susceptible, diagnosed, and recovered population. We define state








Λ− µS − αS(1− S) + αSR
v − (m+ η)D
ηD − µR− βR(1−R) + βRS
 (C.43)
where v represents the actual number of diagnosed patients through the screening.
It is straightforward to check that lv(y) is quasimonotone nondecreasing. Similar
to the proof of Proposition 4.10, by applying Theorem 1.5.4 of (124), when v1(t) ≤
v2(t), we have S1(t) ≤ S2(t) and R1(t) ≤ R2(t), which implies I1(t) + D1(t) ≥
I2(t) +D2(t) for all t, leading to a lower objective value of (4.25).
Therefore, given that the treatment is saturated with the maximum rate, it is
optimal to increase the number of screening as much as possible, i.e., by allocating
all remaining budget to screening. 
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